International Flavors and Fragrances Inc (IFF)

IFF and ISIPCA Mark 10 Years of Joint Scent Design and Creation Master’s-Level ProgramJune 16, 2026 11:00 AM
Business Wire A pioneering perfumery program that develops industry-ready talent IFF — a global leader in flavors, fragrances, food ingredients and health & biosciences — celebrates the 10th anniversary of its industry-leading accredited master's-level program for scent design and creation, developed in partnership with ISIPCA, the world-renowned school for careers in perfume, cosmetics and food flavors. Since its launch in 2016, the IFF ISIPCA program has trained more than 180 professionals from 40 countries, with 130 graduates to date, and a 100% job landing rate up to six months after graduation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615461626/en/The IFF ISIPCA Scent Design and Creation program has been pioneering fragrance education and excellence since 2016.  “Over the past decade, IFF ISIPCA has built a strong pipeline of diverse, high-potential fragrance experts, combining creative excellence, scientific expertise and a global perspective,” says Valery Claude, program sponsor and senior vice president of digital for IFF Scent. “The future looks bright with the next generation of scent talent who are poised to drive innovation across the industry.” IFF ISIPCA is a breakthrough graduate program that offers a point of entry for careers in the field of scent. Combining IFF’s more than 135-year creative legacy and science-led innovation with ISIPCA’s academic excellence, the specialized scent design and creation program has expanded access to perfumery careers. The program prepares students for roles across fragrance development, marketing, sales and perfumery creation, helping build the future of fragrance. The accredited program selects candidates based on olfactory ability, academic strength and individual talent — without requiring a scientific background — bringing greater diversity of perspectives to fragrance creation. Graduates have gone on to careers across the fragrance ecosystem, including at IFF (in Europe, Asia, the Middle East and the Americas) and in fast-moving consumer goods (FMCG) organizations, demonstrating the program’s impact. “The program trains profiles that combine creativity, olfactory culture and technical expertise,” says Nicholas Salado, general director, ISIPCA. “It supports talents that are now fully integrated into the industry, aligned with its evolving challenges and dynamics.” As the industry evolves, education, knowledge transfer and sustained innovation remain at the foundation of the IFF ISIPCA program. The 10-year anniversary milestone reflects IFF’s commitment to investing in the future of fragrance and driving innovation in olfactory experiences that make a meaningful impact for customers and consumers. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved View source version on businesswire.com: https://www.businesswire.com/news/home/20260615461626/en/ Judith Gross, VP, Communications & Branding
Department: Scent
Email: scentmediarequest@iff.com Original: IFF and ISIPCA Mark 10 Years of Joint Scent Design and Creation Master’s-Level Program

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVCMay 29, 2026 6:50 AM
Business Wire Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be a more focused company with improved cash flow characteristics, greater financial flexibility, and a stronger position to achieve its growth and profitability objectives. “This transaction represents an important strategic milestone in our ongoing portfolio optimization initiative, allowing us to further concentrate resources on our higher-growth, higher-margin segments,” said Erik Fyrwald, CEO of IFF. “By simplifying our portfolio to where we can create the greatest value, IFF will accelerate innovation, drive investment in R&D, and further integrate our biotechnology and naturals capabilities more effectively across our global platform. Importantly, by retaining a minority stake in Food Ingredients, we will continue to participate in the future upside of a strong business under dedicated ownership. This transaction creates substantial value for shareholders while positioning IFF to drive sustained, profitable long-term growth.” IFF’s Food Ingredients business is a globally recognized leader in texturants, emulsifiers, plant-based solutions, and other specialty ingredients serving multinational food and beverage customers. In 2025, the Food Ingredients business that will be divested generated nearly $3.1 billion in annual sales and approximately $430 million of EBITDA. “We are proud of the strong market positions, customer relationships, and talented team that have made Food Ingredients a strong business,” Fyrwald added. “We are confident CVC is the right owner for its next chapter and that this transaction creates significant value for IFF shareholders while giving Food Ingredients an excellent platform for future success.” “We are delighted to welcome IFF’s Food Ingredients business to CVC’s U.S. portfolio,” said Lorne Somerville, managing partner and co-head of North American private equity at CVC. “The business has built a strong position in an attractive, resilient sector supported by long-term growth trends, including increasing global food consumption and demand for clean-label products. Its global reach and proprietary technical capabilities provide a clear competitive advantage, and we see significant opportunity for continued growth.” James Christopoulos, partner at CVC, added: “The Food Ingredients management team has done an exceptional job building a business with meaningful scale and technical depth. We look forward to partnering with the team and with IFF as co-shareholders to accelerate the next phase of growth through scale and commercial expansion.” Transaction Benefits and Portfolio Positioning Over the last several years, IFF has taken decisive action to simplify its portfolio, sharpen strategic focus, and strengthen its financial foundation. Including this transaction, IFF has divested 13 non-core businesses, generating nearly $10 billion in gross proceeds, which have supported balance sheet improvement and reinvestment in the company’s highest-return businesses. Upon completion of the Food Ingredients transaction, IFF will be centered on three market-leading businesses serving attractive end markets supported by long-term megatrends in health, well-being, food, and sustainability. Each business is well positioned for strong revenue and EBITDA growth opportunities and powered by shared naturals and biosciences capabilities: Taste: Unique, technology-enabled flavor solutions for global food and beverage customers Scent: Leading positions in fine fragrance, consumer fragrance across personal and home care categories, and fragrance ingredients Health & Biosciences: Innovation-led solutions spanning probiotics, enzymes, cultures, and bioactive health ingredients With a more streamlined portfolio, IFF expects to be better positioned to accelerate innovation, improve execution, enhance free cash flow conversion, and deliver a stronger long-term financial profile. Over time, in a normalized environment, IFF expects to achieve mid-single-digit revenue growth and high-single-digit adjusted EBITDA growth, underpinned by the differentiated and innovation-led nature of its remaining business. Use of Proceeds and Financial Impact IFF expects to receive net cash proceeds of approximately $3.8 billion at closing, reflecting the rolled-over equity, customary purchase price adjustments, costs incurred to stand up and carve out the business and taxes. The company intends to prioritize use of proceeds toward: Debt reduction to accelerate deleveraging and reinforce balance sheet strength Targeted share repurchases, as authorized by the Board of Directors Reinvestment in high-return growth and high-return opportunities across the core portfolio The transaction is expected to be dilutive to adjusted EPS in the first 12 months following closing, prior to the benefits from capital deployment and any actions to address stranded overhead costs. IFF believes the strategic and financial benefits of a more focused portfolio, stronger balance sheet and improved cash generation profile outweigh the near-term earnings impact. Furthermore, the company has implemented a plan to address all of the stranded overhead costs that are a consequence of the transaction. IFF is also reiterating its previously communicated full-year 2026 guidance ranges. The company expects full year 2026 sales to be in the range of $10.5 billion to $10.8 billion and full year 2026 adjusted operating EBITDA to be in the range of $2.05 billion to $2.15 billion. IFF continues to expect comparable currency neutral sales growth to be between 1% to 4%, and comparable currency neutral adjusted operating EBITDA growth to be 3% to 8%. Transaction Details The transaction is expected to close by the end of the second quarter of 2027, subject to applicable information and/or consultation requirements and customary closing conditions, including regulatory approvals, where required. As part of the retained 10% equity interest, IFF will also hold a board seat in the new company. J.P. Morgan Securities LLC (lead) and BofA Securities are serving as IFF’s financial advisors, and Skadden, Arps, Slate, Meagher & Flom LLP & Affiliates is serving as legal advisor. Cautionary Statement Under The Private Securities Litigation Reform Act of 1995 This press release includes statements that are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management’s current assumptions, estimates and expectations, including with respect to our financial and operational outlook (sales, adjusted operating EBITDA and cash flow), portfolio optimization initiatives (including the anticipated closing date of the sale of our Food Ingredients division), pricing, productivity and cost-discipline actions, capital allocation, future operations, growth potential, strategic investments and the expected effects of foreign exchange. These statements reflect management’s present views, are based on a series of expectations, assumptions, estimates and projections about the company, are subject to change, and involve uncertainties that could cause actual results to differ materially. Certain of such forward-looking information may be identified by such terms as “expect”, “anticipate”, “believe”, “intend”, “outlook”, “may”, “will”, “would”, “estimate”, “should”, “predict”, “plan”, “project”, “could”, “potential”, “seek”, “target”, “continue”, “future”, and similar terms or variations thereof. These statements are not guarantees of future performance and are subject to risks and uncertainties that could lead to materially different outcomes. Such risks, uncertainties and other factors include, among others, the following: (1) demand trends, competitive dynamics and customer concentration in our end markets; (2) execution of our strategic transformation and other strategic transactions, divestitures, acquisitions, collaborations and joint ventures; (3) working capital and inventory management; (4) outcomes of legal claims, disputes, regulatory investigations and litigation; (5) tariffs and trade actions, supply chain disruptions and macro events, including geopolitical developments, climate events, natural disasters, public health crises; (6) 4 volatility in input costs (such as raw materials, transportation and energy); (7) attraction, retention and turnover of key employees and executives; (8) product innovation, time-to-market, product safety and quality; (9) cybersecurity incidents, artificial intelligence related risks, data privacy and compliance with data protection laws; (10) exposure to emerging markets, foreign currency fluctuations and international regulatory and political risks; (11) capital allocation, dividend policy and potential impairments of tangible or intangible assets; (12) our indebtedness, credit rating, liquidity, and access to capital; (13) pension and postretirement obligations; (14) compliance with federal, state, local and international rules and regulations, and regulatory, environmental, anti-corruption and sanctions laws and related ethical business practices; (15) protection and enforcement of intellectual property; (16) changes in tax laws and policies, tax audits and outcomes, including potential tax liabilities related to prior transactions; and (17) changes in federal, state, local and international rules and regulations. The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. Important factors are described under “Risk Factors” in our most recent Annual Report on Form 10-K and in our subsequent filings with the SEC, and those disclosures are incorporated herein by reference. We intend our forward-looking statements to speak only as of the time of such statements and do not undertake or plan to update or revise them as more information becomes available or to reflect changes in expectations, assumptions or results, whether as a result of new information, future events or otherwise. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this press release or included in our other periodic reports filed with the SEC could materially and adversely impact our operations and our future financial results. Any public statements or disclosures made by us following this press release that modify or impact any of the forward-looking statements contained in or accompanying this press release will be deemed to modify or supersede such outlook or other forward-looking statements in or accompanying this press release. Use of Non-GAAP Financial Measures We provide in this press release non-GAAP financial measures, including: (i) comparable currency neutral sales; and (ii) adjusted operating EBITDA and comparable currency neutral adjusted operating EBITDA. Our non-GAAP financial measures are defined below. Currency Neutral metrics eliminate the effects that result from translating non-U.S. currencies to U.S. dollars. We calculate currency neutral numbers by translating current year invoiced sale amounts at the exchange rates used for the corresponding prior year period. We use currency neutral results in our analysis of segment performance. We also use currency neutral numbers when analyzing our performance against that of our competitors. Comparable results exclude the impact of divestitures. Adjusted operating EBITDA and adjusted operating EBITDA margin exclude depreciation and amortization, interest expense, other expense, net, and certain non-recurring or unusual items that are not part of recurring operations such as impairment of goodwill, restructuring and other charges, divestiture costs, strategic initiatives costs, regulatory costs and other items. These non-GAAP measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, as well as the impact of exchange rate fluctuations. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company’s results under GAAP and may not be comparable to other companies’ calculation of such metrics. The Company cannot reconcile its expected adjusted operating EBITDA under “Use of Proceeds and Financial Impact” without unreasonable effort because certain items that impact net income and other reconciling metrics are out of the Company's control and/or cannot be reasonably predicted at this time. These items include but are not limited to divestiture costs, gains (losses) on business disposals, and regulatory costs. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. About CVC CVC is a leading global private markets manager with a network of 29 office locations throughout EMEA, the Americas, and Asia, with approximately €209 billion of assets under management. CVC has seven complementary strategies across private equity, secondaries, credit and infrastructure, for which CVC funds have secured commitments of over €257 billion from some of the world's leading pension funds and other institutional investors. Funds managed or advised by CVC’s private equity strategy are invested in approximately 150+ companies worldwide, which have combined annual sales of over €240 billion and employ over 660,000 people. For further information about CVC please visit: https://www.cvc.com/. Follow us on LinkedIn. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260529975821/en/ Media Relations:
Jennifer McGowan
848.358.1680
Media.request@iff.com Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com Original: IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC

LMR by IFF Inaugurates New Experimental Field in GrasseMay 28, 2026 5:00 AM
Business Wire Furthering IFF’s leadership in natural ingredients for perfumery. LMR Naturals by IFF—a global leader in natural ingredients for perfumery, cosmetics and flavors—today inaugurated its new experimental field, Domaine des Naturels LMR. The field is dedicated to advancing research in natural ingredients, preserving Grasse’s agricultural heritage and expanding education in naturals. The inauguration, attended by Grasse Mayor Jérôme Viaud, a long-standing supporter of the perfume industry, underscores IFF and LMR’s ongoing commitment to the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527694524/en/At Domaine des Naturels LMR, R&D experts research new natural species, variety breeding, cultivation methods and production techniques. “This inauguration reflects over two decades of continuous investment in Grasse and in naturals,” said Ana Paula Mendonça, president, Scent, IFF. “With Domaine des Naturels LMR, we are bringing together innovation, preservation and knowledge sharing to shape the next chapter of natural ingredients, powered by deep scientific expertise and a truly global innovation network. What matters most is what this unlocks for our customers: more creative freedom, more distinctive ingredients, and ultimately true differentiation.” Driving sustainable innovation in naturals
The 1.8-hectare experimental field operates as an integrated research and development platform. Located near LMR’s Grasse headquarters and its high-end creation site, L’Atelier du Parfumeur, Domaine des Naturels LMR enables a seamless approach from seed to fragrance. Sabrya Meflah, president of fine fragrance, Scent, IFF, said, “The Domaine des Naturels LMR is a fantastic creative playground for our artists of perfumery to find inspiration and invent the signatures of tomorrow, building on our unique Grasse and global innovation ecosystem.” Acquired by IFF in 2025, the field builds on the legacy of pioneering farmer Constant Viale, its former owner. Domaine des Naturels LMR maintains a collection of endemic species, including rose, jasmine, tuberose, iris, narcissus and olive trees. Combining traditional cultivation methods with advanced agronomic approaches, LMR continues to protect and develop Grasse’s distinctive know-how. Terraced farming, organic practices and biodiversity initiatives help preserve both the landscape and its ecological balance. The experimental field allows local teams to explore plant varieties, refine cultivation techniques and assess bio-based inputs under real-world conditions. By integrating agronomy, extraction and perfumery—supported by a multidisciplinary team of more than 10 botanical experts—LMR enhances its ability to design, validate and scale distinctive natural raw materials while supporting more resilient agricultural systems. With a comprehensive approach to sustainability, the field includes diversified water sourcing, support for pollinators and the development of habitats for local wildlife, further strengthening LMR’s long-standing commitment to environmental stewardship. Stewardship and education
Domaine des Naturels LMR also serves as an immersive environment dedicated to natural ingredients education, offering customers, partners and perfumers direct insight into the realities of sourcing and cultivating natural materials. The site will gradually host the LMR Naturals Academy, with training programs and hands-on experiences to deepen expertise and ensure the transmission of this specialized knowledge. “By bringing together innovation, heritage and education, LMR Naturals by IFF continues to shape what comes next for naturals,” said Bertrand de Préville, general manager of LMR Naturals by IFF. “We’re anchored in Grasse, connected to a global network and driven by a long-term vision.” Since acquiring LMR Naturals in 2000, IFF has steadily invested in Grasse. Building on the pioneering vision of LMR founder Monique Rémy, this sustained commitment continues to elevate standards in natural ingredients by blending science, agriculture and the art of perfumery. It also anchors Grasse within a global research network spanning Brazil, the United States, Asia and beyond, enabling knowledge generated at Domaine des Naturels LMR to extend across IFF’s 14 innovation platforms worldwide. About LMR Naturals by IFF
Founded in 1983 by Monique Rémy and acquired by IFF in 2000, LMR Naturals is a trademarked capability within IFF dedicated to the development of high-quality, innovative and sustainably sourced natural ingredients. LMR Naturals supports perfumers worldwide with a broad portfolio of naturals across fine fragrance, beauty, personal care, home care and flavorists with taste applications. For more information, visit https://www.iff.com/scent/lmr-naturals/. Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved View source version on businesswire.com: https://www.businesswire.com/news/home/20260527694524/en/ Judith Gross, VP, Communications & Branding
Department: Scent
Email: scentmediarequest@iff.com Original: LMR by IFF Inaugurates New Experimental Field in Grasse

IFF???????????·???????·???????May 11, 2026 4:34 PM
Business Wire ?????????????????·?????????? (???????) -- ?????????????????????&??????????????????????????IFF(NYSE: IFF)?????????????·???????·????(Vanilla Innovation Center)??????????????????????????IFF??????????????????????????????????????????????????????????? ?????????????????????????????????????????????:https://www.businesswire.com/news/home/20260508548122/ja/IFF's Vanilla Innovation Center in Madagascar ????????????IFF???????·??????????????????????????????IFF Taste??????·???????&??????????????????????·????????????????????????????????????????????????????????????????????????????????????????????????????????? ?????????????????????????????????????????????????????????650?????????????????????????????????????????????1???????????????????????????????????IFF?????????????????????????????????????????????????????????????????????????? ?????????????????1??????????????????????????(??·??·??)??????????????????????????????????????????????????????????????????IFF??????????????????????????????????????????????????????????????????????????????????????? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ???·???????·?????????·???????????? ????????????????????????????????????????????IFF????????????·??????????????????? ???????????????????????????????????????????????????????????? ??????????????????????????????????????????????????????????????????????????????????????????????????????? ???????????????????????????????????????????????????The Bloomery? ???·???????·????????????????????????????????????RE-MASTER VANILLA™??????????????????????????????????????????????????????????????????????????????????·???????????????? ??????????????????????????????????IFF Taste??????????????????????·???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ????????????IFF??????·???·?????????????????????????????????????????????????????????????????????????IFF??????????????????????????????????????????????????????????????????????????????????????????????????1??????????????????????????????????? ????IFF? IFF(NYSE: IFF)?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????iff.com?LinkedIn?Instagram?Facebook ???????? © 2026 International Flavors & Fragrances Inc. IFF?????????????????? ????????????????????????BtoB????????????????????????????IFF???????????????????IFF?????????????????????????????????????IFF??????????????????????????????????????????????????????????????IFF????????????IFF??IFF????????????????????????????????????????????IFF???????????????????????????????????????????????????????????????????????????????????????????????????????·?????????????????????????? ?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? businesswire.com????????????:https://www.businesswire.com/news/home/20260508548122/ja/ Media Relations:
Lynette Wong
PR and Social Media Manager
Lynette.wong@iff.com
+65 8093 0122 Original: IFF???????????·???????·???????

IFF inaugure un Centre d'innovation pour la vanille à MadagascarMay 11, 2026 4:34 PM
Business Wire Faire progresser l'innovation en matière d'arômes grâce à la science sur les lieux de production de la vanille IFF (NYSE : IFF), leader mondial dans les secteurs des arômes, des parfums, des ingrédients alimentaires, de la santé et des biosciences, a annoncé aujourd'hui l'ouverture de son Centre d'innovation pour la vanille à Madagascar, confirmant ainsi la place de la vanille comme tonalité stratégique et prioritaire pour IFF et renforçant sa capacité d'innovation à la source. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20260508750435/fr/IFF's Vanilla Innovation Center in Madagascar « L’ouverture de ce centre marque une étape importante dans notre approche de l'innovation en matière de vanille », a déclaré Adam Janczuk, Ph.D., vice-président senior chargé de la recherche, de la création du design de la division « Taste » (Saveur), chez IFF. « En renforçant notre présence à la source, nous tissons des liens plus étroits entre science, créativité et développement durable, ce qui nous permet de faire face aux changements climatiques, de garantir la qualité et de créer de la valeur tout au long de la chaîne d’approvisionnement. » Situé à Toamasina, principal port de Madagascar, à proximité des zones de production de vanille et des sites de transformation post-récolte, ce centre de 650 mètres carrés regroupe en un seul lieu les analyses de laboratoire, l'extraction, la création de parfums et d'arômes, ainsi que le développement d'applications. En intégrant ces capacités au plus près de la production, IFF peut mieux appréhender la variabilité naturelle et traduire les insights terrain en solutions sur mesure auprès de ses clients du monde entier. La vanille, l'un des ingrédients naturels les plus complexes au monde, dépend du climat, des méthodes de traitement post-récolte et de l'affinage. L'espace d'innovation d'IFF lui permet de suivre le parcours de cet ingrédient, de son extraction à la source et des tests sur le terrain, en passant par des analyses de laboratoire de pointe jusqu'à la création des arômes. Ce processus fluide permet d'approfondir la connaissance de la matière première, de raccourcir les cycles de développement et de proposer des solutions tenant compte des conditions réelles de production. Innover à la source développe la durabilité et la résilience de l'ensemble de la chaîne d'approvisionnement et de valeur de la vanille. La proximité des zones de production favorise une collaboration plus étroite avec les réseaux de producteurs, une meilleure traçabilité et un approvisionnement éthique, ainsi qu'une réactivité plus rapide aux changements climatiques. Ce lien direct entre les conditions de culture et la conception des arômes renforce les fondements de l'innovation et permet ainsi d'offrir une vanille au goût plus agréable, à la qualité et à l'approvisionnement plus constants, afin que les clients puissent proposer en toute confiance des expériences vanillées uniques sur le marché. Le Centre d'innovation pour la vanille comprend : Des capacités d'analyse en laboratoire qui appliquent des protocoles de détection des contaminants et des maladies garantissant l'intégrité du produit, ainsi que le profilage moléculaire afin de décoder et développer des signatures IFF distinctives Des sites d'extraction dotés d'équipements modulables permettant d'étudier les différents types de vanille et d'optimiser les variables d'extraction et de post-récolte Une division de création d'arômes permettant de réaliser des profils régionaux personnalisés, notamment un laboratoire d'application pour le secteur laitier, la boulangerie-confiserie, afin de valider les performances dans des prototypes destinés au marché La Bloomery, une serre de recherche qui contient diverses variétés de vanille et soutient les futures recherches sur les performances variétales et les techniques post-récolte Le Centre d'innovation de la vanille fonctionne également comme une plaque tournante de partage des connaissances et de développement des compétences. En collaboration avec l'équipe dédiée RE-MASTER VANILLA™, il propose des formations pratiques, des ateliers et des programmes de laboratoire qui rassemblent des experts, des clients et des équipes locales, favorisant ainsi les meilleures pratiques et renforçant les capacités d'innovation dans le secteur de la vanille. « Ce centre a été conçu pour passer du stade d'insights à des actions concrètes », a déclaré Marcus Pesch, vice-président de la recherche et développement de la division « Taste » (Saveur), chez IFF. « En regroupant la science, la création d'arômes et le développement d'applications à la source, nous pouvons collaborer plus étroitement avec nos clients, gagner en rapidité et en constance, et proposer des solutions prêtes à être commercialisées qui restent ancrées dans les réalités de la production de vanille. » Intégrée au réseau mondial de vanille d’IFF, l’usine de Madagascar complète les capacités existantes en matière d’approvisionnement, d’extraction, de conception d’arômes et de développement d’applications. Les découvertes provenant de ce centre se traduiront par de nouveaux outils, insights et compétences pour les créatifs d’IFF. Les arômes pourront être ainsi élaborés dans chaque région en fonction des préférences des consommateurs locaux, tout en contribuant à un avenir plus résilient et plus durable pour l’un des ingrédients naturels les plus précieux au monde. Bienvenue chez IFF Chez IFF (NYSE : IFF), nous mettons de la joie dans la vie grâce à la science, à la créativité et à l’engagement. Leader mondial du goût, des saveurs, des ingrédients alimentaires, de la santé et des biosciences, nous innovons pour l’avenir. Chaque jour, nous proposons des solutions innovantes et durables qui subliment les produits préférés des consommateurs, contribuant ainsi au bien-être, à l’éveil des sens et à l’épanouissement personnel. Pour en savoir plus, rendez-vous sur iff.com, LinkedIn, Instagram et Facebook. © 2026 International Flavors & Fragrances Inc. IFF est une marque déposée. Tous droits réservés. Ces informations sont destinées aux fabricants (B2B) de produits et compléments alimentaires. Elles ne s'adressent pas aux consommateurs finaux. Elles sont issues de nos propres travaux de recherche et développement et sont, à notre connaissance, fiables. Toutefois, rien dans ce document ne constitue une garantie concernant les produits d'IFF ou de ses filiales, ni les informations qui y sont contenues. IFF décline toute responsabilité quant aux risques liés à l'utilisation de ses produits ou des informations présentées, les conditions d'utilisation échappant à notre contrôle. Les déclarations relatives à l'utilisation possible des produits d'IFF ou de ses filiales ne constituent en aucun cas une recommandation d'utilisation susceptible d'enfreindre les droits de brevet, la réglementation ou les restrictions légales. Il appartient aux fabricants de vérifier la réglementation locale applicable à toute allégation en fonction de l'utilisation prévue de leur produit. Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence. Consultez la version source sur businesswire.com : https://www.businesswire.com/news/home/20260508750435/fr/ Relations médias :
Lynette Wong
Responsable des relations publiques et des réseaux sociaux
Lynette.wong@iff.com
+65 8093 0122 Original: IFF inaugure un Centre d'innovation pour la vanille à Madagascar

IFF eröffnet Vanilla Innovation Center in MadagaskarMay 11, 2026 2:32 PM
Business Wire Mit dem Center soll wissenschaftlich fundierte Aromeninnovation dort vorangetrieben werden, wo Vanille angebaut wird IFF (NYSE: IFF) — ein Weltmarktführer für Aromen, Duftstoffe, Lebensmittelzutaten sowie Gesundheits- und Biowissenschaften — hat heute die Eröffnung seines Vanilla Innovation Center in Madagaskar bekannt gegeben und damit Vanille als strategischen und prioritären Schwerpunkt für IFF bekräftigt sowie seine Innovationsfähigkeit direkt am Ursprungsort gestärkt. Diese Pressemitteilung enthält multimediale Inhalte. Die vollständige Mitteilung hier ansehen: https://www.businesswire.com/news/home/20260508089312/de/IFF's Vanilla Innovation Center in Madagascar „Die Eröffnung des Centers markiert einen wichtigen Meilenstein für unseren Ansatz im Bereich der Vanille-Innovation“, so Adam Janczuk, Ph.D., Senior Vice President, Research, Creation and Design, Taste, IFF. „Indem wir unsere Präsenz an den Anbauorten verstärken, verbinden wir Wissenschaft, Kreativität und Nachhaltigkeit enger miteinander, reagieren auf klimatische Veränderungen, sichern die Qualität und schaffen Mehrwert entlang der gesamten Lieferkette.“ Das 650 Quadratmeter große Center befindet sich in Toamasina, dem wichtigsten Seehafen Madagaskars, in unmittelbarer Nähe zu den Vanilleanbaugebieten und den Einrichtungen zur Nachernteverarbeitung. Unter dem Dach dieses Centers vereint IFF Laboranalysen, Extraktion, die Entwicklung von Duft- und Aromastoffen sowie die Anwendungsentwicklung an einem einzigen Standort. Indem diese Kompetenzen in direkter Nachbarschaft zum Anbaugebiet angesiedelt werden, kann IFF die natürlichen Schwankungen besser verstehen und die vor Ort gewonnenen Erkenntnisse in individuell auf Kunden in aller Welt zugeschnittene Lösungen übersetzen. Vanille gehört zu den komplexesten natürlichen Inhaltsstoffen der Welt, da das Klima, die Nacherntebehandlung und die Trocknungsmethoden die Qualität stark beeinflussen. Der Innovationsbereich unterstützt die Möglichkeiten von IFF, den Weg des Inhaltsstoffs von der Gewinnung am Ursprungsort und Feldtests über fortschrittliche Laboranalysen bis hin zur Entwicklung von Aromen zu verfolgen und bietet so einen durchgängigen Weg zur Vertiefung des Materialverständnisses, zur Verkürzung der Entwicklungszyklen und zur Erarbeitung von Lösungen, die auf den tatsächlichen Anbaubedingungen basieren. Innovationen am Ursprungsort fördern die Nachhaltigkeit und Resilienz der gesamten Liefer- und Wertschöpfungskette für Vanille. Die Nähe zu den Anbaugebieten erlaubt eine engere Zusammenarbeit mit Bauernnetzwerken, eine bessere Rückverfolgbarkeit und ethische Beschaffung sowie eine schnellere Anpassung an klimatische Veränderungen. Diese direkte Verbindung zwischen den Anbaubedingungen und der Entwicklung des Aromas stärkt die Basis für Innovationen und führt zu einer geschmacklich besseren Vanille mit höherer Konsistenz in Bezug auf Qualität und Beschaffung. Gleichzeitig unterstützt sie Kunden dabei, den Markt mit einzigartigen Vanilleerlebnissen zu versorgen. Das Vanilla Innovation Center verfügt über: Laboranalysefunktionen, die Protokolle zur Erkennung von Verunreinigungen und Krankheitserregern anwenden, um die Produktintegrität sicherzustellen, sowie molekulares Profiling zur Entschlüsselung und Entwicklung charakteristischer IFF-Signaturen Extraktionsanlagen mit skalierbaren Riggs zur Erforschung verschiedener Vanillesorten und zur Optimierung der Extraktions- und Nachernteparameter Eine Einheit zur Aromenentwicklung, mit der sich auf die jeweiligen Regionen zugeschnittene Profile erstellen lassen, einschließlich eines Anwendungslabors für Milchprodukte, Backwaren und Süßwaren zur Überprüfung der Leistungsfähigkeit anhand von marktnahen Prototypen The Bloomery, ein Forschungsgewächshaus, in dem verschiedene Vanillesorten vorgestellt werden und das die zukünftige Erforschung der Sortenleistung sowie von Nachernteverfahren unterstützt Darüber hinaus dient das Vanilla Innovation Center als Zentrum für Wissensaustausch und Kompetenzaufbau. Gemeinsam mit dem engagierten RE-MASTER VANILLA™-Team veranstaltet es praxisorientierte Schulungen, Workshops und Laborprogramme, die Experten, Kunden und lokale Teams zusammenbringen — um bewährte Verfahren zu fördern und die Innovationskompetenzen im Bereich Vanille zu stärken. „Dieses Center wurde geschaffen, um Erkenntnisse in die Tat umzusetzen“, so Marcus Pesch, Vice President, Research and Development, Taste, IFF. „Indem wir Wissenschaft, Kreation von Aromen und Anwendungsentwicklung direkt am Ursprungsort zusammenführen, können wir kooperativer mit unseren Kunden zusammenarbeiten, Geschwindigkeit und Konsistenz verbessern und marktreife Lösungen bereitstellen, die unter Berücksichtigung der realen Bedingungen der Vanilleproduktion entwickelt wurden.“ Die vollständig in das globale Vanille-Netzwerk von IFF integrierte Anlage in Madagaskar ergänzt die bestehenden Kompetenzen in den Bereichen Beschaffung, Extraktion, Aromendesign und Anwendungsentwicklung. Die dort gewonnenen Erkenntnisse werden in neue Tools, Einblicke und Kompetenzen für die Kreativteams von IFF übersetzt, sodass Aromen in jeder Region entsprechend den lokalen Verbraucherpräferenzen entwickelt werden können — und gleichzeitig eine widerstandsfähigere und nachhaltigere Zukunft für einen der weltweit wertvollsten natürlichen Inhaltsstoffe gefördert wird. Willkommen bei IFF Wir bei IFF (NYSE: IFF) begeistern mit Wissenschaft, Kreativität und Herz. Als Weltmarktführer für Geschmack, Duft, Lebensmittelzutaten, Gesundheit und Biowissenschaften entwickeln wir Innovationen für die Zukunft. Wir liefern tagtäglich bahnbrechende, nachhaltige Lösungen, die von Menschen geliebte Produkte noch besser machen. So fördern wir das Wohlbefinden, erfreuen die Sinne und bereichern das Leben. Erfahren Sie mehr unter iff.com, LinkedIn, Instagram und Facebook. © 2026 by International Flavors & Fragrances Inc. IFF ist eine eingetragene Marke. Alle Rechte vorbehalten. Diese B2B-Informationen richten sich an Hersteller von Lebensmitteln und Nahrungsergänzungsmitteln und sind nicht für den Endverbraucher bestimmt. Sie basieren auf unseren eigenen Forschungs- und Entwicklungsarbeiten und sind unserer Ansicht nach zuverlässig. Die vorliegenden Informationen sind jedoch keine Garantie oder Gewährleistung in Bezug auf Produkte von IFF oder dessen verbundenen Unternehmen, und IFF übernimmt keinerlei Haftung oder Risiko im Zusammenhang mit der Verwendung seiner Produkte oder der vorliegenden Informationen, da die Nutzungsbedingungen außerhalb unserer Kontrolle liegen. Aussagen über die mögliche Verwendung von Produkten von IFF oder seinen verbundenen Unternehmen sind nicht als Empfehlungen für eine Verwendung zu verstehen, die gegen Patentrechte, Vorschriften oder gesetzliche Beschränkungen verstoßen würde. Hersteller sollten sich über die lokalen Vorschriften hinsichtlich etwaiger Angaben entsprechend dem Verwendungszweck ihres Produkts informieren. Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab. Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260508089312/de/ Ansprechpartner für Medien:
Lynette Wong
PR and Social Media Manager
Lynette.wong@iff.com
+65 8093 0122 Original: IFF eröffnet Vanilla Innovation Center in Madagaskar

IFF Opens Vanilla Innovation Center in MadagascarMay 11, 2026 8:15 AM
Business Wire Advancing science-led flavor innovation where vanilla is grown IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health & bioscience—today announced the opening of its Vanilla Innovation Center in Madagascar, reinforcing vanilla as a strategic and priority tonality for IFF and strengthening its ability to innovate at origin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260508110162/en/IFF's Vanilla Innovation Center in Madagascar “The opening of the center marks an important step in how we approach vanilla innovation,” said Adam Janczuk, Ph.D., senior vice president, research, creation and design, Taste, IFF. “By strengthening our presence at origin, we connect science, creativity and sustainability more closely, responding to climate changes, safeguarding quality and creating value across the supply chain.” Located in Toamasina, Madagascar’s principal seaport, near vanilla growing areas and post-harvest processing activities, the 650-square-meter center brings together lab analysis, extraction, scent and flavor creation, and application development in a single site. By embedding these capabilities close to the crop, IFF can better understand natural variability and translate on-the-ground insights into tailored solutions for customers globally. As one of the world’s most complex natural ingredients, vanilla is shaped by climate, post-harvest handling and curing methods. The innovation space supports IFF’s ability to follow the ingredient’s journey from origin extraction and in-field testing, through advanced lab analysis to flavor creation—providing a seamless path that deepens material understanding, shortens development cycles and enables solutions informed by real crop conditions. Innovating at origin strengthens sustainability and resilience across the vanilla supply and value chain. Proximity to growing areas enables closer collaboration with farmer networks, improved traceability and ethical sourcing, and a faster response to climate-related changes. This direct connection between growing conditions and flavor design strengthens the foundation for innovation, delivering better-tasting vanilla with greater consistency in quality and supply, while helping customers bring distinctive vanilla experiences to market with confidence. The Vanilla Innovation Center features: Lab analysis capabilities that apply contaminant and disease-detection protocols to safeguard product integrity, alongside molecular profiling to decode and develop distinctive IFF signatures Extraction facilities with scalable rigs to explore vanilla types and optimize extraction and post-harvest variables Flavor creation unit that enables tailored regional profiles, including Application Lab capabilities for dairy, bakery and confectionery to validate performance in real market prototypes The Bloomery, a research greenhouse showcasing diverse vanilla varieties and supporting future exploration of varietal performance and post-harvest techniques The Vanilla Innovation Center also serves as a hub for knowledge sharing and capability building. Together with the dedicated RE-MASTER VANILLA™ team, it delivers hands-on training, workshops and laboratory programs that bring together experts, customers and local teams—advancing best practices and strengthening vanilla innovation capabilities. “This center is built to turn insight into action,” said Marcus Pesch, vice president, research and development, Taste, IFF. “By bringing science, flavor creation and application development together at origin, we can work more collaboratively with customers, improve speed and consistency, and deliver solutions that are market-ready and grounded in the realities of vanilla production.” Fully integrated into IFF’s global vanilla network, the Madagascar facility complements existing capabilities across sourcing, extraction, flavor design and application development. Discoveries generated at the hub will translate into new tools, insights and capabilities for IFF’s creation teams. This enables flavors to be crafted in each region according to local consumer preferences, while supporting a more resilient and sustainable future for one of the world’s most valued natural ingredients. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. This is business-to-business information intended for food and supplement producers and is not intended for the final consumer. This information is based on our own research and development work and is, to the best of our knowledge, reliable. However, nothing herein shall constitute a guarantee or warranty with respect to products of IFF or its affiliates or information contained herein and IFF does not assume any liability or risk involved in the use of its products or the information contained herein, as conditions of use are beyond our control. Statements concerning possible use of products of IFF or its affiliates are not to be construed as recommendations for any use which would violate any patent rights, regulations or statutory restrictions. Manufacturers should check local regulatory status of any claims according to the intended use of their product. View source version on businesswire.com: https://www.businesswire.com/news/home/20260508110162/en/ Media Relations:
Lynette Wong
PR and Social Media Manager
Lynette.wong@iff.com
+65 8093 0122 Original: IFF Opens Vanilla Innovation Center in Madagascar

LMR Naturals präsentiert seine Führungsrolle im Bereich natürlicher Inhaltsstoffe auf der SIMPPAR, der internationalen Fachmesse für Rohstoffe der ParfümerieMay 8, 2026 10:07 AM
Business Wire Förderung nachhaltiger, hochwertiger Naturstoffe durch ganzheitliche Verantwortung LMR Naturals by IFF – ein weltweit führender Anbieter von natürlichen Inhaltsstoffen für Parfümerie, Kosmetik und Aromen – wird seine neuesten Innovationen auf der Internationalen Fachmesse für Rohstoffe der Parfümerie (SIMPPAR) vom 26. bis 27. Mai in Grasse vorstellen. Während der Branchenveranstaltung wird IFF neue Ergänzungen seiner LMR Hearts-Kollektion präsentieren und dabei sein Know-how im Bereich Naturstoffe sowie seine wegweisende Wissenschaft hervorheben. Diese Pressemitteilung enthält multimediale Inhalte. Die vollständige Mitteilung hier ansehen: https://www.businesswire.com/news/home/20260506873616/de/Bernard Blerot, VP R&D Naturals at IFF, smelling geranium in a botanical research laboratory. „Verantwortungsvolle Innovation stand bei LMR schon immer im Mittelpunkt“, sagte Bertrand de Préville, Geschäftsführer von LMR. „Unsere Stärke liegt in unserer Fähigkeit, das gesamte Spektrum natürlicher Technologien zu beherrschen, um die Kreativität der Parfümeure zu unterstützen. Wir verbinden Natur, Wissenschaft und Kreativität, um nachhaltiges Wachstum voranzutreiben und unseren Kunden weltweit einen Mehrwert zu bieten.“ Vier neue LMR Hearts auf der SIMPPAR vorgestellt
Die neuen LMR Hearts von LMR Naturals , die jeweils durch langfristige Beschaffungspartnerschaften, nachhaltige landwirtschaftliche Praktiken sowie präzise molekulare Destillation und Fraktionierung am LMR-Standort in Grasse entwickelt wurden, umfassen: Lavandin Heart France, mit einem ausgeprägten Cumarin-Profil für eine üppigere Note Armoise Heart Morocco, das reichhaltiger an Thujonen ist und eine frischere, besser sich ausbreitende Wirkung hat Ylang Heart Madagascar, das ein einzigartiges „Extra-Grade“-Profil mit cremigen und sonnigen Duftnoten bietet Geranium Heart Egypt, das sich durch ein fruchtiges Litschi-Profil ohne die üblichen minzigen Aspekte auszeichnet „Diese neuen Hearts veranschaulichen, wie Wissenschaft und Beschaffungskompetenz natürliche Inhaltsstoffe aufwerten können“, sagte Bernard Blerot, VP R&D Naturals bei IFF. „Sie bieten eine höhere Reinheit und Fokussierung bei gleichzeitiger Wahrung der Integrität des natürlichen Rohstoffs und demonstrieren die wissenschaftliche Kompetenz unseres Teams.” Innovationen bei natürlichen Inhaltsstoffen
Die vier auf der SIMPPAR vorgestellten LMR-Herzen folgen auf mehrere Innovationen bei natürlichen Inhaltsstoffen, die bereits früher in diesem Jahr vorgestellt wurden, darunter: Tonka-Bohne CO2 Absolute, hergestellt mittels erneuerbarer überkritischer CO2-Extraktion im LMR-Werk in Aumont-Aubrac, Frankreich Osmanthus-Absolue Fruity China, eine fruchtbetonte Interpretation, die als firmeneigener Naturstoff für IFF-Parfümeure entwickelt wurde Pulpextract™ Passionsfrucht und Himbeere, zwei neue Fruchtinhaltsstoffe mit lebendigen, saftigen Profilen, exklusiv für IFF-Parfümeure Jeder neue natürliche Inhaltsstoff entspricht dem anhaltenden Interesse der Verbraucher an fruchtigen und Gourmand-Duftnoten, die laut IFF-Erkenntnissen einen bedeutenden und beständigen Anteil an Damendüften ausmachen. LMR ist bestrebt, die Palette der Parfümeure kontinuierlich um Naturstoffe zu erweitern, die Innovation, Nachhaltigkeit und olfaktorischen Ausdruck vereinen. Diese Markteinführungen untermauern IFFs 25-jähriges Engagement für LMR und nachhaltige, natürliche Rohstoffe und integrieren wegweisende Wissenschaft – vom Saatgut über den Anbau bis hin zur Ernte und Extraktion – in großem Maßstab in die Kreativität der Parfümeure. Ende Mai wird IFF dieses integrierte Ökosystem mit der Einweihung der Domaine des Naturals LMR in Grasse weiter stärken, einem speziellen Versuchsfeld für Rohstoffe, das das langfristige Engagement des Unternehmens für die Zukunft von Naturstoffen und Innovation unterstreicht. Die integrierte Plattform für natürliche Inhaltsstoffe von LMR Naturals vereint langfristige Beschaffungspartnerschaften, agronomisch ausgerichtete Nachhaltigkeitsprogramme und intern betriebene Extraktionstechnologien – darunter molekulare Destillation, Fraktionierung, CO2-Extraktion und mehr. Durch den Einsatz dieser Technologien an eigenen Standorten können sich LMR Naturals und sein internes Expertenteam auf die von Parfümeuren ausgewählten, besonders begehrten Duftmoleküle konzentrieren. Mit diesem Ansatz liefert LMR Naturals rückverfolgbare, nachhaltige und leistungsorientierte natürliche Inhaltsstoffe für Luxusparfüms und andere Anwendungen. Über LMR Naturals by IFF
Gegründet 1983 von Monique Rémy und übernommen von IFF im Jahr 2000, ist LMR Naturals eine markenrechtlich geschützte Sparte innerhalb von IFF und widmet sich der Entwicklung hochwertiger, innovativer und nachhaltig gewonnener natürlicher Inhaltsstoffe. LMR Naturals unterstützt Parfümeure weltweit mit einem breiten Portfolio an Naturstoffen für die Bereiche Parfümerie, Kosmetik, Körperpflege, Haushaltspflege sowie Aromen für Geschmacksanwendungen. Weitere Informationen finden Sie unter https://www.iff.com/scent/lmr-naturals/. Willkommen bei IFF
Bei IFF (NYSE: IFF) schaffen wir Freude durch Wissenschaft, Kreativität und Herz. Als weltweit führendes Unternehmen in den Bereichen Geschmack, Duft, Lebensmittelzutaten, Gesundheit und Biowissenschaften entwickeln wir Innovationen für die Zukunft. Jeden Tag liefern wir bahnbrechende, nachhaltige Lösungen, die Produkte, die Menschen lieben, aufwerten – sie fördern das Wohlbefinden, begeistern die Sinne und bereichern das menschliche Erlebnis. Erfahren Sie mehr auf iff.com, LinkedIn, Instagram und Facebook. © 2026 by International Flavors & Fragrances Inc. IFF ist eine eingetragene Marke. Alle Rechte vorbehalten Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab. Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260506873616/de/ Judith Gross, VP, Communications & Branding
Abteilung: Scent
E-Mail: scentmediarequest@iff.com Original: LMR Naturals präsentiert seine Führungsrolle im Bereich natürlicher Inhaltsstoffe auf der SIMPPAR, der internationalen Fachmesse für Rohstoffe der Parfümerie

LMR Naturals???????????SIMPPAR???????????????????May 8, 2026 9:51 AM
Business Wire ??????????????????????????????? (???????) -- LMR Naturals by IFF????????????????????????????????5?26~27?????????????????????(SIMPPAR)???????????????????IFF?????????LMR Hearts????????????????????????????????????????? ?????????????????????????????????????????????:https://www.businesswire.com/news/home/20260506638319/ja/Bernard Blerot, VP R&D Naturals at IFF, smelling geranium in a botanical research laboratory. LMR?????·?????????????·??·???????????????????????????????????LMR?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? SIMPPAR?4?????LMR Hearts???
LMR Naturals????LMR Hearts????????????????????????????????LMR??????????????????·??????????????4???????? Lavandin Heart France???????·???????????????????????? Armoise Heart Morocco????????????????????????????????? Ylang Heart Madagascar??????????·????????????????????????????????? Geranium Heart Egypt?????????????????????????????????????? IFF????????????????????????????·?????????????????????????Hearts????????????????????????????????????????????????????????????????????????????????????????????????????? ????????????
SIMPPAR??????4??LMR Hearts?????????????????????????????????????????????? Tonka Bean CO2 Absolute????????LMR?Aumont-Aubrac????????????CO2?????????? Osmanthus Absolute Fruity China?IFF???????????????????????????????????? Pulpextract™ Passion Fruit and Raspberry???????????????????????IFF???????2????????? ????????????????????????????????????·??????????????????????????IFF???????????????????????????????????????????????LMR???????????????????????????????????????????????????????????????? ???????LMR??????????????IFF?25???????????????????????·??????·?????????????????????????????????????5??????IFF???????Domaine des Naturals LMR??????????????????????????????????????????????????????????????IFF???????????????????? LMR Naturals??????????????????????????????????????????????????????????CO2??????????????????????????LMR Naturals?????????????????????????????????????????????????????????????????????LMR Naturals????????????????????????????????????????????????????????? LMR Naturals by IFF????
1983??????·?????????2000??IFF?????LMR Naturals??IFF???????????????????????????????????????????????????????LMR Naturals????????????????????????????????????????????????????????????????????????????????????????????????????? ???? https://www.iff.com/scent/lmr-naturals/ ???????? IFF?????
IFF(NYSE:IFF)??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????iff.com?LinkedIn?Instagram?Facebook???????? © 2026 International Flavors & Fragrances Inc. IFF????????????·???????? ?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? businesswire.com????????????:https://www.businesswire.com/news/home/20260506638319/ja/ Judith Gross, VP, Communications & Branding
Department: Scent
Email: scentmediarequest@iff.com Original: LMR Naturals???????????SIMPPAR???????????????????

LMR Naturals mettra en avant son leadership dans le domaine des ingrédients naturels lors du SIMPPAR, le Salon international des matières premières pour la parfumerieMay 8, 2026 9:57 AM
Business Wire Promouvoir des ingrédients naturels durables et de haute qualité grâce à une gestion responsable de bout en bout LMR Naturals by IFF, leader mondial des ingrédients naturels pour la parfumerie, les cosmétiques et les arômes, présentera ses dernières innovations au Salon international des matières premières pour la parfumerie (SIMPPAR), les 26 et 27 mai à Grasse. Lors de cet événement professionnel, IFF dévoilera les nouveaux produits de sa collection LMR Hearts, mettant en avant son expertise en matière d’ingrédients naturels et sa science pionnière. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20260506287324/fr/Bernard Blerot, VP R&D Naturals at IFF, smelling geranium in a botanical research laboratory. « L’innovation responsable a toujours été au cœur de LMR », déclare Bertrand de Préville, directeur général de LMR. « Notre force réside dans notre capacité à maîtriser toute la gamme des technologies naturelles afin de soutenir la créativité des parfumeurs. Nous mettons en relation la nature, la science et la création pour favoriser une croissance durable et offrir une valeur ajoutée à nos clients à l’échelle mondiale. » Quatre nouveaux LMR Hearts présentés au SIMPPAR
Les nouveaux LMR Hearts de LMR Naturals, chacun développé grâce à des partenariats d’approvisionnement à long terme, des pratiques agricoles durables et une distillation et un fractionnement moléculaires de précision sur le site de LMR à Grasse, comprennent : Lavandin Heart France, avec un profil coumarinique prononcé pour une note plus gourmande Armoise Heart Morocco, plus riche en thujones pour un impact plus frais et plus diffus Ylang Heart Madagascar, offrant un profil olfactif unique de « qualité supérieure », crémeux et solaire Geranium Heart Egypt, présentant un profil fruité de litchi sans les aspects mentholés conventionnels « Ces nouveaux Hearts illustrent comment la science et l’expertise en approvisionnement peuvent sublimer les ingrédients naturels », déclare Bernard Blerot, vice-président R&D Naturals chez IFF. « Ils offrent une plus grande pureté et une meilleure concentration tout en préservant l’intégrité de la matière première naturelle, et témoignent de l’expertise scientifique de notre équipe. » Innovation en matière d’ingrédients naturels
Les quatre cœurs LMR lancés lors du SIMPPAR font suite à plusieurs innovations en matière d’ingrédients naturels présentées plus tôt cette année, notamment : L’absolu de fève tonka au CO2, produit par extraction au CO2 supercritique renouvelable dans l’usine LMR d’Aumont-Aubrac en France L’absolu d’osmanthus Fruity China, une interprétation fruitée développée en exclusivité pour les parfumeurs d’IFF Pulpextract™ Passion Fruit et Raspberry, deux nouveaux ingrédients fruités offrant des profils vifs et juteux, réservés aux parfumeurs d’IFF Chaque nouvel ingrédient naturel répond à l’intérêt soutenu des consommateurs pour les notes fruitées et gourmandes, qui, selon les études d’IFF, constituent une part importante et durable des parfums féminins. LMR s’efforce d’élargir en permanence la palette des parfumeurs avec des ingrédients naturels alliant innovation, durabilité et expression olfactive. Ces lancements viennent soutenir l’investissement de 25 ans d’IFF dans LMR et les matières premières naturelles et durables, en intégrant une science pionnière, de la graine et la culture à la récolte et l’extraction, à la créativité des parfumeurs à grande échelle. Fin mai, IFF renforcera encore cet écosystème intégré avec l’inauguration du Domaine des Naturals LMR à Grasse, un champ expérimental dédié aux matières premières qui souligne son engagement à long terme en faveur de l’avenir des ingrédients naturels et de l’innovation. La plateforme intégrée d’ingrédients naturels de LMR Naturals combine des partenariats d’approvisionnement à long terme, des programmes de durabilité axés sur l’agronomie et des technologies d’extraction gérées en interne, notamment la distillation moléculaire, le fractionnement, l’extraction au CO2 et bien d’autres. En exploitant ces technologies sur ses propres sites, LMR Naturals et son équipe interne d’experts peuvent se concentrer sur les molécules olfactives les plus recherchées, sélectionnées par les parfumeurs. Grâce à cette approche, LMR Naturals fournit des ingrédients naturels traçables, durables et axés sur la performance pour la parfumerie fine et d’autres applications. À propos de LMR Naturals by IFF
Fondée en 1983 par Monique Rémy et rachetée par IFF en 2000, LMR Naturals est une entité de marque déposée au sein d’IFF dédiée au développement d’ingrédients naturels de haute qualité, innovants et issus de sources durables. LMR Naturals accompagne les parfumeurs du monde entier grâce à un large portefeuille d’ingrédients naturels destinés aux parfums de luxe, aux produits de beauté, aux soins personnels, aux produits d’entretien ménager et aux arômes alimentaires . Pour plus d’informations, rendez-vous sur https://www.iff.com/scent/lmr-naturals/. Bienvenue chez IFF
Chez IFF (NYSE : IFF), nous créons de la joie grâce à la science, à la créativité et à la passion. En tant que leader mondial dans les domaines du goût, des parfums, des ingrédients alimentaires, de la santé et des biosciences, nous innovons pour l’avenir. Chaque jour, nous proposons des solutions révolutionnaires et durables qui améliorent les produits que les gens aiment, favorisent le bien-être, ravissent les sens et enrichissent l’expérience humaine. Pour en savoir plus, rendez-vous sur iff.com, LinkedIn, Instagram et Facebook. © 2026 par International Flavors & Fragrances Inc. IFF est une marque déposée. Tous droits réservés Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence. Consultez la version source sur businesswire.com : https://www.businesswire.com/news/home/20260506287324/fr/ Judith Gross, vice-présidente de la communication et de l’image de marque
Département : Parfumerie
E-mail : scentmediarequest@iff.com Original: LMR Naturals mettra en avant son leadership dans le domaine des ingrédients naturels lors du SIMPPAR, le Salon international des matières premières pour la parfumerie

LMR Naturals to Showcase Leadership in Natural Ingredients at SIMPPAR, the International Exhibition of Raw Materials for PerfumeryMay 7, 2026 3:00 AM
Business Wire Advancing sustainable, high-quality naturals through end-to-end stewardship LMR Naturals by IFF — a global leader in natural ingredients for perfumery, cosmetics and flavors — will debut its latest innovations at the International Exhibition of Raw Materials for Perfumery (SIMPPAR), May 26–27 in Grasse. During the industry event, IFF will unveil new additions to its LMR Hearts collection, highlighting its naturals expertise and pioneering science. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506065669/en/Bernard Blerot, VP R&D Naturals at IFF, smelling geranium in a botanical research laboratory. “Responsible innovation has always been central to LMR,” said Bertrand de Préville, general manager of LMR. “Our strength lies in our ability to master the full range of natural technologies to support perfumers’ creativity. We’re connecting nature, science and creation to drive sustainable growth and deliver added value to our customers at global scale.” Four New LMR Hearts Introduced at SIMPPAR
LMR Naturals’ new LMR Hearts, each developed through long-term sourcing partnerships, sustainable agricultural practices and precision molecular distillation and fractionation at LMR’s Grasse site include: Lavandin Heart France, with a strong coumarin profile for a more gourmand note Armoise Heart Morocco, which is richer in thujones for a fresher, more diffusive impact Ylang Heart Madagascar, offering a unique “extra grade”, creamy and solar olfactive profile Geranium Heart Egypt, featuring a fruity-lychee profile without conventional minty aspects “These new Hearts illustrate how science and sourcing expertise can elevate natural ingredients,” said Bernard Blerot, VP R&D Naturals at IFF. “They provide greater purity and focus while maintaining the integrity of the natural material and demonstrate our team’s scientific stewardship.” Natural Ingredients Innovation
The four LMR Hearts launched at SIMPPAR follow several natural ingredient innovations introduced earlier this year, including: Tonka Bean CO2 Absolute, produced using renewable supercritical CO2 extraction at LMR’s Aumont-Aubrac facility in France Osmanthus Absolute Fruity China, a fruit-forward interpretation developed as a captive natural for IFF perfumers Pulpextract™ Passion Fruit and Raspberry, two new fruit ingredients offering vivid, juicy profiles exclusively for IFF perfumers Each new natural ingredient responds to sustained consumer interest in fruity and gourmand fragrance notes, which IFF insights show make up a significant and enduring share of women’s fragrances. LMR strives to continuously expand the perfumer’s palette with naturals that combine innovation, sustainability and olfactive expression. These launches support IFF’s 25-year investment in LMR and sustainable, natural materials, embedding pioneering science — from seed and cultivation to harvesting and extraction — in perfumers' creativity at scale. In late May, IFF will further strengthen this integrated ecosystem with the inauguration of the Domaine des Naturals LMR in Grasse, a dedicated experimental field for raw materials that underscores its long-term commitment to the future of naturals and innovation. LMR Naturals’ integrated natural ingredients platform combines long-term sourcing partnerships, agronomy-led sustainability programs and internally operated extraction technologies — including molecular distillation, fractionation, CO2 extraction and more. By operating these technologies on its own sites, LMR Naturals and its internal team of experts can focus on the most desirable olfactive molecules as selected by perfumers. With this approach, LMR Naturals delivers traceable, sustainable and performance-driven natural ingredients for fine fragrance and other applications. About LMR Naturals by IFF
Founded in 1983 by Monique Rémy and acquired by IFF in 2000, LMR Naturals is a trademarked capability within IFF dedicated to the development of high-quality, innovative and sustainably sourced natural ingredients. LMR Naturals supports perfumers worldwide with a broad portfolio of naturals across fine fragrance, beauty, personal care, home care and flavorists with taste applications. For more information, visit https://www.iff.com/scent/lmr-naturals/. Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved View source version on businesswire.com: https://www.businesswire.com/news/home/20260506065669/en/ Judith Gross, VP, Communications & Branding
Department: Scent
Email: scentmediarequest@iff.com Original: LMR Naturals to Showcase Leadership in Natural Ingredients at SIMPPAR, the International Exhibition of Raw Materials for Perfumery

IFF Reports First Quarter 2026 ResultsMay 5, 2026 4:15 PM
Business Wire Delivered solid top and bottom line Q1 results Progressing disciplined sale process for Food Ingredients business Reaffirms Full Year 2026 Financial Guidance IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Reported (GAAP)   Adjusted (Non-GAAP)1 Sales   Income Before Taxes   EPS   Operating EBITDA   Operating EBITDA Margin   EPS ex Amortization $2.7 B   $209 M   $0.66   $568 M   20.7%   $1.25 Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, we are running a disciplined sale process for Food Ingredients to ensure we maximize value for shareholders.” First Quarter 2026 Consolidated Financial Results Reported net sales for the first quarter were $2.74 billion, a decrease of 4% versus the prior-year period. On a comparable basis2, currency neutral sales1 increased 3% versus the prior-year period with broad based growth across all businesses. Income before taxes on a reported basis for the first quarter was $209 million. Adjusted operating EBITDA1 for the first quarter was $568 million. On a comparable basis2, currency neutral adjusted operating EBITDA1 improved 8% versus the prior-year period, driven by volume growth and productivity gains. Reported earnings per share (EPS) for the first quarter was $0.66. Adjusted EPS excluding amortization1 was $1.25 per diluted share. Cash flows from operations for the first quarter were $257 million, increasing $130 million year-over-year, and free cash flow1 defined as cash flows from operations less capital expenditures totaled $92 million, increasing $144 million year-over-year. Total debt to trailing twelve months net income at the end of the first quarter was 7.2x. Net debt to credit adjusted EBITDA1 at the end of the first quarter was 2.5x. First Quarter 2026 Segment Summary: Growth vs. Prior Year   Reported (GAAP)   Comparable Currency Neutral (Non-GAAP)1 2   Adjusted (Non-GAAP)1   Comparable Currency Neutral Adjusted (Non-GAAP)1 2   Sales   Sales   Operating
EBITDA   Operating
EBITDA Taste 5%   2%   17%   18% Health & Biosciences 10%   5%   11%   7% Scent 6%   1%   3%   (2)% Food Ingredients 5%   3%   3%   12% Consolidated (4)%   3%   (2)%   8% Taste Segment On a reported basis, first quarter sales were $656 million. On a comparable basis2, currency neutral sales1 increased 2% with broad-based growth in all regions. Taste adjusted operating EBITDA1 was $153 million and adjusted operating EBITDA margin1 was 23.3% in the first quarter. On a comparable basis2, currency neutral adjusted operating EBITDA1 increased 18% led by volume growth, favorable net pricing and productivity gains. Health & Biosciences Segment On a reported basis, first quarter sales were $595 million. On a comparable basis2, currency neutral sales1 increased 5% with growth in nearly all businesses, led by Animal Nutrition and Food Biosciences. Health & Biosciences adjusted operating EBITDA1 was $153 million and adjusted operating EBITDA margin1 was 25.7% in the first quarter. On a comparable basis2, currency neutral adjusted operating EBITDA1 increased 7% primarily driven by volume growth. Scent Segment On a reported basis, first quarter sales were $651 million. On a comparable basis2, currency neutral sales1 increased 1% as growth in Consumer Fragrances and Fine Fragrances was partially offset by a decline in Fragrance Ingredients. Scent adjusted operating EBITDA1 was $148 million and adjusted operating EBITDA margin1 was 22.7% in the first quarter. On a comparable basis2, currency neutral adjusted operating EBITDA1 decreased (2)% as volume growth and productivity gains were more than offset by unfavorable price to input cost. Food Ingredients Segment On a reported basis, first quarter sales were $839 million. On a comparable basis2, currency neutral sales1 increased 3% led by volume growth in nearly all businesses. Food Ingredients adjusted operating EBITDA1 was $114 million and adjusted operating EBITDA margin1 was 13.6% in the first quarter. On a comparable basis2, currency neutral adjusted operating EBITDA1 increased 12% driven by volume growth and productivity gains. Financial Guidance The Company continues to expect full year 2026 sales to be in the range of $10.5 billion to $10.8 billion and full year 2026 adjusted operating EBITDA to be in the range of $2.05 billion to $2.15 billion. Full year guidance now includes two months (previously three months) of Soy Crush, Concentrates, and Lecithin business results with the divestiture closing on March 2, 2026 (previously expected to close on April 1, 2026). The Company continues to expect comparable currency neutral sales growth to be between 1% to 4%, and comparable currency neutral adjusted operating EBITDA growth to be 3% to 8%. Based on recent market foreign exchange rates, the Company continues to expect that foreign exchange will have an approximately 1% positive impact on sales growth and have no impact on adjusted operating EBITDA growth in 2026. The Company also continues to expect that divestitures will have an approximately 5% adverse impact on both sales and adjusted operating EBITDA growth in 2026. Audio Webcast A live webcast to discuss the Company’s first quarter 2026 financial results will be held on May 6, 2026, at 9:00 a.m. ET. The webcast and accompanying slide presentation may be accessed on the Company’s IR website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available on the Company’s website approximately one hour after the event and will remain available on IFF’s website for one year. Cautionary Statement Under The Private Securities Litigation Reform Act of 1995 This press release includes statements that are not historical facts and are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management’s current assumptions, estimates and expectations, including with respect to our financial and operational outlook (sales, adjusted operating EBITDA and cash flow), portfolio optimization initiatives (including the ongoing sale process for our Food Ingredients division), pricing, productivity and cost-discipline actions, capital allocation, future operations, growth potential, strategic investments and the expected effects of foreign exchange. These statements reflect management’s present views, are based on a series of expectations, assumptions, estimates and projections about the Company, are subject to change, and involve uncertainties that could cause actual results to differ materially. Certain of such forward-looking information may be identified by such terms as “expect”, “anticipate”, “believe”, “intend”, “outlook”, “may”, “will”, “would”, “estimate”, “should”, “predict”, “plan”, “project”, “could”, “potential”, “seek”, “target”, “continue”, “future”, and similar terms or variations thereof. These statements are not guarantees of future performance and are subject to risks and uncertainties that could lead to materially different outcomes. Such risks, uncertainties and other factors include, among others, the following: (1) demand trends, competitive dynamics and customer concentration in our end markets; (2) execution of our strategic transformation and other strategic transactions, divestitures, acquisitions, collaborations and joint ventures; (3) working capital and inventory management; (4) outcomes of legal claims, disputes, regulatory investigations and litigation; (5) tariffs and trade actions, supply chain disruptions and macro events, including geopolitical developments, climate events, natural disasters, public health crises; (6) volatility in input costs (such as raw materials, transportation and energy); (7) attraction, retention and turnover of key employees and executives; (8) product innovation, time-to-market, product safety and quality; (9) cybersecurity incidents, artificial intelligence related risks, data privacy and compliance with data protection laws; (10) exposure to emerging markets, foreign currency fluctuations and international regulatory and political risks; (11) capital allocation, dividend policy and potential impairments of tangible or intangible assets; (12) our indebtedness, credit rating, liquidity, and access to capital; (13) pension and postretirement obligations; (14) compliance with federal, state, local and international rules and regulations, and regulatory, environmental, anti-corruption and sanctions laws and related ethical business practices; (15) protection and enforcement of intellectual property; (16) changes in tax laws and policies, tax audits and outcomes, including potential tax liabilities related to prior transactions; and (17) changes in federal, state, local and international rules and regulations. The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. Important factors are described under “Risk Factors” in our most recent Annual Report on Form 10-K and in our subsequent filings with the SEC, and those disclosures are incorporated herein by reference. We intend our forward-looking statements to speak only as of the time of such statements and do not undertake or plan to update or revise them as more information becomes available or to reflect changes in expectations, assumptions or results, whether as a result of new information, future events or otherwise. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this press release or included in our other periodic reports filed with the SEC could materially and adversely impact our operations and our future financial results. Any public statements or disclosures made by us following this press release that modify or impact any of the forward-looking statements contained in or accompanying this press release will be deemed to modify or supersede such outlook or other forward-looking statements in or accompanying this press release. Use of Non-GAAP Financial Measures We provide in this press release non-GAAP financial measures, including: (i) comparable currency neutral sales; (ii) adjusted operating EBITDA and comparable currency neutral adjusted operating EBITDA; (iii) adjusted operating EBITDA margin; (iv) adjusted EPS ex amortization; (v) free cash flow; and (vi) net debt to credit adjusted EBITDA. Our non-GAAP financial measures are defined below. Currency Neutral metrics eliminate the effects that result from translating non-U.S. currencies to U.S. dollars. We calculate currency neutral numbers by translating current year invoiced sale amounts at the exchange rates used for the corresponding prior year period. We use currency neutral results in our analysis of segment performance. We also use currency neutral numbers when analyzing our performance against that of our competitors. Comparable results for the first quarter exclude the impact of divestitures. Adjusted operating EBITDA and adjusted operating EBITDA margin exclude depreciation and amortization, interest expense, other expense, net, and certain non-recurring or unusual items that are not part of recurring operations such as impairment of goodwill, restructuring and other charges, divestiture costs, strategic initiatives costs, regulatory costs and other items. Adjusted EPS ex Amortization excludes the impact of non-operational items including restructuring and other charges, divestiture costs, losses (gains) on business disposals, strategic initiatives costs, regulatory costs and other items that are not a part of recurring operations. Free Cash Flow is operating cash flow (i.e., cash flow from operations) less capital expenditures. Net debt to credit adjusted EBITDA is the leverage ratio used in our credit agreements and defined as net debt (which is debt for borrowed money less cash and cash equivalents) divided by the trailing 12-month credit adjusted EBITDA. Credit adjusted EBITDA is defined as income (loss) before interest expense, income taxes, depreciation and amortization, specified items and non-cash items. These non-GAAP measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, as well as the impact of exchange rate fluctuations. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company’s results under GAAP and may not be comparable to other companies’ calculation of such metrics. The Company cannot reconcile its expected adjusted operating EBITDA under "Financial Guidance" without unreasonable effort because certain items that impact net income and other reconciling metrics are out of the Company's control and/or cannot be reasonably predicted at this time. These items include but are not limited to divestiture costs, gains (losses) on business disposals, and regulatory costs. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. __________________ 1 Schedules at the end of this release contain reconciliations of reported GAAP to Non-GAAP metrics. See Use of Non-GAAP Financial Measures for explanations of our Non-GAAP metrics. 2 Comparable results for the first quarter exclude the impact of divestitures.   International Flavors & Fragrances Inc. Consolidated Statements of Income (Loss) (Amounts in millions except per share data) (Unaudited)     Three Months Ended March 31,     2026     2025     % Change Net sales $ 2,741   $ 2,843     (4 )% Cost of sales   1,723     1,808     (5 )% Gross profit   1,018     1,035     (2 )% Research and development expenses   166     164     1 % Selling and administrative expenses   427     461     (7 )% Amortization of acquisition-related intangibles   146     143     2 % Impairment of goodwill   —     1,153     NMF Restructuring and other charges   6     17     (65 )% Operating profit (loss)   273     (903 )   (130 )% Interest expense   44     71     (38 )% Losses on business disposals   7     —     NMF Other expense, net   13     20     (35 )% Income (loss) before taxes   209     (994 )   (121 )% Provision for income taxes   39     23     70 % Net income (loss)   170     (1,017 )   (117 )% Net income attributable to non-controlling interests   1     1     — % Net income (loss) attributable to IFF shareholders $ 169   $ (1,018 )   (117 )%             Net income (loss) per share - basic and diluted $ 0.66   $ (3.98 )                 Average number of shares outstanding - basic   256     256       Average number of shares outstanding - diluted   257     256         NMF Not meaningful     International Flavors & Fragrances Inc. Condensed Consolidated Balance Sheets (Amounts in millions) (Unaudited)     March 31,
2026   December 31,
2025     Cash and cash equivalents $ 562   $ 590 Receivables, net   1,830     1,731 Inventories   2,250     2,245 Assets held for sale   —     151 Prepaid expenses and other current assets   795     877 Total current assets   5,437     5,594         Property, plant and equipment, net   3,997     4,029 Goodwill and other intangibles, net   14,087     14,312 Other assets   1,623     1,604 Total assets $ 25,144   $ 25,539         Short-term borrowings $ 1,078   $ 1,254 Other current liabilities   2,567     2,679 Total current liabilities   3,645     3,933         Long-term debt   4,739     4,740 Non-current liabilities   2,607     2,680         Total Shareholders' equity including Non-controlling interests   14,153     14,186 Total liabilities and shareholders' equity $ 25,144   $ 25,539   International Flavors & Fragrances Inc. Consolidated Statements of Cash Flows (Amounts in millions) (Unaudited)     Three Months Ended March 31,     2026       2025   Cash flows from operating activities:       Net income (loss) $ 170     $ (1,017 ) Adjustments to reconcile to net cash provided by operating activities       Depreciation and amortization   246       236   Deferred income taxes   (15 )     (61 ) Losses on business disposals   7       —   Stock-based compensation   16       19   Pension contributions   (5 )     (5 ) Impairment of goodwill   —       1,153   Changes in assets and liabilities, net of acquisitions:       Trade receivables   (107 )     (116 ) Inventories   (33 )     (92 ) Accounts payable   176       154   Accruals for incentive compensation   (140 )     (246 ) Other assets/liabilities, net   (58 )     102   Net cash provided by operating activities   257       127   Cash flows from investing activities:       Additions to property, plant and equipment   (165 )     (179 ) Net proceeds received from business disposals   198       —   Cash (paid) received on foreign currency forward contracts   (10 )     22   Net cash provided by (used in) investing activities   23       (157 ) Cash flows from financing activities:       Cash dividends paid to shareholders   (102 )     (102 ) Net (repayments) borrowings of commercial paper (maturities less than three months)   (160 )     292   Principal payments of debt   —       (16 ) Purchases of treasury stock   (35 )     —   Other, net   (4 )     (5 ) Net cash (used in) provided by financing activities   (301 )     169   Effect of exchange rate changes on cash and cash equivalents   (7 )     40   Net change in cash and cash equivalents   (28 )     179   Cash and cash equivalents at beginning of year   590       471   Cash and cash equivalents at end of period $ 562     $ 650   The following table reconciles cash and cash equivalents between the Company's statement of cash flows for the periods ended March 31, 2026 and March 31, 2025 to the amounts reported on the Company's balance sheet: AMOUNTS IN MILLIONS March 31, 2026   December 31, 2025   March 31, 2025   December 31, 2024 Current assets               Cash and cash equivalents $ 562   $ 590   $ 613   $ 469 Cash and cash equivalents included in Assets held for sale   —     —     37     2 Cash and cash equivalents $ 562   $ 590   $ 650   $ 471 The Company had no restricted cash as of March 31, 2026 and December 31, 2025.   International Flavors & Fragrances Inc. Reportable Segment Performance (Amounts in millions) (Unaudited)     Three Months Ended March 31, 2026   Taste   Food Ingredients   Health & Biosciences   Scent   Total Net Sales $ 656     $ 839     $ 595     $ 651     $ 2,741 Cost of Sales   (375 )     (646 )     (327 )     (375 )     Research & development expenses   (43 )     (14 )     (55 )     (54 )     Selling & administrative expenses   (101 )     (99 )     (92 )     (92 )     Depreciation expense add-back (a)   16       34       32       18       Adjusted Operating EBITDA $ 153     $ 114     $ 153     $ 148     $ 568 Reconciliation of Adjusted Operating EBITDA:   Total Adjusted Operating EBITDA $ 568   Depreciation & Amortization   (246 ) Interest Expense   (44 ) Other Expense, net   (13 ) Restructuring and Other Charges (b)   (6 ) Losses on Business Disposals (d)   (7 ) Divestiture Costs (e)   (24 ) Strategic Initiative Costs (f)   (9 ) Regulatory Costs (g)   (10 ) Income Before Taxes $ 209   Segment Adjusted Operating EBITDA Margin   Taste 23.3 % Food Ingredients 13.6 % Health & Biosciences 25.7 % Scent 22.7 % Consolidated 20.7 %   International Flavors & Fragrances Inc. Reportable Segment Performance (Amounts in millions) (Unaudited)     Three Months Ended March 31, 2025   Taste   Food Ingredients   Health & Biosciences   Scent   Pharma Solutions   Total Net Sales $ 627     $ 796     $ 540     $ 614     $ 266     $ 2,843 Cost of Sales   (377 )     (609 )     (298 )     (344 )     (180 )     Research & development expenses   (40 )     (12 )     (52 )     (55 )     (5 )     Selling & administrative expenses   (94 )     (92 )     (81 )     (86 )     (32 )     Depreciation expense add-back (a)   15       28       29       15       5       Adjusted Operating EBITDA $ 131     $ 111     $ 138     $ 144     $ 54     $ 578 Reconciliation of Adjusted Operating EBITDA:   Total Adjusted Operating EBITDA $ 578   Depreciation & Amortization   (236 ) Interest Expense   (71 ) Other Expense, net   (20 ) Restructuring and Other Charges (b)   (17 ) Impairment of Goodwill (c)   (1,153 ) Divestiture Costs (e)   (51 ) Strategic Initiatives Costs (f)   (8 ) Regulatory Costs (g)   (11 ) Other (h)   (5 ) Loss Before Taxes $ (994 ) Segment Adjusted Operating EBITDA Margin   Taste 20.9 % Food Ingredients 13.9 % Health & Biosciences 25.6 % Scent 23.5 % Pharma Solutions 20.3 % Consolidated 20.3 % (a) There is depreciation recorded within cost of sales, research & development expenses, and selling & administrative expenses, which is then added back to calculate segment Adjusted Operating EBITDA. This reflects how the CODM reviews Segment results. (b) Represents costs related to severance as part of the IFF Productivity Program. (c) For 2025, represents the impairment of goodwill related to the Food Ingredients reporting unit. (d) For 2026, primarily represents losses recognized as part of the divestiture of the Soy, Concentrates and Lecithin disposal group. (e) For 2026 and 2025, primarily represents costs related to the Company’s completed and anticipated divestitures. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. (f) Represents costs related to the Company’s strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services (GBS) Centers. In 2026, the GBS reorganization has been expanded to include additional functions such as customer service, supply chain and logistics in addition to human resources, accounting and finance, as well as additional efforts to automate processes and expand the use of artificial intelligence (AI) for these functions. These costs primarily consisted of external consulting fees and salaries of individuals who are fully dedicated to such efforts. Costs to develop software and AI are only included to the extent that they do not qualify for capitalization. (g) Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses. (h) For 2025, represents the net impact of costs related to severance, including accelerated stock compensation expense, for certain executives who have separated from the Company, in addition to consulting costs related to the Company’s implementation of a phased restructuring initiative aimed at optimizing its legal entity framework.   International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited) The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP. For the three months ended March 31, 2026 and 2025, there was no difference between Reported (GAAP) and Adjusted (Non-GAAP) gross profit. Reconciliation of Selling and Administrative Expenses   First Quarter (DOLLARS IN MILLIONS)   2026       2025   Reported (GAAP) $ 427     $ 461   Divestiture Costs (c)   (24 )     (51 ) Strategic Initiative Costs (e)   (9 )     (8 ) Regulatory Costs (f)   (10 )     (11 ) Other (g)   —       (6 ) Adjusted (Non-GAAP) $ 384     $ 385   International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited) The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP. Reconciliation of Net Income (Loss) and EPS   First Quarter   2026   2025 (DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS) Income (Loss) before taxes   Provision for income taxes (h)   Net income (loss) attributable to IFF (i)   Diluted EPS   (Loss) Income before taxes   Provision for income taxes (h)   Net (loss) income attributable to IFF (i)   Diluted EPS Reported (GAAP) $ 209   $ 39   $ 169   $ 0.66   $ (994 )   $ 23   $ (1,018 )   $ (3.98 ) Restructuring and Other Charges (a)   6     2     4     0.02     17       4     13       0.05   Impairment of Goodwill (b)   —     —     —     —     1,153       7     1,146       4.48   Divestiture Costs (c)   24     5     19     0.07     51       12     39       0.15   Losses on Business Disposals (d)   7     1     6     0.02     —       —     —       —   Strategic Initiative Costs (e)   9     3     6     0.03     8       2     6       0.02   Regulatory Costs (f)   10     3     7     0.03     11       3     8       0.03   Other (g)   —     —     —     —     5       1     4       0.02   Adjusted (Non-GAAP) $ 265   $ 53   $ 211   $ 0.83   $ 251     $ 52   $ 198     $ 0.77   Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization   First Quarter (DOLLARS AND SHARE AMOUNTS IN MILLIONS) 2026   2025 Numerator       Adjusted (Non-GAAP) Net Income $ 211   $ 198 Amortization of Acquisition related Intangible Assets   146     143 Tax impact on Amortization of Acquisition related Intangible Assets (h)   36     35 Amortization of Acquisition related Intangible Assets, net of tax (j)   110     108 Adjusted (Non-GAAP) Net Income ex. Amortization $ 321   $ 306         Denominator       Weighted average shares assuming dilution (diluted)   257     256 Adjusted (Non-GAAP) EPS ex. Amortization $ 1.25   $ 1.20 (a) Represents costs related to severance as part of the IFF Productivity Program. (b) For 2025, represents the impairment of goodwill related to the Food Ingredients reporting unit. (c) For 2026 and 2025, primarily represents costs related to the Company’s completed and anticipated divestitures. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. (d) For 2026, primarily represents losses recognized as part of the divestiture of the Soy, Concentrates and Lecithin disposal group. (e) Represents costs related to the Company’s strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services (GBS) Centers. In 2026, the GBS reorganization has been expanded to include additional functions such as customer service, supply chain and logistics in addition to human resources, accounting and finance, as well as additional efforts to automate processes and expand the use of artificial intelligence (AI) for these functions. These costs primarily consisted of external consulting fees and salaries of individuals who are fully dedicated to such efforts. Costs to develop software and AI are only included to the extent that they do not qualify for capitalization. (f) For 2026 and 2025, represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance business. (g) For 2025, represents the net impact of costs related to severance, including accelerated stock compensation expense, for certain executives who have separated from the Company, in addition to consulting costs related to the Company’s implementation of a phased restructuring initiative aimed at optimizing its legal entity framework. (h) The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at 0%. The tax benefit for amortization is calculated in a similar manner as the tax effects of the non-GAAP adjustments. (i) For 2026 and 2025, reported and adjusted net income (loss) are each decreased by income attributable to non-controlling interest of $1 million. (j) Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax. International Flavors & Fragrances Inc.
Debt Covenants
(Amounts in millions)
(Unaudited) The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP. Reconciliation of Credit Adjusted EBITDA to Net Loss (DOLLARS IN MILLIONS) Twelve Months Ended March 31, 2026 Net income $ 815   Interest expense   202   Income taxes   (24 ) Depreciation and amortization   972   Specified items(1)   (178 ) Non-cash items(2)   307   Credit Adjusted EBITDA $ 2,094   ____________________ (1) Specified items consisted of restructuring and other charges, divestiture costs, strategic initiatives costs, regulatory costs, gain on debt extinguishment, and other costs that are not related to recurring operations. (2) Non-cash items consisted of losses on business disposals, loss on assets classified as held for sale, and stock based compensation. Net Debt to Total Debt (DOLLARS IN MILLIONS) March 31, 2026 Total debt(1) $ 5,850 Adjustments:   Cash and cash equivalents   562 Net debt $ 5,288 ____________________ (1) Total debt used for the calculation of net debt consisted of short-term debt, long-term debt, short-term finance lease obligations and long-term finance lease obligations.   International Flavors & Fragrances Inc.
Comparable Reportable Segment Performance
(Amounts in millions)
(Unaudited) The following information and schedule provides reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedule is not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.   Three Months Ended March 31,     2026       2025   Net Sales       Taste(1) $ 656     $ 621   Food Ingredients(2)   839       779   Health & Biosciences   595       540   Scent   651       614   Pharma Solutions(3)   —       —   Consolidated $ 2,741     $ 2,554   Segment Adjusted Operating EBITDA(5)       Taste(1) $ 153     $ 125   Food Ingredients(2)   114       108   Health & Biosciences   153       135   Scent   148       141   Pharma Solutions(3)   —       —   Total   568       509   Depreciation & Amortization   (246 )     (236 ) Interest Expense   (44 )     (71 ) Other Expense, Net   (13 )     (20 ) Restructuring and Other Charges   (6 )     (17 ) Impairment of Goodwill   —       (1,153 ) Losses on Business Disposals   (7 )     —   Divestiture Costs   (24 )     (51 ) Strategic Initiative Costs   (9 )     (8 ) Regulatory Costs   (10 )     (11 ) Other   —       (5 ) Impact of Business Divestitures(4)   —       69   Income (Loss) Before Taxes $ 209     $ (994 ) Segment Adjusted Operating EBITDA Margin       Taste   23.3 %     20.1 % Food Ingredients   13.6 %     13.9 % Health & Biosciences   25.7 %     25.0 % Scent   22.7 %     23.0 % Consolidated   20.7 %     19.9 % ____________________  (1) Taste sales and segment adjusted operating EBITDA information exclude the results of the Rene Laurent business that was divested on December 1, 2025, to present fully comparable scenarios. (2) Food Ingredients sales and segment adjusted operating EBITDA information exclude the results of the Soy Crush, Concentrates, and Lecithin business (the “SCL disposal group”) that was divested on March 2, 2026, to present fully comparable scenarios. (3) Pharma Solutions sales and segment adjusted operating EBITDA information exclude the results of the Pharma Solutions disposal group and Nitrocellulose business that were divested on May 1, 2025 and May 9, 2025, respectively, to present fully comparable scenarios. (4) Amounts exclude the results of the Rene Laurent business that was divested on December 1, 2025, the SCL disposal group that was divested on March 2, 2026, and the Pharma Solutions disposal group and Nitrocellulose business that were divested on May 1, 2025 and May 9, 2025, respectively, to present fully comparable scenarios. (5) Following the completed divestitures of the Pharma Solutions disposal group on May 1, 2025 and the Nitrocellulose business on May 9, 2025, the Company reallocated certain corporate costs previously attributed to the Pharma Solutions segment. These costs have been redistributed across the Taste, Food Ingredients, Health & Biosciences, and Scent segments.       For the Three Months Ended March 31, 2025       Selling & Administrative Expenses   Total EBITDA Impact   Taste   $ 3   $ (3 )   Food Ingredients     4     (4 )   Health & Biosciences     3     (3 )   Scent     3     (3 )   Total   $ 13   $ (13 )   International Flavors & Fragrances Inc. GAAP to Non-GAAP Reconciliation Comparable Foreign Exchange Impact (Unaudited)   Q1 2026 Taste   Sales   Segment Adjusted Operating EBITDA   Segment Adjusted Operating EBITDA Margin % Change - Reported   5%   17%   2.4% Portfolio Impact   1%   6%   0.8% % Change - Comparable   6%   22%   3.2% Currency Impact   (4)%   (4)%   (0.1)% % Change - Currency Neutral   2%   18%   3.1%               Q1 2026 Food Ingredients   Sales   Segment Adjusted Operating EBITDA   Segment Adjusted Operating EBITDA Margin % Change - Reported   5%   3%   (0.3)% Portfolio Impact   2%   3%   0.0% % Change - Comparable   8%   6%   (0.3)% Currency Impact   (5)%   6%   1.5% % Change - Currency Neutral   3%   12%   1.2%               Q1 2026 Health & Biosciences   Sales   Segment Adjusted Operating EBITDA   Segment Adjusted Operating EBITDA Margin % Change - Reported   10%   11%   0.1% Portfolio Impact   0%   2%   0.6% % Change - Comparable   10%   13%   0.7% Currency Impact   (5)%   (6)%   (0.1)% % Change - Currency Neutral   5%   7%   0.6%               Q1 2026 Scent   Sales   Segment Adjusted Operating EBITDA   Segment Adjusted Operating EBITDA Margin % Change - Reported   6%   3%   (0.8)% Portfolio Impact   0%   2%   0.5% % Change - Comparable   6%   5%   (0.3)% Currency Impact   (5)%   (7)%   (0.5)% % Change - Currency Neutral   1%   (2)%   (0.8)%               Q1 2026 Consolidated   Sales   Adjusted Operating EBITDA   Adjusted Operating EBITDA Margin % Change - Reported   (4)%   (2)%   0.4% Portfolio Impact   11%   13%   0.4% % Change - Comparable   7%   12%   0.8% Currency Impact   (4)%   (4)%   0.3% % Change - Currency Neutral   3%   8%   1.1% ____________________ Note: The sum of these items may not foot due to rounding.   View source version on businesswire.com: https://www.businesswire.com/news/home/20260505710460/en/ Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com Original: IFF Reports First Quarter 2026 Results

IFF Declares Dividend for Second Quarter 2026April 29, 2026 4:25 PM
Business Wire
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 10, 2026 to shareholders of record as of June 18, 2026.


Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.


© 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260429658065/en/
Media Relations:

Paulina Heinkel

332.877.5339

Media.request@iff.com
Investor Relations:

Michael Bender

212.708.7263

Investor.Relations@iff.com


Original: IFF Declares Dividend for Second Quarter 2026

IFF to Release First Quarter 2026 Results on May 5, 2026April 14, 2026 4:15 PM
Business Wire
IFF (NYSE: IFF) today announced that it will release its first quarter 2026 earnings results following the market close on Tuesday, May 5, 2026. The management team will host a live webcast on Wednesday, May 6, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community.


Investors may access the live webcast and accompanying slide presentation on the company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay.


Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260414067146/en/
Media Relations:

Paulina Heinkel

332.877.5339

Media.request@iff.com


Investor Relations:

Michael Bender

212.708.7263

Investor.Relations@iff.com


Original: IFF to Release First Quarter 2026 Results on May 5, 2026

IFF untersucht auf der In-Cosmetics Global 2026 die wissenschaftlichen Hintergründe des WohlbefindensApril 13, 2026 3:51 PM
Business Wire
Neuigkeiten bei Wellness-orientierten, umweltfreundlichen Duftinnovationen


IFF (NYSE: IFF) – ein Weltmarktführer im Bereich Aromen, Duftstoffe, Lebensmittelzutaten, Gesundheit und Biowissenschaften – wird bei der In-Cosmetics Global 2026, die vom 14. bis zum 16. April in Paris Expo Porte de Versailles stattfindet, Duft- und Biowissenschaftsinnovationen mit dem Schwerpunkt Wellness und Nachhaltigkeit präsentieren.

Diese Pressemitteilung enthält multimediale Inhalte. Die vollständige Mitteilung hier ansehen: https://www.businesswire.com/news/home/20260410178151/de/IFF showcases wellness innovation for beauty.
Während der Veranstaltung, die Erfahrungen und Live-Sessions umfasst, wird IFF zeigen, wie wissenschaftsgeleitete Zutaten die täglichen Schönheitsroutinen und Dufterlebnisse bereichern können, indem sie physische und emotionale Vorteile liefern und gleichzeitig umweltfreundlich sind. Die Präsentation umfasst Duftlösungen, die wissenschaftsbasierte Wellness unterstützen sollen, natürliche Duftinhaltsstoffe mit bewährtem kosmetischem Nutzen von LMR – der IFF-Sparte für natürliche Inhaltsstoffe –, die durch fortschrittliche Extraktionstechnologien gewonnen werden, und nachhaltige, bioaktive und funktionale Inhaltsstoffe für die Haut- und Haarpflege.


Die Besucher können am IFF-Stand Duftlösungen kennenlernen, die mit METAMOOD™ entwickelt wurden, das Daten zur Verbraucherwahrnehmung, Neurowissenschaft und KI-geführte Erstellung kombiniert, um emotionalen Nutzen wie Energie, Entspannung und Freude zu entfalten. Im In-Cosmetics Innovation Lab finden sie den METAMOOD™ X LMR-Sinnesbereich.


Besucher von In-Cosmetics können auch natürliche Duftinhaltsstoffe aus der Kollektion LMR Active Essences ausprobieren, die für ihre adaptogenen und nootropischen Vorteile und die wissenschaftlich belegten Haut- und Haarpflegeeigenschaften bekannt ist.


Zudem wird IFF seine METASLEEP™-Duftlösungen vorstellen, die die Entspannung fördern und einen erholsamen Schlaf unterstützen sollen.


Am 15. April wird IFF-Anwendungsspezialist Morgane Piet ein technisches Seminar abhalten, um zu erzählen, wie Verbraucher Haarpflegeprodukte erleben, und zwar vom ersten Eindruck bis zum Gefühl nach der Nutzung. IFF wird zeigen, wie AURIST™ AGC, das preisgekrönte, Biotech-gestützte Haarkonditionierungspolymer von IFF, das Designed Enzymatic Biomaterials™ (DEB) von IFF enthält, als Formulierungsinstrument für gezielte sensorische und Leistungsvorteile eingesetzt werden kann.


IFF wird außerdem drei Tage lang eine Live-Session abhalten, in der reale Erkenntnisse der Verbraucher geteilt werden und gezeigt wird, wie die GENENCARE®-Reihe von IFF neue Formulierungsmöglichkeiten für Marken schafft, die moderne Hautpflegeroutinen entwickeln.


Bei der In-Cosmetics Global 2026 wird IFF Wissenschaft, sensorische Konzeption und Leistungsfähigkeit vereinen, um verbraucherorientierte Innovationen mit Wellness-Vorzügen vorzustellen. Sowohl bei den Erfahrungen als auch bei den Live-Sessions wird das Science of Wellness-Programm von IFF durch Düfte zum Leben erweckt, die die Laune heben und Freude verbreiten sollen, um die Kraft der Schönheit zu steigern.


Weitere Informationen zum Science of Wellness-Programm von IFF finden Sie unter iff.com/scent/science-of-wellness/.


Willkommen bei IFF

Wir bei IFF (NYSE: IFF) möchten durch Wissenschaft, Kreativität und Herzblut Freude bereiten. Als Weltmarktführer auf dem Gebiet der Aromen, Duftstoffe, Lebensmittelzutaten, Gesundheits- und Biowissenschaften liefern wir wegweisende, nachhaltige Innovationen, die Alltagsprodukte besser machen – für mehr Wohlbefinden, Sinnesfreuden und eine höhere Lebensqualität. Weitere Informationen erhalten Sie unter iff.com, LinkedIn, Instagram und Facebook.


LMR Naturals von IFF

LMR ist eine Sparte von IFF, die das Beste aus Natur und modernster Technologie vereint, um eine breite Palette purer Inhaltsstoffe für Parfümerie, Kosmetik und Aromen herzustellen. Die Agrarwissenschaftler und Forscher von LRM, dessen Hauptsitz Grasse ist, bereisen die ganze Welt, um natürliche Inhaltsstoffe höchster Qualität zu entdecken, anzubauen, zu ernten und zu extrahieren und Duftstoffe, Kosmetika und Aromen zu einem unvergesslichen Erlebnis zu machen. Weitere Informationen finden Sie auf lmrnaturals.iff.com, LinkedIn und Instagram.


© 2026 by International Flavors & Fragrances Inc. IFF ist eine eingetragene Marke. Alle Rechte vorbehalten.


Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.

Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260410178151/de/
Judith Gross, VP, Kommunikation & Branding

Abteilung: Scent

E-Mail: Scentmediarequest@iff.com


Original: IFF untersucht auf der In-Cosmetics Global 2026 die wissenschaftlichen Hintergründe des Wohlbefindens

IFF explore la science du bien-être au salon In-Cosmetics Global 2026April 13, 2026 3:51 PM
Business Wire
Présentation des dernières innovations en matière de parfums écologiques orientés vers le bien-être


IFF (NYSE : IFF), leader mondial des arômes, des parfums, des ingrédients alimentaires et des biosciences et santé, présentera des innovations en matière de parfums et de biosciences orientés vers le bien-être et la durabilité au salon In-Cosmetics Global 2026, qui se tiendra du 14 au 16 avril au Paris Expo Porte de Versailles.

Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20260410262090/fr/IFF showcases wellness innovation for beauty.
Tout au long de l'événement, grâce à des expériences et des sessions en direct, IFF expliquera comment des ingrédients issus de la science peuvent enrichir les routines beauté quotidiennes et les expériences olfactives, offrant des bienfaits physiques et émotionnels tout en respectant l'environnement. L'événement présentera des solutions parfumées conçues pour favoriser un bien-être fondé sur des données scientifiques ; des ingrédients de parfumerie naturels aux bienfaits cosmétiques avérés, issus de LMR (le département d'ingrédients naturels d'IFF) et obtenus grâce à des technologies d'extraction de pointe ; ainsi que des ingrédients durables, bioactifs et fonctionnels pour les soins de la peau et des cheveux.


Les visiteurs pourront découvrir des solutions olfactives conçues avec METAMOOD™, qui associe des données de perception des consommateurs, les neurosciences et une création alimentée par l'IA afin d'apporter des bienfaits émotionnels tels que l'énergie, la relaxation et le bonheur. Rendez-vous sur le stand IFF et dans l'espace d'exposition sensoriel METAMOOD™ X LMR au sein du laboratoire d'innovation In-Cosmetics.


Les participants au salon In-Cosmetics pourront également découvrir les ingrédients de parfums naturels de la collection LMR Active Essences, reconnus pour leurs bienfaits adaptogènes et nootropiques ainsi que pour leurs propriétés validées par la science en matière de soins de la peau et des cheveux.


De plus, IFF mettra l'accent sur ses solutions parfumées METASLEEP™, conçues pour favoriser la relaxation et un sommeil réparateur.


Le 15 avril, Morgane Piet, spécialiste d'application chez IFF, animera un séminaire technique pour échanger des insights sur la manière dont les consommateurs vivent leur expérience en produits de soins capillaires, dès leurs premières impressions jusqu'à l'après-utilisation. IFF montrera comment AURIST™ AGC, polymère de conditionnement capillaire primé, issu des biotechnologies et de la technologie Designed Enzymatic Biomaterials™ (DEB) d'IFF, peut servir d'outil de formulation pour offrir des bénéfices sensoriels et de performance ciblés.


IFF organisera également une session en direct d'une durée de trois jours, pour échanger des insights sur le véritable usage fait par les consommateurs et souligner comment la gamme GENENCARE® d'IFF crée de nouvelles possibilités de formulation pour les marques qui s'adaptent aux routines modernes de soins de la peau.


À l'occasion du salon In-Cosmetics Global 2026, IFF regroupera science, design sensoriel et performance pour présenter des innovations orientées vers le bien-être des consommateurs. Au travers d'expériences immersives sur son stand et de sessions en direct, le programme « Science du bien-être » d'IFF se concrétisera grâce à des parfums conçus pour susciter la bonne humeur et des moments de joie, mettant ainsi en valeur le pouvoir de la beauté.


Pour en savoir plus sur le programme « Science du bien-être » d'IFF, rendez-vous sur iff.com/scent/science-of-wellness/.


Bienvenue chez IFF

Chez IFF (NYSE : IFF), nous créons de la joie grâce à la science, la créativité et l’engagement. Leader mondial du goût, des parfums, des ingrédients alimentaires, de la santé et des biosciences, nous innovons en pensant à l’avenir. Chaque jour, nous proposons des solutions novatrices et durables qui mettent en valeur les produits préférés de tous, contribuant ainsi au bien-être, à l’éveil des sens et à l’épanouissement personnel. Pour en savoir plus, rendez-vous sur iff.com, LinkedIn, Instagram et Facebook.


LMR Naturals by IFF

LMR, filiale d'IFF, allie le meilleur de la nature et des technologies de pointe pour élaborer une vaste gamme d'ingrédients purs destinés à la parfumerie, aux cosmétiques et aux arômes. Située à Grasse, son équipe d'agronomes et de scientifiques parcourt le monde pour découvrir, cultiver, récolter les meilleurs ingrédients naturels, puis les extraire. Ces ingrédients constituent la signature de parfums, de cosmétiques et d'arômes inoubliables. En savoir plus sur lmrnaturals.iff.com, LinkedIn, et Instagram.


© 2026 International Flavors & Fragrances Inc. IFF est une marque déposée. Tous droits réservés.


Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Consultez la version source sur businesswire.com : https://www.businesswire.com/news/home/20260410262090/fr/
Judith Gross, vice-présidente de la communication et de l'image de marque

Département des parfums

E-mail : Scentmediarequest@iff.com


Original: IFF explore la science du bien-être au salon In-Cosmetics Global 2026

IFF?In-Cosmetics Global 2026??????????????????April 13, 2026 3:52 PM
Business Wire
???????????????????????????????

(???????) --
?????????????????????&???????????????????????IFF(NYSE:IFF)??4?14???16?????·????·???·?·????????????In-Cosmetics Global 2026???????????????????????????????????????????????????????

?????????????????????????????????????????????:https://www.businesswire.com/news/home/20260410056020/ja/IFF showcases wellness innovation for beauty.
???????IFF?????????????????????????????????????????????????????????????????????·?????????????????????????????????????????????????????????IFF?????????????LMR????????????????????????????????????????????????????????????????????????????????


?????IFF??????In-Cosmetics????????????METAMOOD™ X LMR Sensory Bar Display?????????????????????AI????????????????????????????????????????????????????METAMOOD™????????????????????????????


In-Cosmetics?????????????????????????????????????????????????????????LMR Active Essense??????????????????????


???IFF??????????????????????????????????????????????????METASLEEP™????????


4?15????IFF???????????????????????·???????????????????????????????????????????????????????????????????????IFF????????????????????Designed Enzymatic Biomaterials™(DEB)??????????????????????AURIST™ AGC??????????????????????????????????????????????


IFF????3?????????????????????????????????????????????????IFF??GENENCARE®???????????????????????????????????????????????????????


IFF??In-Cosmetics Global 2026???????????????????????????????????????????????????????????????????????????????????Science of Wellness(????????)????????????????????????????????????????????????????????


IFF??Science of Wellness(????????)???????????????iff.com/scent/science-of-wellness/????????


IFF????

IFF(NYSE:IFF)???????????????????????????????????????????????????????????????????????IFF???????????????????????????????????????????????????????????????????????????????????????????????????????????????iff.com?????????LinkedIn?Instagram?Facebook????????????


LMR Naturals????

LMR??IFF?????????????????????????????????????????????????????????????????LMR??????????????????????????????????????????????????????????????????????????????lmrnaturals.iff.com?????????LinkedIn???Instagram????????????


© 2026 International Flavors & Fragrances Inc. IFF????????????·??????


??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????

businesswire.com????????????:https://www.businesswire.com/news/home/20260410056020/ja/
Judith Gross, VP, Communications & Branding

Department: Scent

Email: Scentmediarequest@iff.com


Original: IFF?In-Cosmetics Global 2026??????????????????

IFF???????????????????????PureStrong™????April 2, 2026 6:14 PM
Business Wire (???????) --
IFF(NYSE:IFF)???????????????????????&??????????????????????????????????????????????????????PureStrong™?????????

?????????????????????????????????????????????:https://www.businesswire.com/news/home/20260401349017/ja/IFF introduces PureStrong™, a probiotic made specifically for dogs.
????????????????????????????????????????????????????????32??????????????????????????????????????????????????????????????????PureStrong™????????????????????????????????????????????????


IFF???????????????????????????????·????????????????????PureStrong™???????????????????????????????????????????????????????????????????????????????????????????????IFF????????????????????????????????????????????????


????????????????????HOWARU® Pet??????HOWARU® Pet??????????????????????????????????·??????????????????IFF??????????????????????????????????????????????????????IFF???????????????????????????????????????????????


??????????????????????

???????????????????????????PureStrong™??Limosilactobacillus reuteri???1????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????1?????????????????????????????


??????????????

???????????????????????????????????????????????????????


????????????????????????????????????????????????????????????????????????????????????????PureStrong™?????????????????????????????????????????????????????????????????????PureStrong™???????????????????????????????????????????????????????????????????


IFF Pet Health?????????????????·????????????????????????????????????????????????????????????????????????PureStrong™????????????????????????????????????????????????????????????????????????????????????????


PureStrong™?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????PureStrong™???IFF???????????????????https://iff.co/4sy7WJL????????


IFF????

IFF(NYSE:IFF)???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????iff.com???????????LinkedIn?Instagram????Facebook????????


©2026 International Flavors & Fragrances Inc.(IFF)?IFF?IFF??????™?SM???®??????????????????????????????????IFF???IFF????????????????????????


??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????

businesswire.com????????????:https://www.businesswire.com/news/home/20260401349017/ja/
Mariah Saerndahl

Communications Manager

Media.request@iff.com


Original: IFF???????????????????????PureStrong™????

IFF lanciert PureStrong™, ein Probiotikum speziell für HundeApril 2, 2026 5:57 PM
Business Wire
IFF (NYSE: IFF), ein weltweit führendes Unternehmen in den Bereichen Aromen, Duftstoffe, Lebensmittelzutaten sowie Gesundheits- und Biowissenschaften, lanciert PureStrong™, ein neues Probiotikum, das eigens zur Förderung einer gesunden Verdauung bei Hunden entwickelt wurde.

Diese Pressemitteilung enthält multimediale Inhalte. Die vollständige Mitteilung hier ansehen: https://www.businesswire.com/news/home/20260401734790/de/IFF introduces PureStrong™, a probiotic made specifically for dogs.
Hunde sind heutzutage oftmals Teil der Familie. Diese Entwicklung fördert ein schnelles Wachstum des 3,2-Milliarden-Dollar-Marktes der Nahrungsergänzungsmittel für Haustiere. Fast die Hälfte der Haustierhalter in den USA haben bereits Probiotika für ihre Hunde gekauft oder überlegt, dies zu tun. In diesem Rahmen legt PureStrong™ einen neuen Standard fest: haustierorientierte Wissenschaft, die genau auf die Hundebiologie abgestimmt ist.


„PureStrong™ wird direkt aus dem Mikrobiom gesunder Hunde gewonnen und soll die tatsächliche Lebensweise von Hunden unterstützen – wie sie essen, reisen, altern und sich an Veränderungen anpassen“, sagte Allyson Fish, Senior Vice President für Gesundheitswissenschaften für IFF. „So bringt IFF Haustier-Wellness voran: wissenschaftsgetriebene Innovation, die in der Praxis funktioniert.“


Dieses einzigartige Probiotikum für Hunde ist Teil von HOWARU® Pet, dem IFF-Portfolio hunde- und katzenspezifischer probiotischer Stämme, das auf Mikrobiom-Wissenschaft, hochwertiger Herstellung und klinischer Bewertung basiert. IFF blickt auf mehrere Jahrzehnte Erfahrung an der Spitze von Probiotika und Biowissenschaft zurück und kann daher Marken für Haustiergesundheit dabei helfen, über pure trendorientierte Formulierungen hinauszugehen und gezielt Wellness zu fördern.


Für Hunde entwickelt, nicht umformuliert

Anders als viele Probiotika auf dem Markt basiert PureStrong™ auf einem spezifischen Limosilactobacillus reuteri-Stamm, anstatt auf einer Mischung generischer Stämme, die ursprünglich für Menschen oder Nutztiere entwickelt wurden. Da dieser Stamm direkt aus dem Mikrobiom des Hundes stammt, ist er natürlich darauf ausgelegt, im Darm eines Hundes zu überleben und zu wirken. Dieser fokussierte, auf einem einzigen Stamm basierende Ansatz versetzt Marken, die Nahrungsergänzungsmittel für Haustiere herstellen, in die Lage, einfache, sehr zielgerichtete, niedrig dosierte Produkte zu entwickeln, die genau auf den biologischen Bedarf von Hunden abgestimmt sind. Der Stamm wird für die Formate entwickelt, denen Haustiereltern bereits vertrauen, darunter Puder, Kapseln, Tabletten und Sticks. Gleichzeitig erhalten Marken ein klares Unterscheidungsmerkmal in einer der am schnellsten wachsenden Kategorien der Haustierpflege.


Bedeutung für Haustierbesitzer

Die Verdauungsgesundheit betrifft nahezu jeden Teil des täglichen Lebens eines Hundes, von Wohlbefinden und Hydratation bis hin zu Nährstoffaufnahme und Immunsystem.


Ernährungsveränderungen, Reisen, Stress und Alterung können den Darm eines Hundes stören und sich oft an Symptomen bemerkbar machen, die Besitzer sofort erkennen, etwa im Bereich Stuhleigenschaften und Verdauungsprobleme. PureStrong™ soll Hunde durch alltägliche Momente begleiten, die die Verdauungsgesundheit belasten können. In einer kontrollierten Studie an gesunden Hunden, die einer abrupten Ernährungsumstellung ausgesetzt wurden, zeigten Hunde, die PureStrong™ erhielten, verbesserte Marker für Verdauungsgesundheit sowie Hydratations- und Ernährungstoleranz, was zu festerem Stuhl ohne Verstopfung führte.


„Hunde erleben Veränderungen genau wie wir, von neuem Futter über neue Umgebungen bis hin zu neuen Lebensabschnitten“, sagte Danielle Rendina, leitende Wissenschaftlerin für IFF Pet Health. „PureStrong™ arbeitet mit dem natürlichen Mikrobiom eines Hundes und unterstützt die Verdauung sanft und effektiv, sodass sich Hundeeltern gut informiert, bewusst und persönlich um ihren Hund kümmern können.“


PureStrong™ vermittelt Hundebesitzern eine klare und beruhigende Botschaft: dieses Probiotikum wurde für Hunde entwickelt, gestützt auf wissenschaftliche Erkenntnisse und unterstützt von einem Unternehmen mit umfangreicher Expertise im Bereich des Mikrobioms. Dieses neue Probiotikum für Hunde zeigt eine breitere Entwicklung in der Haustierpflege – Hunde werden mit derselben Aufmerksamkeit, derselben Rigorosität und demselben Respekt behandelt wie die Menschen, die sie lieben. Weitere Informationen über PureStrong™ und die Gesundheitslösungen für Haustiere von IFF finden Sie auf https://iff.co/4sy7WJL.


Willkommen bei IFF

Bei IFF (NYSE: IFF) schaffen wir Freude durch Wissenschaft, Kreativität und Herzblut. Als weltweit führendes Unternehmen in den Bereichen Geschmack, Duft, Lebensmittelzutaten, Gesundheit und Biowissenschaften treiben wir Innovationen für die Zukunft voran. Täglich liefern wir innovative, nachhaltige Lösungen, die Produkte, die Menschen schätzen, auf ein neues Niveau heben – sie fördern das Wohlbefinden, erfreuen die Sinne und verbessern die menschliche Erfahrung. Weitere Informationen finden Sie unter iff.com, LinkedIn, Instagram und Facebook.


©2026 International Flavors & Fragrances Inc. (IFF). IFF, das IFF-Logo und alle Marken und Dienstleistungsmarken, die mit ™, SM oder® gekennzeichnet sind, sind Eigentum von IFF oder Tochtergesellschaften von IFF, sofern nicht anders angegeben. Alle Rechte vorbehalten.


Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.

Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260401734790/de/
Mariah Saerndahl

Communications Manager

Media.request@iff.com


Original: IFF lanciert PureStrong™, ein Probiotikum speziell für Hunde

IFF lance PureStrong™, un probiotique spécialement conçu pour les chiensApril 2, 2026 5:14 PM
Business Wire
IFF (NYSE : IFF), leader mondial des arômes, des parfums, des ingrédients alimentaires et du domaine Santé et Biosciences, lance PureStrong™, un nouveau probiotique développé exclusivement pour la santé digestive des chiens.

Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20260401485993/fr/IFF introduces PureStrong™, a probiotic made specifically for dogs.
Aujourd'hui, nombreux sont ceux qui considèrent leur chien comme un membre à part entière de la famille. Cette tendance alimente la croissance rapide du marché américain des compléments alimentaires pour animaux de compagnie, qui représente 3,2 milliards de dollars. Avec près de la moitié des propriétaires d'animaux de compagnie aux États-Unis ayant déjà acheté ou envisageant d'acheter des probiotiques pour leur chien, PureStrong™ établit une nouvelle norme : une science orientée vers le bien-être animal et spécifiquement conçue pour la biologie canine.


« PureStrong™ est directement issu du microbiome de chiens en bonne santé et conçu pour s'adapter à leur mode de vie réel : leur alimentation, leurs déplacements, leur vieillissement et leur capacité d'adaptation », explique Allyson Fish, vice-présidente principale des sciences de la santé chez IFF. « C'est ainsi qu'IFF est à la pointe du bien-être des animaux de compagnie : une innovation scientifique efficace en situation réelle. »


Ce probiotique unique pour chiens fait partie de HOWARU® Pet, le portefeuille de souches probiotiques spécifiques aux chiens et aux chats d'IFF, soutenu par la science du microbiome, une fabrication de qualité et une évaluation clinique. Forte de plusieurs décennies d'expertise en probiotiques et en bioscience, IFF aide les marques de santé des animaux de compagnie à passer des formulations dictées par les tendances à un bien-être de précision.


Conçu pour les chiens, et non pas reconverti pour eux

Contrairement à de nombreux probiotiques disponibles sur le marché, PureStrong™ est formulé à partir d'une souche spécifique de Limosilactobacillus reuteri, et non de mélanges de souches génériques initialement développées pour les humains ou le bétail. Puisque cette souche provient directement du microbiome canin, elle est naturellement adaptée pour survivre, s'implanter et prospérer dans l'intestin du chien. Cette approche ciblée, basée sur une seule souche, permet aux marques de compléments alimentaires pour animaux de compagnie de créer des produits à faible dose et hautement ciblés, sans complexité inutile, apportant un soutien efficace et adapté aux besoins biologiques des chiens. La souche est conçue pour les formats auxquels les propriétaires d'animaux font déjà confiance (poudres, gélules, comprimés et sticks), tout en offrant aux marques un avantage concurrentiel incontestable dans l'un des segments les plus dynamiques des soins pour animaux de compagnie.


Pourquoi les propriétaires de chiens y attachent-ils de l'importance ?

La santé digestive influe sur presque tous les aspects de la vie quotidienne d'un chien, allant de leur confort et de l'hydratation à l'absorption des nutriments et à la santé immunitaire.


Les changements d'alimentation, les voyages, le stress et le vieillissement peuvent perturber le système digestif du chien, se manifestant souvent par des changements de qualité des selles et des troubles digestifs immédiatement perceptibles par les maîtres. PureStrong™ est conçu pour accompagner les chiens au quotidien, dans les situations qui peuvent mettre à l'épreuve leur santé digestive. Lors d'une étude contrôlée menée sur des chiens en bonne santé soumis à un changement brutal d'alimentation, les chiens ayant reçu PureStrong™ ont présenté une amélioration des indicateurs de santé digestive, d'hydratation et de tolérance alimentaire, se traduisant par des selles plus fermes et une diminution de la constipation.


« Les chiens, tout comme nous, vivent des changements : nouvel aliment, nouvel environnement, nouvelles étapes de la vie… », explique Danielle Rendina, scientifique principale chez IFF Pet Health. « PureStrong™ agit en harmonie avec le microbiome naturel du chien afin de favoriser une digestion douce et efficace. Ceci permet ainsi aux maîtres de prendre soin de leur animal de manière éclairée, intentionnelle et personnalisée. »


PureStrong™ adresse un message clair et rassurant aux propriétaires de chiens : ce probiotique est conçu pour les chiens, il est fondé sur la science et bénéficie du soutien d’une entreprise possédant une profonde expertise du microbiome. Ce nouveau probiotique pour chiens témoigne d’une évolution plus large dans les soins aux animaux de compagnie, où les chiens sont traités avec la même attention, la même rigueur et le même respect que leurs maîtres. Pour en savoir plus sur PureStrong™ et les solutions de santé animale d’IFF, rendez-vous sur https://iff.co/4sy7WJL.


Bienvenue chez IFF

Chez IFF (NYSE : IFF), nous cultivons la joie grâce à la science, la créativité et l’engagement. Leader mondial du goût, des parfums, des ingrédients alimentaires, de la santé et des biosciences, nous innovons pour l’avenir. Chaque jour, nous proposons des solutions innovantes et durables qui valorisent les produits préférés des consommateurs, contribuant ainsi au bien-être, à l’éveil des sens et à l’épanouissement personnel. Pour en savoir plus, rendez-vous sur iff.com, LinkedIn, Instagram et Facebook.


© 2026 International Flavors & Fragrances Inc. (IFF). IFF, le logo IFF et toutes les marques commerciales et marques de service désignées par ™, SM ou ® sont la propriété d’IFF ou de ses sociétés affiliées, sauf indication contraire. Tous droits réservés.


Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Consultez la version source sur businesswire.com : https://www.businesswire.com/news/home/20260401485993/fr/
Mariah Saerndahl

Directrice de la communication

Media.request@iff.com


Original: IFF lance PureStrong™, un probiotique spécialement conçu pour les chiens

IFF Launches PureStrong™, a Probiotic Made Specifically for DogsApril 2, 2026 8:15 AM
Business Wire
IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients and health & biosciences—is introducing PureStrong™, a new probiotic developed exclusively for canine digestive health.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401736960/en/IFF introduces PureStrong™, a probiotic made specifically for dogs.
Today, many people consider their pet dogs part of the family. This shift is fueling rapid growth in the $3.2 billion U.S. pet supplement market. With nearly half of U.S. pet owners having purchased or considering probiotics for their dogs, PureStrong™ sets a new standard: pet-first science built specifically for canine biology.


“PureStrong™ is sourced directly from the microbiome of healthy canines and designed to support how dogs actually live—how they eat, travel, age and adapt to change,” said Allyson Fish, senior vice president of health sciences for IFF. “That’s how IFF leads pet wellness: science-driven innovation that performs in the real world.”


This unique probiotic for dogs is part of HOWARU® Pet, IFF’s portfolio of canine and feline-specific probiotic strains backed by microbiome science, quality manufacturing and clinical evaluation. With decades of leadership in probiotics and bioscience, IFF is helping pet health brands move beyond trend-driven formulations toward precision wellness.


Built for dogs, not repurposed for them

Unlike many probiotics on the market today, PureStrong™ is built around one targeted strain of Limosilactobacillus reuteri, rather than blends of generic strains originally developed for humans or livestock. Because this strain comes directly from the canine microbiome, it is naturally equipped to survive, attach and compete in a dog’s gut. This focused, single-strain approach allows pet supplement brands to create low-dose, highly targeted products without unnecessary complexity, delivering effective support that aligns with the biological needs of dogs. The strain is designed for the formats pet parents already trust—including powders, capsules, tablets and sticks—while giving brands a clear point of differentiation in one of the fastest-growing categories in pet care.


Why this matters for dog owners

Digestive health affects nearly every part of a dog’s daily life from comfort and hydration to nutrient absorption and immune health.


Diet changes, travel, stress and aging can all disrupt a dog’s gut, often showing up in ways pet parents notice immediately, like stool quality and digestive upset. PureStrong™ is designed to support dogs through everyday moments that can challenge digestive health. In a controlled study of healthy dogs undergoing an abrupt diet change, dogs receiving PureStrong™ showed improved markers of digestive health and hydration and diet tolerance, resulting in firmer stools without constipation.


“Dogs experience change just like we do from new food to new environments to new stages of life,” said Danielle Rendina, senior scientist for IFF Pet Health. “PureStrong™ works with a dog’s natural microbiome to support digestion gently and effectively, helping pet parents care for their dogs in a way that feels informed, intentional and personal.”


PureStrong™ delivers a clear and reassuring message to dog owners: this probiotic is made for dogs, powered by science, and supported by a company with deep microbiome expertise. This new probiotic for dogs reflects a broader evolution in pet care—one where dogs are treated with the same thoughtfulness, rigor and respect as the people who love them. To learn more about PureStrong™ and IFF’s pet health solutions, visit https://iff.co/4sy7WJL.


Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.


©2026 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401736960/en/
Mariah Saerndahl

Communications Manager

Media.request@iff.com


Original: IFF Launches PureStrong™, a Probiotic Made Specifically for Dogs

IFF??????????????????????????????????March 31, 2026 9:41 PM
Business Wire
????????????·??????????????????????

(???????) --
?????????????????????·???????????????????????IFF(NYSE:IFF)???????????????????????????????·??????????????(FSANZ)?????????????????????????????????????????????·?????????????????????????????????????????????????????

?????????????????????????????????????????????:https://www.businesswire.com/news/home/20260330355123/ja/First heart health claim approved for soy protein in Australia and New Zealand.
?IFF????????????????????????????????????????????????????????IFF Food Ingredients??????·????????????????????????·?????????????????????????????????????????????????????IFF???????????????????????????????????????????????????????????????????????????????????????


??????IFF?Soy Nutrition Institute Global???????????(USSEC)??????????????????????????????????????????????????????????????????????????????????????????????????????1????20~25g?????????????????????????????????????????????????


??????????90%??????????????9???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????


?????????????????????????????????????????????????????FSANZ?????????????????·???????????????????????????????????60%1??????????????????????????????????????????????????????????????????????????????????????????


???????????????????????????????????????????????????????????11?????????IFF?? SOLAE® SUPRO® ???????????????????????????????????????????????·????????????????????????????????????????????????????


??????????????https://www.iff.com/food-beverage/food-ingredients/protein-solutions/soy-protein-and-fiber/


1 https://www.abs.gov.au/statistics/health/health-conditions-and-risks/national-health-measures-survey/latest-release


IFF????

IFF(NYSE:IFF)?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????iff.com?LinkedIn?Instagram?Facebook????????


© 2026 International Flavors & Fragrances Inc. IFF????????????·????????


??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????

businesswire.com????????????:https://www.businesswire.com/news/home/20260330355123/ja/
Jasmine Chia

Global Communications Director, Food Ingredients

+65 98273808

Jasmine.Chia@iff.com


Original: IFF??????????????????????????????????

IFF erhält erste gesundheitsbezogene Angabe zur Herzgesundheit für Sojaprotein in Australien und NeuseelandMarch 31, 2026 9:04 PM
Business Wire
Regulatorischer Meilenstein eröffnet Lebensmittel- und Getränkeherstellern Wachstumschancen im Bereich Herzgesundheit


IFF (NYSE: IFF), ein weltweit führendes Unternehmen in den Bereichen Aromen, Duftstoffe, Lebensmittelzutaten sowie Gesundheits- und Biowissenschaften, gab heute bekannt, dass eine neue gesundheitsbezogene Angabe zur Herzgesundheit für isoliertes Sojaprotein von der Food Standards Australia New Zealand (FSANZ) genehmigt wurde. Die Genehmigung ermöglicht es Lebensmittel- und Getränkeherstellern in Australien und Neuseeland, den Verzehr von Sojaprotein mit einem gesunden Cholesterinspiegel im Blut in Verbindung zu bringen.

Diese Pressemitteilung enthält multimediale Inhalte. Die vollständige Mitteilung hier ansehen: https://www.businesswire.com/news/home/20260330926609/de/First heart health claim approved for soy protein in Australia and New Zealand.
„Seit Jahrzehnten investiert IFF in die wissenschaftliche Erforschung von Sojaprotein und dessen Beitrag zur Herz-Kreislauf-Gesundheit“, sagte Tony Andrew, Vice President für Proteinlösungen bei IFF Food Ingredients. „Diese anerkannte Angabe bestätigt jahrelange intensive Forschung und Zusammenarbeit. Dank unserer fundierten Fachkenntnisse in den Bereichen Inhaltsstoffwissenschaft, Anwendung und Skalierung sind wir bestens aufgestellt, um unseren Kunden dabei zu helfen, diesen Meilenstein in differenzierte Produkte umzusetzen, die in puncto Gesundheit, Geschmack und Nachhaltigkeit überzeugen.“


Diese Angabe stützt sich auf eine mehrjährige, kontinentübergreifende Forschungskooperation, die von IFF, dem Soy Nutrition Institute Global und dem U.S. Soybean Export Council gefördert wurde und an der Forscher aus Australien sowie von der University of Toronto beteiligt waren. Gemäß der neuen Zulassung dürfen Lebensmittel, die so formuliert sind, dass sie den Verbrauchern helfen, eine tägliche Zufuhr von 20–25 Gramm isoliertem Sojaprotein zu erreichen, und die im Rahmen einer gesunden, ausgewogenen Ernährung verzehrt werden, die gesundheitsbezogene Angabe zur Herzgesundheit tragen.


Isoliertes Sojaprotein ist ein zu 90 % pflanzliches, hochwertiges Vollprotein, das alle neun essenziellen Aminosäuren enthält. Aufgrund seiner funktionellen Vielseitigkeit wird es häufig in Getränken, Milchalternativen, Energieriegeln, Snacks und pflanzlichen Lebensmitteln verwendet – Kategorien, in denen Verbraucher zunehmend nach Produkten suchen, die Geschmack mit klinisch belegten gesundheitlichen Vorteilen verbinden. Diese Zulassung stellt einen bedeutenden Meilenstein für die pflanzliche Ernährung dar und bietet Marken neue Möglichkeiten, Produkte zu entwickeln, die die Herzgesundheit unterstützen.


„Die klinischen Erkenntnisse stützen einen kausalen Zusammenhang zwischen dem Verzehr von isoliertem Sojaprotein und verbesserten Blutfettwerten“, sagte Dr. Alan Barclay, Ph.D., Hauptautor des FSANZ-Antrags. „Da rund 60 Prozent der erwachsenen Australier1und viele Neuseeländer von Dyslipidämie betroffen sind, stellt der tägliche Verzehr von Sojaprotein eine praktische ernährungsbasierte Strategie dar, um den Cholesterinspiegel zu regulieren und das Risiko für Herz-Kreislauf-Erkrankungen zu senken.“


Australien und Neuseeland schließen sich elf weiteren Ländern an, darunter die Vereinigten Staaten, Kanada und Japan, die den Zusammenhang zwischen dem Verzehr von Sojaprotein und der Herzgesundheit anerkennen. Auf der Grundlage jahrzehntelanger Forschung und Innovation im Bereich des SOLAE® SUPRO® -Sojaprotein-Portfolios arbeitet IFF mit Lebensmittel- und Getränkeherstellern in der gesamten Region zusammen, um Produkte der nächsten Generation zu entwickeln, die Ernährungswissenschaft, Funktionalität und Verbraucherattraktivität vereinen.


Für weitere Informationen besuchen Sie bitte https://www.iff.com/food-beverage/food-ingredients/protein-solutions/soy-protein-and-fiber/


1 https://www.abs.gov.au/statistics/health/health-conditions-and-risks/national-health-measures-survey/latest-release


Willkommen bei IFF

Bei IFF (NYSE: IFF) schaffen wir Freude durch Wissenschaft, Kreativität und Herzblut. Als weltweit führendes Unternehmen in den Bereichen Geschmack, Duft, Lebensmittelzutaten, Gesundheit und Biowissenschaften treiben wir Innovationen für die Zukunft voran. Täglich liefern wir innovative, nachhaltige Lösungen, die Produkte, die Menschen schätzen, auf ein neues Niveau heben – sie fördern das Wohlbefinden, erfreuen die Sinne und verbessern die menschliche Erfahrung. Weitere Informationen finden Sie unter iff.com, LinkedIn, Instagram und Facebook.


© 2026 von International Flavors & Fragrances Inc. IFF ist eine eingetragene Marke. Alle Rechte vorbehalten.


Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.

Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260330926609/de/
Jasmine Chia

Global Communications Director, Food Ingredients

+65 98273808

Jasmine.Chia@iff.com


Original: IFF erhält erste gesundheitsbezogene Angabe zur Herzgesundheit für Sojaprotein in Australien und Neuseeland

IFF obtient la première allégation relative à la santé cardiovasculaire pour la protéine de soja en Australie et en Nouvelle-ZélandeMarch 31, 2026 7:23 PM
Business Wire
Cette nouvelle étape réglementaire ouvre des opportunités de croissance en santé cardiaque pour les fabricants d'aliments et de boissons


IFF (NYSE : IFF), leader mondial dans le domaine des arômes, des parfums, des ingrédients alimentaires et des sciences de la santé et de la vie, annonce aujourd'hui qu'une nouvelle allégation de santé cardiaque pour la protéine de soja isolée a été acceptée par les Food Standards Australia New Zealand (FSANZ). L'approbation permet aux fabricants d'aliments et de boissons en Australie et en Nouvelle-Zélande de lier la consommation de protéines de soja à des taux de cholestérol sanguin sains.

Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20260330821155/fr/First heart health claim approved for soy protein in Australia and New Zealand.
« Pendant des décennies, IFF a investi dans la science derrière les protéines de soja et son rôle dans le soutien à la santé cardiovasculaire », déclare Tony Andrew, vice-président des solutions protéiques pour IFF Food Ingredients. « Cette allégation approuvée valide des années de recherche et de collaboration rigoureuses. Grâce à notre expertise approfondie en matière de science des ingrédients, d’application et d’échelle, nous avons toutes les cartes en main pour aider nos clients à traduire ce nouveau jalon en produits différenciés qui respectent la santé, le goût et la durabilité. »


L'allégation est appuyée par une collaboration de recherche intercontinentale pluriannuelle soutenue par IFF, le Soy Nutrition Institute Global et le Soybean Export Council des États-Unis, avec la participation de chercheurs d'Australie et de l'Université de Toronto. En vertu de la nouvelle autorisation, les aliments formulés pour aider les consommateurs à atteindre un apport quotidien de 20 à 25 grammes de protéines de soja isolées, consommées dans le cadre d'une alimentation saine et équilibrée, peuvent porter l'allégation de santé cardiaque.


La protéine de soja isolée est une protéine complète à base de plantes à 90%, de haute qualité, contenant les neuf acides aminés essentiels. Sa polyvalence fonctionnelle la rend largement utilisée dans les boissons, les substituts laitiers, les barres nutritionnelles, les collations et les aliments à base de plantes, des catégories dans lesquelles les consommateurs recherchent de plus en plus des produits qui combinent le goût avec des avantages cliniquement soutenus. Cette approbation marque une étape importante pour la nutrition à base de plantes, offrant aux marques de nouvelles opportunités de développer des produits positionnés pour soutenir la santé cardiaque.


« Les preuves cliniques étayent une relation causale entre la consommation isolée de protéines de soja et l’amélioration des lipides sanguins », déclare Dr Alan Barclay, Ph.D., auteur principal de la soumission à la FSANZ. « La dyslipidémie touchant environ 60% des adultes australiens1 et de nombreux Néo-Zélandais, la consommation quotidienne de protéines de soja offre une stratégie nutritionnelle pratique basée sur les aliments pour aider à gérer le cholestérol et réduire le risque cardiovasculaire. »


L'Australie et la Nouvelle-Zélande rejoignent 11 autres pays, dont les États-Unis, le Canada et le Japon, qui reconnaissent le lien entre la consommation de protéines de soja et la santé cardiaque. Soutenu par des décennies de recherche et d'innovation dans le portefeuille de protéines de soja SOLAE® SUPRO®, IFF travaille avec les fabricants d'aliments et de boissons de la région pour développer des produits de nouvelle génération qui combinent science de la nutrition, fonctionnalité et attrait pour les consommateurs.


Pour de plus amples renseignements, veuillez visiter https://www.iff.com/food-beverage/food-ingredients/protein-solutions/soy-protein-and-fiber/


1 https://www.abs.gov.au/statistics/health/health-conditions-and-risks/national-health-measures-survey/latest-release


Bienvenue chez IFF

Chez IFF (NYSE : IFF), nous créons de la joie grâce à la science, à la créativité et à la passion. En tant que leader mondial dans les domaines du goût, des parfums, des ingrédients alimentaires, de la santé et des biosciences, nous innovons pour l’avenir. Chaque jour, nous proposons des solutions révolutionnaires et durables qui améliorent les produits que les gens aiment, favorisent le bien-être, ravissent les sens et enrichissent l’expérience humaine. Pour en savoir plus, rendez-vous sur iff.com, LinkedIn, Instagram et Facebook.


© 2026 par International Flavors & Fragrances Inc. IFF est une marque déposée. Tous droits réservés.


Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Consultez la version source sur businesswire.com : https://www.businesswire.com/news/home/20260330821155/fr/
Jasmine Chia

Directrice mondiale de la communication, Food Ingredients

+65 98273808

Jasmine.Chia@iff.com


Original: IFF obtient la première allégation relative à la santé cardiovasculaire pour la protéine de soja en Australie et en Nouvelle-Zélande

IFF erweitert Präsenz in Lateinamerika mit neuem Enzymzentrum und Anwendungslabor in BrasilienMarch 11, 2026 10:52 AM
Business Wire
IFF (NYSE: IFF) – ein weltweit führendes Unternehmen in den Bereichen Aromen, Duftstoffe, Lebensmittelzutaten sowie Gesundheits- und Biowissenschaften – erweitert seine regionalen Produktions- und Innovationskapazitäten, um das anhaltende Wachstum seines Geschäftsbereichs Gesundheits- und Biowissenschaften (H&B) in Lateinamerika, einem der am schnellsten wachsenden Märkte für das Unternehmen, besser zu unterstützen. Zu den Maßnahmen gehören die Umwandlung des Standorts Arroyito in Argentinien in das erste vollständig auf Fermentation basierende Enzymproduktionszentrum von IFF in der Region sowie die Eröffnung eines Anwendungslabors für Haushaltspflegeprodukte im IFF- Innovationszentrum in Brasilien. Zusammen erweitern diese Verbesserungen die regionale Präsenz von IFF und sollen die Geschwindigkeit, Zuverlässigkeit und lokal relevanten Lösungen für Märkte wie Brauerei, Tierernährung, Biokraftstoffe und Haushaltspflege verbessern.

Diese Pressemitteilung enthält multimediale Inhalte. Die vollständige Mitteilung hier ansehen: https://www.businesswire.com/news/home/20260310240335/de/IFF's home care application lab in Brazil.
„Es geht darum, wissenschaftliche Erkenntnisse dort umzusetzen, wo sie am dringendsten benötigt werden“, erklärte Letícia Gonçalves, President von IFF H&B. „Durch die Einführung von erstklassigen Fermentations- und Anwendungskapazitäten in Lateinamerika beschleunigen wir Innovationen für unsere Kunden und setzen diese in bessere Lebensmittel, effektivere Reinigungslösungen und Alltagsprodukte um, die die Lebensqualität von Millionen von Verbrauchern in der gesamten Region verbessern.“


Aufbau eines regionalen Zentrums für die Enzymproduktion

Die umfassende Expertise von IFF im Bereich der Fermentationstechnologie bildet das Herzstück der Erweiterung in Arroyito und ermöglicht die Herstellung von hochleistungsfähigen Enzymen durch kontrollierte biologische Prozesse, die unter realen Produktionsbedingungen konsistente Ergebnisse liefern und gleichzeitig die Umweltbelastung reduzieren. Dank dieser Verbesserungen wird IFF nun Enzyme bereits in der ersten biologischen Phase vor Ort produzieren, anstatt sich ausschließlich auf die letzten Verarbeitungs- und Verpackungsschritte zu verlassen. Dies verbessert die Zuverlässigkeit der Leistung, erhöht die Verarbeitungseffizienz und ermöglicht schnellere Anpassungen, wenn sich die Kundenbedürfnisse in verschiedenen Anwendungsbereichen wie Brauerei, Tierernährung, Biokraftstoffe und Haushaltspflege weiterentwickeln.


Förderung angewandter Innovationen im Bereich Haushalts- und Körperpflege

Ergänzend zur Umgestaltung des Werks in Arroyito wurde das neue Anwendungslabor für Haushaltspflegeprodukte von IFF in Brasilien eingerichtet, um Kunden dabei zu unterstützen, die Enzymleistung unter realen regionalen Bedingungen zu bewerten und zu optimieren. Das Labor unterstützt Anwendungen in den Bereichen Wäschepflege und Geschirrspülen, ermöglicht schnellere Tests, eine verbesserte Formulierungsgenauigkeit und eine engere Zusammenarbeit mit Kunden, die Reinigungsprodukte der nächsten Generation entwickeln.


„Lateinamerika ist ein dynamischer Wachstumsmarkt für biowissenschaftliche Lösungen“, erklärte Deia Vilela, Vice President Lateinamerika bei IFF H&B. „Besonders spannend ist, wie diese Dynamik durch intensivere Partnerschaften mit Kunden und Teams in der gesamten Region geprägt wird und damit eine solide Grundlage für nachhaltige Innovation und gemeinsames Wachstum in den kommenden Jahren schafft.“


Aufbauend auf mehr als vier Jahrzehnten Führungsrolle in der industriellen Biotechnologie unterstreicht die Investition von IFF das langfristige Engagement des Unternehmens in der Region und positioniert den Geschäftsbereich Gesundheit und Biowissenschaften so, dass er von künftigen Wachstumsmöglichkeiten in den Bereichen Lebensmittel, Haushalts- und Körperpflege, Tierernährung und bioindustrielle Märkte profitieren kann.


Warnhinweis gemäß dem Private Securities Litigation Reform Act von 1995

Diese Pressemitteilung enthält „zukunftsgerichtete Aussagen“ im Sinne der US-amerikanischen Wertpapiergesetze, einschließlich Abschnitt 27A des Securities Act und Abschnitt 21E des Securities Exchange Act von 1934 in der jeweils gültigen Fassung (der „Exchange Act“). Zukunftsgerichtete Aussagen beziehen sich häufig auf die erwartete zukünftige Geschäfts- und Finanzentwicklung sowie die Finanzlage und enthalten häufig Wörter wie „planen“, „erwarten“, „voraussehen“, „beabsichtigen“, „glauben“, „anstreben“, „sehen“, „werden“, „würden“, „anstreben“ oder ähnliche Ausdrücke sowie Variationen oder Verneinungen dieser Wörter oder Ausdrücke. Zukunftsgerichtete Aussagen beziehen sich naturgemäß auf Angelegenheiten, die in unterschiedlichem Maße unsicher sind, wie beispielsweise Aussagen über den Zeitpunkt oder die Art der neuen Anlagen. Die in dieser Pressemitteilung enthaltenen zukunftsgerichteten Aussagen gelten nur zum Zeitpunkt ihrer Veröffentlichung, und wir übernehmen keine Verpflichtung, diese zukunftsgerichteten Aussagen zu aktualisieren, um spätere Ereignisse oder Umstände widerzuspiegeln.


Willkommen bei IFF

Bei IFF (NYSE: IFF) schaffen wir Freude durch Wissenschaft, Kreativität und Herzblut. Als weltweit führendes Unternehmen in den Bereichen Geschmack, Duft, Lebensmittelzutaten, Gesundheit und Biowissenschaften treiben wir Innovationen für die Zukunft voran. Täglich liefern wir innovative, nachhaltige Lösungen, die Produkte, die Menschen schätzen, auf ein neues Niveau heben – sie fördern das Wohlbefinden, erfreuen die Sinne und verbessern die menschliche Erfahrung. Weitere Informationen finden Sie unter iff.com, LinkedIn, Instagram und Facebook.


©2026 International Flavors & Fragrances Inc. (IFF). IFF, das IFF-Logo und alle mit ™, SM oder® gekennzeichneten Marken und Dienstleistungsmarken sind Eigentum von IFF oder verbundenen Unternehmen von IFF, sofern nicht anders angegeben. Alle Rechte vorbehalten.


Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.

Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260310240335/de/
Medienarbeit:

Paulina Heinkel

332.877.5339

Media.request@iff.com


Investorenbeziehungen:

Michael Bender

212.708.7263

Investor.Relations@iff.com


Original: IFF erweitert Präsenz in Lateinamerika mit neuem Enzymzentrum und Anwendungslabor in Brasilien

IFF?????????????????????????????????????????March 11, 2026 11:00 AM
Business Wire (???????) --
????????????????????????????????????????????????IFF (NYSE:IFF) ?????????????????????????????????????&????????(H&B)?????????????????????????????????????????????????????????????????Arroyito??????????????????????????????????????????IFF?????????????????????????????????????????????????IFF??????????????????????????????????????????????????????????????????????????????????

?????????????????????????????????????????????:https://www.businesswire.com/news/home/20260310535280/ja/IFF's home care application lab in Brazil.
??????????????????????????????????????IFF H&B???????????????·????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????


????????????

IFF?????????????????Arroyito??????????????????????????????????????????????????????????????????????????????????????????????????????IFF?????·???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????


?????·?????????????????????????

Arroyito?????????????IFF???????????????????????????????????????????·?????????????????????????????????????????????????????????????????????????????????????????????


?????????????????????????????????????????????????????IFF H&B??????????????????????Deia Vilela??????????????????????????????????????????????????????????????????????????????????????????????????????


40????????????????????????????????????IFF?????????????????????????????????????????&????????????????????????????????????????????????????????????????????


1995?????????????????????

????????????????(??1934???????27A? 1934???????27A??????1934???????21E????)?????????????????????????????????????????????????·??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????·????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????


IFF?????

IFF(NYSE:IFF)????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????iff.com?LinkedIn?Instagram?Facebook????????


© 2026 International Flavors & Fragrances Inc.(IFF)?IFF?IFF???????™?SM???®???????????????????????????????????IFF???IFF??????????????????·????????


??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????

businesswire.com????????????:https://www.businesswire.com/news/home/20260310535280/ja/
Media Relations:

Paulina Heinkel

332.877.5339

Media.request@iff.com


Investor Relations:

Michael Bender

212.708.7263

Investor.Relations@iff.com


Original: IFF?????????????????????????????????????????

IFF étend sa présence en Amérique latine avec un nouveau centre dédié aux enzymes et un laboratoire d’application au BrésilMarch 11, 2026 10:22 AM
Business Wire
IFF (NYSE : IFF), leader mondial dans le domaine des arômes, des parfums, des ingrédients alimentaires et des sciences de la santé et de la vie, renforce ses capacités de production et d’innovation régionales afin de mieux soutenir la croissance continue de son activité Santé et Sciences de la vie (H&B) en Amérique latine, l’un des marchés les plus dynamiques pour l’entreprise. Cette initiative comprend la transformation du site d’Arroyito en Argentine en premier centre de production d’enzymes entièrement basé sur la fermentation dans la région, ainsi que l’ouverture d’un laboratoire d’application dédié aux produits d’entretien ménager au sein du centre d’innovation d’IFF au Brésil. Ensemble, ces améliorations élargissent la présence régionale d’IFF et devraient permettre d’améliorer la rapidité, la fiabilité et la pertinence locale des solutions proposées sur des marchés tels que la brasserie, la nutrition animale, les biocarburants et les produits d’entretien ménager.

Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20260310053933/fr/IFF's home care application lab in Brazil.
« Il s’agit de transformer la science en impact là où cela compte le plus », déclare Letícia Gonçalves, présidente d’IFF H&B. « En apportant des capacités de fermentation et d’application de classe mondiale en Amérique latine, nous accélérons l’innovation pour nos clients et la traduisons en une meilleure alimentation, des solutions de nettoyage plus efficaces et des produits quotidiens qui améliorent la qualité de vie de millions de consommateurs dans toute la région. »


Création d’un centre régional de production d’enzymes

L’expertise approfondie d’IFF en matière de technologie de fermentation est au cœur de l’expansion d’Arroyito, permettant la production d’enzymes hautement performantes grâce à des processus biologiques contrôlés qui fournissent des résultats constants dans des conditions de fabrication réelles tout en réduisant l’impact environnemental. Grâce à ces améliorations, IFF produira désormais des enzymes localement dès le stade biologique initial, plutôt que de se limiter aux étapes finales de transformation et de conditionnement, ce qui améliorera la fiabilité des performances, augmentera l’efficacité du traitement et permettra des ajustements plus rapides à mesure que les besoins des clients évoluent dans des domaines tels que la brasserie, la nutrition animale, les biocarburants et les produits d’entretien ménager.


Faire progresser l’innovation appliquée dans les soins à domicile et les soins personnels

En complément de la transformation de l’usine d’Arroyito, le nouveau laboratoire d’application des soins ménagers d’IFF au Brésil est conçu pour aider les clients à évaluer et à optimiser les performances des enzymes dans des conditions régionales réelles. Le laboratoire prend en charge les applications de lessive et de lavage de la vaisselle, permettant des tests plus rapides, une meilleure précision des formulations et une collaboration plus étroite avec les clients qui développent des produits de nettoyage de nouvelle génération.


« L’Amérique latine est un marché en pleine croissance pour les solutions issues des sciences biologiques », déclare Deia Vilela, vice-présidente d’IFF H&B pour l’Amérique latine. « Ce qui est le plus enthousiasmant, c’est la manière dont cette dynamique se construit grâce à des partenariats plus étroits avec les clients et les équipes de toute la région, créant ainsi une base solide pour une innovation durable et une croissance partagée dans les années à venir. »


S’appuyant sur plus de quatre décennies de leadership dans le domaine de la biotechnologie industrielle, l’investissement d’IFF renforce son engagement à long terme dans la région et positionne son activité Santé et Biosciences pour saisir la croissance future sur les marchés de l’alimentation, des soins domestiques et personnels, de la nutrition animale et de la bio-industrie.


Mise en garde en vertu du Private Securities Litigation Reform Act de 1995

Le présent communiqué de presse contient des « déclarations prospectives » au sens des lois fédérales sur les valeurs mobilières, notamment la section 27A du Securities Act et la section 21E du Securities Exchange Act de 1934, telle que modifiée (l’« Exchange Act »). Les déclarations prospectives portent souvent sur les performances commerciales et financières futures attendues et sur la situation financière, et contiennent souvent des mots tels que « planifier », « s’attendre à », « anticiper », « avoir l’intention de », « croire », « chercher à », « voir », « vouloir », « cibler », des expressions similaires, ainsi que des variantes ou des négations de ces mots. Les déclarations prospectives, de par leur nature, traitent de questions qui sont, à des degrés divers, incertaines, telles que les déclarations concernant le calendrier ou la nature des nouvelles installations. Les déclarations prospectives incluses dans le présent communiqué ne sont faites qu’à la date de celui-ci, et nous ne sommes pas tenus de les mettre à jour pour tenir compte d’événements ou de circonstances ultérieurs.


Bienvenue chez IFF

Chez IFF (NYSE : IFF), nous créons de la joie grâce à la science, à la créativité et à la passion. En tant que leader mondial dans les domaines du goût, des parfums, des ingrédients alimentaires, de la santé et des biosciences, nous innovons pour l’avenir. Chaque jour, nous proposons des solutions révolutionnaires et durables qui améliorent les produits que les gens aiment, favorisent le bien-être, ravissent les sens et enrichissent l’expérience humaine. Pour en savoir plus, rendez-vous sur iff.com, LinkedIn, Instagram et Facebook.


©2026 International Flavors & Fragrances Inc. (IFF). IFF, le logo IFF et toutes les marques commerciales et marques de service désignées par ™, SM ou ® sont la propriété d’IFF ou de ses filiales, sauf indication contraire. Tous droits réservés.


Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Consultez la version source sur businesswire.com : https://www.businesswire.com/news/home/20260310053933/fr/
Relations médias :

Paulina Heinkel

332.877.5339

Media.request@iff.com


Relations investisseurs :

Michael Bender

212.708.7263

Investor.Relations@iff.com


Original: IFF étend sa présence en Amérique latine avec un nouveau centre dédié aux enzymes et un laboratoire d’application au Brésil

IFF amplía su presencia en América Latina con un nuevo hub de enzimas y un laboratorio de aplicaciones en BrasilMarch 10, 2026 4:30 PM
Business Wire
IFF (NYSE: IFF) — líder global en sabores, fragancias, ingredientes alimentarios y soluciones en salud y biociencias — está fortaleciendo sus capacidades regionales de producción e innovación para apoyar mejor el crecimiento continuo de su negocio de Health & Biosciences (H&B) en América Latina, uno de los mercados de más rápido crecimiento para la compañía. La iniciativa incluye tanto la transformación de la planta de Arroyito, en Argentina, en el primer hub regional de producción de enzimas por fermentación completa de IFF, como la apertura de un laboratorio de aplicaciones para cuidado del hogar en el Centro de Innovación de IFF en Brasil. En conjunto, estas inversiones amplían la presencia regional de IFF y se espera que mejoren la velocidad, la confiabilidad y el desarrollo de soluciones relevantes a nivel local para mercados como cervecería, nutrición animal, biocombustibles y cuidado del hogar.

Este comunicado de prensa trata sobre multimedia. Ver la noticia completa aquí: https://www.businesswire.com/news/home/20260310709502/es/IFF's home care application lab in Brazil.
“Se trata de convertir la ciencia en impacto donde más importa”, afirmó Letícia Gonçalves, presidenta de H&B de IFF. “Al incorporar capacidades de fermentación y aplicación de clase mundial en América Latina, estamos acelerando la innovación para nuestros clientes y traduciéndola en mejores alimentos, soluciones de limpieza más eficaces y productos cotidianos que mejoran la calidad de vida de millones de consumidores en toda la región.”


Construcción de un hub regional de producción de enzimas

La profunda experiencia de IFF en tecnología de fermentación está en el centro de la expansión de Arroyito, permitiendo la producción de enzimas de alto desempeño mediante procesos biológicos controlados que ofrecen resultados consistentes en condiciones reales de manufactura, al tiempo que reducen el impacto ambiental. Con estas mejoras, IFF producirá enzimas localmente desde la etapa biológica inicial, en lugar de depender únicamente de las fases finales de procesamiento y envasado. Esto mejora la confiabilidad del desempeño, incrementa la eficiencia de los procesos y permite ajustes más rápidos a medida que evolucionan las necesidades de los clientes en aplicaciones como cervecería, nutrición animal, biocombustibles y cuidado del hogar.


Impulso a la innovación aplicada en cuidado personal y del hogar

Como complemento a la transformación de la planta en Arroyito, el nuevo laboratorio de aplicaciones para cuidado del hogar de IFF en Brasil fue diseñado para ayudar a los clientes a evaluar y optimizar el desempeño de las enzimas bajo condiciones reales de la región. El laboratorio brinda soporte a aplicaciones de lavado de ropa y vajilla, permitiendo pruebas más rápidas, mayor precisión en las formulaciones y una colaboración más estrecha con los clientes que desarrollan productos de limpieza de próxima generación.


“América Latina es un mercado dinámico de crecimiento para soluciones habilitadas por biociencias”, señaló Deia Vilela, vicepresidenta de IFF H&B para América Latina. “Lo más emocionante es cómo este impulso se está construyendo a través de alianzas más profundas con clientes y equipos en toda la región, creando una base sólida para una innovación sostenida y un crecimiento compartido en los próximos años.”


Con más de cuatro décadas de liderazgo en biotecnología industrial, IFF refuerza, con esta inversión, su compromiso de largo plazo con la región y posiciona su negocio de Health & Biosciences para acelerar el crecimiento futuro en los mercados de alimentos, cuidado del hogar y personal, nutrición animal y bioindustria.


Declaración de advertencia conforme a la Ley de Reforma de Litigios sobre Valores Privados de 1995

Este comunicado de prensa contiene “declaraciones prospectivas” según lo dispuesto por las leyes federales de valores, incluyendo la Sección 27A de la Securities Act y la Sección 21E de la Securities Exchange Act de 1934, según sus enmiendas (“Exchange Act”). Las declaraciones prospectivas suelen referirse al desempeño futuro esperado del negocio y a la situación financiera, y con frecuencia incluyen palabras como “planear”, “esperar”, “anticipar”, “pretender”, “creer”, “buscar”, “ver”, “hará”, “podría”, “objetivo”, u otras expresiones similares, así como sus variaciones o formas negativas. Por su naturaleza, las declaraciones prospectivas abordan asuntos que, en distintos grados, son inciertos, como aquellas relacionadas con el cronograma o la naturaleza de las nuevas instalaciones. Las declaraciones prospectivas incluidas en este comunicado se realizan únicamente a la fecha del mismo, y la compañía no asume obligación alguna de actualizarlas para reflejar eventos o circunstancias posteriores.


Bienvenidos a IFF

En IFF (NYSE: IFF), creamos alegría a través de la ciencia, la creatividad y el corazón. Como líder global en sabor, fragancias, ingredientes alimentarios, salud y biociencias, estamos innovando para el futuro. Cada día, ofrecemos soluciones sostenibles y revolucionarias que elevan los productos que las personas aman, impulsando el bienestar, deleitando los sentidos y mejorando la experiencia humana. Más información en iff.com, LinkedIn, Instagram y Facebook.


© 2026 International Flavors & Fragrances Inc. (IFF). IFF, el logotipo de IFF y todas las marcas comerciales y de servicio indicadas con ™, SM o ® son propiedad de IFF o de sus afiliadas, salvo que se indique lo contrario. Todos los derechos reservados.

Vea la versión original en businesswire.com: https://www.businesswire.com/news/home/20260310709502/es/
Relaciones con los medios:

Paulina Heinkel

332.877.5339

Media.request@iff.com


Relaciones con inversores:

Michael Bender

212.708.7263

Investor.Relations@iff.com


Original: IFF amplía su presencia en América Latina con un nuevo hub de enzimas y un laboratorio de aplicaciones en Brasil

IFF Expands Latin American Footprint With New Enzyme Hub, Brazil Application LabMarch 10, 2026 4:30 PM
Business Wire
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients and health & biosciences — is enhancing regional production and innovation capabilities to better support the continued growth of its Health & Biosciences (H&B) business in Latin America, one of the fastest-growing markets for the company. The effort includes the transformation of the Arroyito site in Argentina into IFF’s first full fermentation-based enzyme production hub in the region and the opening of a household care application laboratory at IFF’s Innovation Center in Brazil. Together, these enhancements expand IFF’s regional footprint and are expected to improve speed, reliability and locally relevant solutions for markets including brewing, animal nutrition, biofuels and home care.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310253993/en/IFF's home care application lab in Brazil.
“This is about turning science into impact where it matters most,” said Letícia Gonçalves, president of IFF H&B. “By bringing world-class fermentation and application capabilities to Latin America, we are accelerating innovation for our customers and translating that into better food, more effective cleaning solutions and everyday products that improve quality of life for millions of consumers across the region.”


Building a regional enzyme production hub

IFF’s deep expertise in fermentation technology is at the heart of the Arroyito expansion, enabling the production of high-performance enzymes through controlled biological processes that deliver consistent results under real-world manufacturing conditions while reducing environmental impact. With the enhancements, IFF will now produce enzymes locally from the initial biological stage rather than relying solely on final processing and packaging steps, improving performance reliability, increasing processing efficiency and enabling faster adjustments as customer needs evolve across applications including brewing, animal nutrition, biofuels and home care.


Advancing applied innovation in home and personal Care

Complementing the Arroyito plant transformation, IFF’s new household care application laboratory in Brazil is designed to help customers evaluate and optimize enzyme performance under real regional conditions. The laboratory supports laundry and dishwashing applications, enabling faster testing, improved formulation accuracy and closer collaboration with customers developing next-generation cleaning products.


“Latin America is a dynamic growth market for bioscience-enabled solutions,” said Deia Vilela, vice president of Latin America for IFF H&B. “What’s most exciting is how this momentum is being shaped through deeper partnerships with customers and teams across the region, creating a strong foundation for sustained innovation and shared growth in the years ahead.”


Building on more than four decades of industrial biotechnology leadership, IFF’s investment reinforces its long-term commitment to the region and positions its Health & Biosciences business to capture future growth across food, home and personal care, animal nutrition and bio-industrial markets.


Cautionary Statement under the Private Securities Litigation Reform Act of 1995

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “”plan”, “expect,” “anticipate,” “intend,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the timing or nature of the new facilities. The forward-looking statements included in this release are made only as of the date hereof, and we undertake no obligation to update the forward-looking statement to reflect subsequent events or circumstances.


Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.


©2026 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310253993/en/
Media Relations:

Paulina Heinkel

332.877.5339

Media.request@iff.com


Investor Relations:

Michael Bender

212.708.7263

Investor.Relations@iff.com


Original: IFF Expands Latin American Footprint With New Enzyme Hub, Brazil Application Lab

IFF expande sua presença na América Latina com novo hub de enzimas e laboratório de aplicações no BrasilMarch 10, 2026 4:30 PM
Business Wire
IFF (NYSE: IFF) — líder global em aromas, fragrâncias, ingredientes alimentícios e soluções em saúde e biociências — está ampliando suas capacidades regionais de produção e inovação para melhor apoiar o crescimento contínuo de seu negócio de Health & Biosciences (H&B) na América Latina, um dos mercados de crescimento mais rápido para a companhia. A iniciativa inclui tanto a transformação da unidade de Arroyito, na Argentina, no primeiro hub completo de produção de enzimas por fermentação da IFF na região, quanto a abertura de um laboratório de aplicações para cuidados com o lar no Centro de Inovação da IFF no Brasil. Em conjunto, os investimentos ampliam a presença regional da IFF e devem melhorar a agilidade, a confiabilidade e o desenvolvimento de soluções localmente relevantes para mercados como cervejaria, nutrição animal, biocombustíveis e cuidados com o lar.

Este comunicado de imprensa inclui multimédia. Veja o comunicado completo aqui: https://www.businesswire.com/news/home/20260310271582/pt/IFF's home care application lab in Brazil.
“Trata-se de transformar ciência em impacto onde isso mais importa”, afirmou Letícia Gonçalves, presidente de H&B da IFF. “Ao levar capacidades de fermentação e aplicação de classe mundial para a América Latina, estamos acelerando a inovação para nossos clientes e traduzindo isso em alimentos melhores, soluções de limpeza mais eficazes e produtos do dia a dia que melhoram a qualidade de vida de milhões de consumidores em toda a região.


Construção de um hub regional de produção de enzimas

A profunda expertise da IFF em tecnologia de fermentação está no centro da expansão de Arroyito, viabilizando a produção de enzimas de alto desempenho por meio de processos biológicos controlados, que entregam resultados consistentes em condições reais de fabricação, ao mesmo tempo em que reduzem o impacto ambiental. Com as melhorias, a IFF passará a produzir enzimas localmente desde a fase biológica inicial, em vez de depender apenas das etapas finais de processamento e envase, aumentando a confiabilidade do desempenho, a eficiência dos processos e permitindo ajustes mais rápidos à medida que as necessidades dos clientes evoluem em aplicações como cervejaria, nutrição animal, biocombustíveis e cuidados com o lar.


Avanço da inovação aplicada em cuidados pessoais e com o lar

Complementando o transformação da unidade de Arroyito, o novo laboratório de aplicações para cuidados com o lar da IFF no Brasil foi projetado para ajudar os clientes a avaliar e otimizar o desempenho das enzimas sob condições reais da região. O laboratório oferece suporte a aplicações de lavagem de roupas e louças, possibilitando testes mais rápidos, maior precisão nas formulações e uma colaboração mais próxima com clientes que desenvolvem produtos de limpeza de próxima geração.


“A América Latina é um mercado dinâmico de crescimento para soluções possibilitadas por biociências”, afirmou Deia Vilela, vice-presidente da IFF H&B para a América Latina. “O mais empolgante é ver como esse momentum está sendo construído por meio de parcerias mais profundas com clientes e equipes em toda a região, criando uma base sólida para inovação contínua e crescimento compartilhado nos próximos anos.”


Com mais de quatro décadas de liderança em biotecnologia industrial, a IFF reforça, com esse investimento, seu compromisso de longo prazo com a região e posiciona o negócio de Health & Biosciences para acelerar o crescimento futuro nos mercados de alimentos, cuidados com o lar e pessoal, nutrição animal e bioindústria.


Declaração de Advertência conforme a Lei de Reforma de Litígios sobre Títulos Privados de 1995

Este comunicado à imprensa contém “declarações prospectivas” nos termos das leis federais de valores mobiliários, incluindo a Seção 27A da Securities Act e a Seção 21E da Securities Exchange Act de 1934, conforme alterada (“Exchange Act”). Declarações prospectivas geralmente abordam expectativas quanto ao desempenho futuro dos negócios, ao desempenho financeiro e à condição financeira, e frequentemente incluem palavras como “planejar”, “esperar”, “antecipar”, “pretender”, “acreditar”, “buscar”, “ver”, “irá”, “poderia”, “meta”, ou expressões semelhantes, bem como variações ou formas negativas desses termos. Por sua natureza, declarações prospectivas tratam de assuntos que, em diferentes graus, são incertos, como declarações relacionadas ao cronograma ou à natureza das novas instalações. As declarações prospectivas incluídas neste comunicado são feitas apenas na data de sua divulgação, e não assumimos qualquer obrigação de atualizá-las para refletir eventos ou circunstâncias posteriores.


Bem-vindo à IFF

Na IFF (NYSE: IFF), criamos alegria por meio da ciência, da criatividade e do coração. Como líder global em sabor, fragrâncias, ingredientes alimentícios, saúde e biociências, estamos inovando para o futuro. Todos os dias, entregamos soluções sustentáveis e pioneiras que elevam os produtos que as pessoas amam — promovendo o bem-estar, encantando os sentidos e aprimorando a experiência humana. Saiba mais em iff.com, LinkedIn, Instagram e Facebook.


© 2026 International Flavors & Fragrances Inc. (IFF). IFF, o logotipo IFF e todas as marcas comerciais e marcas de serviço indicadas com ™, SM ou ® são de propriedade da IFF ou de suas afiliadas, salvo indicação em contrário. Todos os direitos reservados.

Ver a versão original em businesswire.com: https://www.businesswire.com/news/home/20260310271582/pt/
Relações com a mídia:

Paulina Heinkel

332.877.5339

Media.request@iff.com


Relações com Investidores:

Michael Bender

212.708.7263

Investor.Relations@iff.com


Original: IFF expande sua presença na América Latina com novo hub de enzimas e laboratório de aplicações no Brasil

IFF Declares Dividend for First Quarter 2026March 4, 2026 4:15 PM
Business Wire
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 10, 2026 to shareholders of record as of March 20, 2026.


Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.


© 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260304579613/en/
Media Relations:

Paulina Heinkel

332.877.5339

Media.request@iff.com


Investor Relations:

Michael Bender

212.708.7263

Investor.Relations@iff.com


Original: IFF Declares Dividend for First Quarter 2026

IFF Completed the Divestiture of Soy Crush, Concentrates and Lecithin BusinessesMarch 2, 2026 4:15 PM
Business Wire
IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its soy crush, concentrates and lecithin businesses to Bunge. This transaction does not include IFF’s soy isolates business.


Welcome to IFF


At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.


© 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260302231096/en/
Paulina Heinkel

332.877.5339

Media.request@iff.com


Investor Relations:

Michael Bender

212.708.7263

Investor.Relations@iff.com


Original: IFF Completed the Divestiture of Soy Crush, Concentrates and Lecithin Businesses

LMR präsentiert Tonka Bean CO2 Absolute: Gourmand-Exzellenz aus umweltschonender ExtraktionFebruary 25, 2026 9:08 AM
Business Wire
Naturgetreue Gourmand-Fülle dank erneuerbarer CO2-Technologie.


IFF (NYSE: IFF) – LMR Naturals by IFF – ein weltweit führender Anbieter natürlicher Inhaltsstoffe für Parfümerie, Kosmetik und Aromen – hat Tonka Bean CO2 Absolute in seine Conscious Collection aufgenommen, eine Reihe 12 besonders nachhaltiger und rückverfolgbarer natürlicher Inhaltsstoffe für Parfüms und Aromen. Tonka Bean CO2 Absolute ist ein natürlicher Extrakt mit gourmander Duftsignatur. Diese neue Ergänzung der Parfümeurpalette wird mit erneuerbarem und recyceltem superkritischem CO2 am IFF-Extraktionsstandort in Aubrac, Frankreich hergestellt.

Diese Pressemitteilung enthält multimediale Inhalte. Die vollständige Mitteilung hier ansehen: https://www.businesswire.com/news/home/20260224022768/de/Tonka Bean CO2 Absolute extracted by LMR.
„Unsere CO2-Extraktionseinheit in Aubrac hat LMR in die Lage versetzt, eine Kollektion von Extrakten zu entwickeln, die Nachhaltigkeit nahtlos mit hohen hedonischen Profilen für Parfümeure verbindet“, sagte Bertrand de Préville, Geschäftsleiter von LMR Naturals by IFF. „Mit der Einführung von Tonka Bean CO2 Absolute bekräftigen wir unseren Einsatz für eine umweltbewusste superkritische CO2-Extraktion sowie Parfümerie-Innovationen – und unterstreichen damit unsere führende Position bei hochwertigen natürlichen Inhaltsstoffen für die Feinparfümerie.“


Der neue Tonkabohnenextrakt bietet eine verbesserte Leistungsfähigkeit sowie Kosteneffizienz. Das eingesetzte CO2-Extraktionsverfahren senkt den Energieverbrauch und reduziert damit die Umweltbelastung im Vergleich zur herkömmlichen Lösungsmittelextraktion. Es erfolgt bei niedriger Temperatur, hinterlässt keine petrochemischen Rückstände und schützt flüchtige sowie empfindliche Moleküle. Das Ergebnis ist ein hochwertiger Extrakt, der den authentischen Duft frisch geernteter Tonkabohnen einfängt und im Vergleich zu herkömmlichem Tonka Absolute einen geringeren CO2-Fußabdruck aufweist (Cradle-to-Gate: -34 %).


Mit einer Herkunft, die sich bis in den Amazonas-Regenwald zurückverfolgen lässt, verleiht LMR Tonka Bean CO2 sowohl Düften der Feinparfümerie als auch Verbraucher düfte zusätzliche Natürlichkeit, Wärme und eine luxuriöse Textur. Die cremigen und wohltuenden Facetten des Inhaltsstoffs sprechen Verbraucher an, die Geborgenheit, Nostalgie sowie einen Hauch Verwöhnung suchen. Seine weiche Kopfnote von gerösteter Mandel und die Nuance von sonnengetrocknetem Heu erzeugen in Kombination mit Kakao-Unternoten ein volleres, samtigeres Dufterlebnis als traditionelles Tonka Absolute.


„Ich liebe es, dass es faszinierende neue Dimensionen eröffnet“, sagte Alexandra Carlin, Parfümeurin auf Senior-Ebene bei IFF. „Es hat eine Note von braunem Zucker, einen Hauch von Buchweizen und sogar eine feine Kakaonote. Es ist zugleich unerwartet süß und salzig und ausgesprochen faszinierend.“


Tonka Bean CO2 ist der jüngste Fortschritt von IFF bei der Gestaltung der Zukunft der Duftinnovation. Diese Ankündigung folgt auf die jüngste Einweihung des erweiterten Standorts von LMR Naturals in Grasse, Frankreich. Die Investition des Unternehmens in Höhe von 10 Millionen Euro in die Anlage in Grasse erweitert die Kapazitäten, um Innovationen im Bereich natürlicher Inhaltsstoffe im Herzen der Welthauptstadt des Parfüms voranzutreiben.


LMR Naturals ist eine markenrechtlich geschützte Kompetenz innerhalb von IFF, ursprünglich 1983 von Monique Remy gegründet und von IFF im Jahr 2000 übernommen, um die Fähigkeit von IFF zu stärken, Parfümeuren hochwertige, innovative sowie nachhaltig beschaffte und produzierte natürliche Inhaltsstoffe zu wettbewerbsfähigen Kosten bereitzustellen. Parfümeure weltweit nutzen die tiefgreifende Expertise der LMR-Wissenschaftler, um für Kunden die Signatur unvergesslicher Düfte zu kreieren und Anwendungen in Bereichen wie Feinparfümerie, Kosmetik, Haushaltspflege, Textilpflege sowie Körperpflege zu entwickeln. LMR Naturals liefert zudem Inhaltsstoffe für Geschmacksanwendungen.


Willkommen bei IFF


Bei IFF (NYSE: IFF) schaffen wir Freude durch Wissenschaft, Kreativität und Herz. Als weltweit führendes Unternehmen in den Bereichen Geschmack, Duft, Lebensmittelzutaten, Gesundheit sowie Biowissenschaften entwickeln wir Innovationen für die Zukunft. Jeden Tag liefern wir wegweisende, nachhaltige Lösungen, die Produkte aufwerten, die Menschen lieben — sie fördern Wohlbefinden, begeistern die Sinne und verbessern das menschliche Erleben. Weitere Informationen finden Sie auf iff.com, LinkedIn, Instagram und Facebook.


© 2026 von International Flavors & Fragrances Inc. IFF ist eine eingetragene Marke. Alle Rechte vorbehalten.


Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.

Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260224022768/de/
Pressekontakt:

Judith Gross

Bereichsleiterin für Kommunikation und Markenführung, IFF Scent

332.877.5339

media.request@IFF.com


Original: LMR präsentiert Tonka Bean CO2 Absolute: Gourmand-Exzellenz aus umweltschonender Extraktion

LMR?Tonka Bean CO2 Absolute???:????????????????????February 25, 2026 8:58 AM
Business Wire
?????CO2 ?????????????????????????

(???????) --
IFF(NYSE:IFF)?LMR Naturals by IFF???·???·?????????????????????????????????·????????????????????????????????12????????Conscious Collection???Tonka Bean CO2 Absolute??????????Tonka Bean CO2 Absolute?????????????????????????????????????????????????????IFF???????????CO2???·????????CO2?????????????

?????????????????????????????????????????????:https://www.businesswire.com/news/home/20260224010294/ja/Tonka Bean CO2 Absolute extracted by LMR.
LMR Naturals by IFF??????????????????·?·???????????????????????????CO2?????????????LMR????????????????(???)”????????????????????????????Tonka Bean CO2 Absolute???????????????CO2?????????????????????????????????????????????????????????????????????????????????


???????????????????????????????????CO2?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????Tonka Absolute???????????????????????(cradle-to-gate?-34%)?


??????????????????LMR Tonka Bean CO2?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????Tonka absolute?????????????????????????????????????


IFF????·????????????????·???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????


Tonka Bean CO2????????????????????IFF?????????????????????????????????????????????LMR Naturals???????????????????????1,000?????????????????????????????????????????????????????


LMR Naturals??IFF??????????????????1983??????·?????????2000??IFF?????????????IFF??????????????????????????·????????????????????????????????????????????????????LMR?????????????????????????????????????????????????????????????????????????????LMR Naturals????????????????????


????IFF?


IFF(NYSE:IFF)???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????iff.com?LinkedIn?Instagram?Facebook????????


© 2026 International Flavors & Fragrances Inc. IFF????????????·????????


??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????

businesswire.com????????????:https://www.businesswire.com/news/home/20260224010294/ja/
Media Relations:

Judith Gross

VP, Communications & Branding, IFF Scent

332.877.5339

media.request@IFF.com


Original: LMR?Tonka Bean CO2 Absolute???:????????????????????

LMR présente Tonka Bean CO2 Absolute : l'excellence gourmande issue d'une extraction respectueuse de la planèteFebruary 24, 2026 1:46 PM
Business Wire
Une saveur profonde et authentique obtenue grâce à une technologie d'extraction au CO2 renouvelable.


IFF (NYSE : IFF) — LMR Naturals by IFF, un chef de file mondial des ingrédients naturels pour la parfumerie, la cosmétique et les arômes, vient de lancer Tonka Bean CO2 Absolute dans le cadre de sa collection Conscious, une gamme de 12 ingrédients naturels hautement durables et traçables pour les parfums et les arômes. Tonka Bean CO2 Absolute est un extrait naturel avec une signature olfactive gourmande. Ce nouvel ajout à la palette du parfumeur est produit avec du CO2 supercritique renouvelable et recyclé sur le site d’extraction d’IFF à Aubrac, en France.

Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20260224233348/fr/Tonka Bean CO2 Absolute extracted by LMR.
« Notre unité d'extraction au CO2 à Aubrac a permis à LMR d'élaborer une collection d'extraits qui allie harmonieusement la durabilité à des profils hédoniques exclusifs pour les parfumeurs », déclare Bertrand de Préville, directeur général de LMR Naturals by IFF. « Avec le lancement de Tonka Bean CO2 Absolute, nous réaffirmons notre engagement en faveur de l’extraction au CO2 supercritique et de l'innovation en parfumerie respectueuse de l'environnement, soulignant ainsi notre leadership en matière d’ingrédients naturels de la plus haute qualité pour la parfumerie fine. »


Le nouvel extrait de fève de tonka offre des performances optimisées et un meilleur rapport coût-efficacité. Le procédé d'extraction au CO2 diminue la consommation d'énergie, ce qui réduit l'impact environnemental par rapport à l'extraction au solvant traditionnelle. L'extraction est effectuée à basse température, ne laisse aucun résidu pétrochimique et protège les molécules volatiles et sensibles. On obtient ainsi un extrait de haute qualité qui préserve la senteur authentique des fèves de tonka fraîchement récoltées avec une empreinte carbone plus faible (-34% de la fabrication à la sortie du site de production) par rapport au Tonka Absolute traditionnel.


Avec des origines qui remontent à la forêt amazonienne, le LMR Tonka Bean CO2 apporte de la naturalité, de la chaleur et une texture luxueuse aux parfums fins et grand public. Les caractéristiques crémeuse et réconfortante de l’ingrédient parlent aux consommateurs à la recherche de confort, de nostalgie et d'un petit plaisir. Sa note primaire d'amande torréfiée et sa nuance de foin séché au soleil combinées à des accents de cacao créent une expérience parfumée plus riche et plus veloutée que le Tonka Absolute.


« Ce que j'adore avec ce produit est qu’il apporte de nouvelles dimensions captivantes », déclare Alexandra Carlin, parfumeur senior, IFF. « Il apporte une note de sucre brun, une pointe de sarrasin et même une touche subtile de cacao. C’est à la fois étonnamment sucré et salé, tout en gardant une profondeur enivrante. »


Tonka Bean CO2 marque les dernières avancées d’IFF pour façonner l’avenir de l’innovation en parfumerie. Cette annonce fait suite à l'inauguration récente du site LMR Naturals à Grasse, en France. L’investissement de dix millions d’euros de l’entreprise dans le site de Grasse renforce sa capacité à stimuler l’innovation dans le domaine des ingrédients naturels au cœur de la capitale mondiale de la parfumerie.


LMR Naturals est une marque déposée d’IFF, fondée à l’origine en 1983 par Monique Rémy et acquise par IFF en 2000 afin de renforcer la capacité d’IFF à fournir aux parfumeurs des ingrédients naturels de haute qualité, innovants, issus de sources durables et produits à un coût compétitif. Les parfumeurs du monde entier tirent parti de toute l'expertise des scientifiques de LMR pour créer des parfums inoubliables pour les clients et tous les secteurs d'activité, comme la parfumerie fine, la cosmétique, l'entretien de la maison, l'entretien du linge et les produits de beauté. LMR Naturals fournit également des ingrédients pour les applications gustatives.


Bienvenue chez IFF


Chez IFF (NYSE : IFF), nous créons de la joie grâce à la science, la créativité et la passion. En tant que leader mondial des ingrédients gustatifs, olfactifs et alimentaires, de la santé et des biosciences, nous innovons pour façonner l’avenir. Jour après jour, nous proposons des solutions innovantes et durables qui rehaussent les produits les plus appréciés des clients, pour promouvoir le bien-être, ravir les sens et améliorer l’expérience humaine. Pour de plus amples renseignements, rendez-vous sur iff.com, LinkedIn, Instagram et Facebook.


© 2026 par International Flavors & Fragrances Inc. IFF est une marque déposée. Tous droits réservés.


Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Consultez la version source sur businesswire.com : https://www.businesswire.com/news/home/20260224233348/fr/
Relations avec les médias :

Judith Gross

VP, communications et stratégie de marque, IFF Scent

332.877.5339

media.request@IFF.com


Original: LMR présente Tonka Bean CO2 Absolute : l'excellence gourmande issue d'une extraction respectueuse de la planète

LMR Unveils Tonka Bean CO2 Absolute: Gourmand Excellence from Planet-Friendly ExtractionFebruary 24, 2026 8:15 AM
Business Wire
True-to-nature gourmand richness achieved with renewable CO2 technology.


IFF (NYSE: IFF) — LMR Naturals by IFF—a global leader in natural ingredients for perfumery, cosmetics and flavors—has introduced Tonka Bean CO2 Absolute to its Conscious Collection, a line of 12 highly sustainable and traceable natural ingredients for perfumes and flavors. Tonka Bean CO2 Absolute is a natural extract with a gourmand olfactive signature. This new addition to the perfumer’s palette is produced with renewable and recycled supercritical CO2 at IFF’s extraction site in Aubrac, France.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224233830/en/Tonka Bean CO2 Absolute extracted by LMR.
“Our CO2 extraction unit in Aubrac has enabled LMR to develop a collection of extracts that seamlessly blends sustainability with high hedonic profiles for perfumers," said Bertrand de Préville, general manager of LMR Naturals by IFF. "With the launch of Tonka Bean CO2 Absolute, we’re reaffirming our commitment to planet-conscious supercritical CO2 extraction and perfumery innovation—underscoring our leadership in premium natural ingredients for fine perfumery.”


The new Tonka Bean extract features enhanced performance and cost efficiency. The CO2 extraction process used reduces energy consumption, lowering the environmental impact compared with traditional solvent extraction. It is performed at low temperature, leaves no petrochemical residue and protects volatile and sensitive molecules. The result is a high-quality extract that captures the authentic scent of freshly harvested tonka beans with a lower carbon footprint (-34% cradle-to-gate) compared to traditional Tonka Absolute.


With origins that can be traced to the Amazon rainforest, the LMR Tonka Bean CO2 brings added naturality, warmth and luxurious texture to both fine and consumer fragrances. The ingredient’s creamy and comforting facets speak to consumers looking for comfort, nostalgia and a touch of indulgence. Its smooth roasted-almond top note and sun-dried hay nuance combined with cocoa undertones create a richer, more velvety scent experience than traditional Tonka absolute.


“I love that it brings captivating new dimensions,” said Alexandra Carlin, senior perfumer at IFF. “It has a brown sugar twist, a hint of buckwheat and even a subtle touch of cocoa. It’s unexpectedly sweet and salty at the same time and deeply intriguing."


Tonka Bean CO2 marks IFF’s latest advancement in shaping the future of fragrance innovation. This announcement follows the recent inauguration of the expanded LMR Naturals site in Grasse, France. The company’s €10 million investment in the Grasse facility enhances capacity to drive naturals innovation in the heart of the world’s perfume capital.


LMR Naturals is a trademarked capability within IFF, originally founded in 1983 by Monique Remy and acquired by IFF in 2000 to enhance IFF’s ability to provide perfumers with high-quality, innovative and, sustainably sourced and produced natural ingredients at competitive cost. Perfumers around the world leverage the deep expertise of LMR scientists to create the signature of unforgettable fragrances for customers and across applications such as fine perfumery, cosmetics, home care, fabric care and beauty care. LMR Naturals also provides ingredients for taste applications.


Welcome to IFF


At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.


© 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224233830/en/Media Relations:

Judith Gross

VP, Communications & Branding, IFF Scent

332.877.5339

media.request@IFF.com
Original: LMR Unveils Tonka Bean CO2 Absolute: Gourmand Excellence from Planet-Friendly Extraction

IFF Reports Fourth Quarter and Full Year 2025 ResultsFebruary 11, 2026 4:15 PM
Business Wire
Delivered solid top and bottom-line performance & advanced strategic priorities in 2025


Launched sale process for the Food Ingredients segment


Continuing to drive financial performance in 2026


International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2025.


Full year 2025 Consolidated Summary:




Reported






 






Adjusted








(GAAP)







(Non-GAAP)1








Sales






 






Loss Before Taxes






 






EPS






 






Operating EBITDA






 






Operating EBITDA Margin






 






EPS ex Amortization








$10.9 B






 






$(412) M






 






$(1.46)






 






$2.1 B






 






19.2%






 






$4.20







Management Commentary


“IFF delivered a solid 2025 performance, meeting the full-year financial commitments we set at the start of the year, despite a challenging operating environment,” said Erik Fyrwald, CEO of IFF. “It was also a year of continued strategic progress. We invested in R&D, commercial capabilities, and capacity expansion to better serve customers, advance our innovation pipeline, and support future profitable growth.”


“We also took steps to optimize our portfolio. Through several divestitures and the recent launch of a sale process for our Food Ingredients segment, we sharpened our strategic focus and improved our financial flexibility, allowing us to direct resources to our highest-value businesses.”


“Looking ahead to 2026, we are continuing to serve our customers with leading innovation to grow profitably with them and deliver financial performance across the company. While macroeconomic uncertainty persists, we are encouraged by the strength of our pipeline and the benefits of our reinvestment actions. We enter the year confident in our ability to deliver on our priorities and create long-term value for our shareholders.”


Full year 2025 Consolidated Financial Results



Reported net sales for the full year were $10.89 billion, a decrease of (5)% compared to the prior year. On a comparable basis2, currency neutral sales1 increased 2%, against a strong 6% year ago comparable, with mid-single digit growth in Taste and low-single digit performances in Health & Biosciences and Scent.



Loss before taxes on a reported basis for the full year was $412 million. Adjusted operating EBITDA1 for the full year was $2.086 billion. On a comparable basis2, currency neutral adjusted operating EBITDA1 increased 7%, led by volume growth, productivity gains and favorable net pricing.



Reported earnings (loss) per share (EPS) for the full year was $(1.46). Adjusted EPS excluding amortization1 was $4.20 per diluted share.



Cash flow from operations for the full year was $850 million, and free cash flow1 defined as cash flow from operations less capital expenditures totaled $256 million. Total debt to trailing twelve months net income at the end of the fourth quarter was (16.2)x. Net debt to credit-adjusted EBITDA1 at the end of the full year was 2.6x.



Full year 2025 Segment Summary: Growth vs. Prior Year




 






Reported

(GAAP)






 






Comparable

Currency

Neutral

(Non-GAAP)1 2






 






Adjusted

(Non-GAAP)1






 






Comparable

Currency

Neutral

Adjusted

(Non-GAAP)1 2








 






Sales






 






Sales






 






Operating EBITDA






 






Operating EBITDA








Taste






2%






 






4%






 






4%






 






10%








Health & Biosciences






4%






 






3%






 






3%






 






7%








Scent






2%






 






3%






 






(6)%






 






2%








Food Ingredients






(3)%






 






(3)%






 






4%






 






10%








Pharma Solutions






(65)%






 






12%






 






(65)%






 






16%








Consolidated






(5)%






 






2%






 






(5)%






 






7%







Taste Segment



On a reported basis, sales were $2.48 billion. On a comparable basis2, currency neutral sales1 increased 4% with broad-based growth in all regions.



Taste adjusted operating EBITDA1 was $478 million and adjusted operating EBITDA margin1 was 19.3% for the full year. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 10% led by favorable net pricing, volume growth and productivity gains.



Health & Biosciences Segment



On a reported basis, sales were $2.28 billion. On a comparable basis2, currency neutral sales1 increased 3% driven by growth in nearly all businesses led by a high-single digit increase in Food Biosciences and mid-single digit growth in Home & Personal Care and Animal Nutrition.



Health & Biosciences adjusted operating EBITDA1 was $594 million and adjusted operating EBITDA margin1 was 26.0% for the full year. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 7% led primarily by volume growth and productivity gains.



Scent Segment



On a reported basis, sales were $2.48 billion. On a comparable basis2, currency neutral sales1 improved 3% led by double-digit growth in Fine Fragrance and a low-single digit performance in Consumer Fragrance.



Scent adjusted operating EBITDA1 was $515 million and adjusted operating EBITDA margin1 was 20.8% for the full year. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 2% led primarily by volume growth and productivity gains offset partially by reinvestment and unfavorable net pricing.



Food Ingredients Segment



On a reported basis, sales were $3.28 billion. On a comparable basis2, currency neutral sales1 decreased (3)% as double-digit growth in Inclusions was offset primarily by softness in Protein Solutions as well as the proactive exit of low margin business over the course of 2025.



Food Ingredients adjusted operating EBITDA1 was $423 million and adjusted operating EBITDA margin1 was 12.9% for the full year. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 10% driven primarily by productivity gains and margin improvement initiatives.



Fourth Quarter 2025 Consolidated Summary:




Reported

(GAAP)






 






Adjusted

(Non-GAAP)1








Sales






 






Income Before Taxes






 






EPS






 






Operating EBITDA






 






Operating EBITDA Margin






 






EPS ex Amortization








$2.6 B






 






$22 M






 






$0.07






 






$437 M






 






16.9%






 






$0.80







Fourth Quarter 2025 Consolidated Financial Results



Reported net sales for the fourth quarter were $2.59 billion, a decrease of (7)% compared to the prior year period. On a comparable basis2, currency neutral sales1 increased 1% versus the prior year period, against a strong 6% year ago comparable, led by mid-single digit growth in Health & Biosciences and Scent and a low-single digit performance in Taste.



Income before taxes on a reported basis for the fourth quarter was $22 million. Adjusted operating EBITDA1 for the fourth quarter was $437 million. On a comparable basis2, currency neutral adjusted operating EBITDA1 increased 7% led primarily by productivity gains.



Reported earnings per share (EPS) for the fourth quarter was $0.07. Adjusted EPS excluding amortization1 was $0.80 per diluted share.



Fourth Quarter 2025 Segment Summary: Growth vs. Prior Year




 






Reported

(GAAP)






 






Comparable

Currency Neutral

Adjusted

(Non-GAAP)1 2






 






Adjusted

(Non-GAAP)1






 






Comparable

Currency Neutral

Adjusted

(Non-GAAP)1 2








 






Sales






 






Sales






 






Operating EBITDA






 






Operating EBITDA








Taste






2%






 






2%






 






8%






 






17%








Health & Biosciences






7%






 






5%






 






14%






 






20%








Scent






6%






 






4%






 






0%






 






1%








Food Ingredients






(2)%






 






(4)%






 






(18)%






 






(11)%








Consolidated






(7)%






 






1%






 






(7)%






 






7%







Taste Segment



On a reported basis, sales were $588 million. On a comparable basis2, currency neutral sales1 increased 2%, with broad based growth in all regions led by a strong performance in North America.



Taste adjusted operating EBITDA1 was $94 million and adjusted operating EBITDA margin1 was 16% in the fourth quarter. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 17% led primarily by favorable net pricing and cost discipline.



Health & Biosciences Segment



On a reported basis, sales were $589 million. On a comparable basis2, currency neutral sales1 increased 5% as double-digit performances in Food Biosciences and Animal Nutrition and high-single digit growth in Home & Personal Care was partially offset by softness in Health, specifically in North America.



Health & Biosciences adjusted operating EBITDA1 was $155 million and adjusted operating EBITDA margin1 was 26.3% in the fourth quarter. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 20% led by volume growth and productivity gains.



Scent Segment



On a reported basis, sales were $610 million. On a comparable basis2, currency neutral sales1 improved 4% driven by double digit growth in Fine Fragrance and a mid-single digit performance in Consumer Fragrance.



Scent adjusted operating EBITDA1 was $106 million and adjusted operating EBITDA margin1 was 17.4% in the fourth quarter. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 1% as volume growth and productivity gains were partially offset by unfavorable net pricing.



Food Ingredients Segment



On a reported basis, sales were $802 million. On a comparable basis2, currency neutral sales1 decreased (4)% as growth in Systems and Inclusions was offset primarily by softness in Protein Solutions and Emulsifiers & Sweeteners.



Food Ingredients adjusted operating EBITDA1 was $82 million and adjusted operating EBITDA margin1 was 10.2% in the fourth quarter. On a comparable basis2, currency neutral adjusted operating EBITDA1 declined (11)% as productivity gains were more than offset by lower volumes and unfavorable net price.



2026 Financial Guidance


Full year 2026 sales are expected to be in the range of $10.5 billion to $10.8 billion and full year 2026 adjusted operating EBITDA to be in the range of $2.05 billion to $2.15 billion. Full year guidance includes three months of our Soy Crush, Concentrates, and Lecithin business results with the divestiture assumed to close on March 31, 2026.


The Company expects comparable currency neutral sales growth to be between 1% to 4%. Comparable currency neutral adjusted operating EBITDA is expected to grow at a faster rate than sales, growing 3% to 8% year-over-year.


Based on recent market foreign exchange rates, the Company expects that foreign exchange will have an approximately 1% positive impact to sales growth and have no impact on adjusted operating EBITDA growth in 2026. The Company also expects that divestitures will have an approximately 5% adverse impact to both sales and adjusted operating EBITDA growth in 2026.


A copy of the Company’s Annual Report on Form 10-K will be available on its website at www.iff.com or at www.sec.gov by March 2, 2026.


Audio Webcast


A live webcast to discuss the Company’s fourth quarter and full year 2025 financial results and outlook for 2026 will be held on February 12, 2026, at 9:00 a.m. ET. The webcast and accompanying slide presentation may be accessed on the Company’s IR website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available on the Company’s website approximately one hour after the event and will remain available on IFF’s website for one year.


Cautionary Statement Under The Private Securities Litigation Reform Act of 1995


This press release includes statements that are not historical facts and are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management’s current assumptions, estimates and expectations, including with respect to our financial and operational outlook (sales, adjusted operating EBITDA and cash flow), portfolio optimization initiatives (including the ongoing sale process for our Food Ingredients division), pricing, productivity and cost-discipline actions, capital allocation, future operations, growth potential, strategic investments and the expected effects of foreign exchange. These statements reflect management’s present views, are based on a series of expectations, assumptions, estimates and projections about the Company, are subject to change, and involve uncertainties that could cause actual results to differ materially.


Certain of such forward-looking information may be identified by such terms as “expect”, “anticipate”, “believe”, “intend”, “outlook”, “may”, “estimate”, “should”, “predict”, “plan”, “project”, “could”, and similar terms or variations thereof. These statements are not guarantees of future performance and are subject to risks and uncertainties that could lead to materially different outcomes.


Such risks, uncertainties and other factors include, among others, the following: (1) demand trends, competitive dynamics and customer concentration in our end markets; (2) execution of our strategic transformation and other strategic transactions, divestitures, acquisitions, collaborations and joint ventures; (3) working capital and inventory management; (4) outcomes of legal claims, disputes, regulatory investigations and litigation; (5) tariffs and trade actions, supply chain disruptions and macro events, including geopolitical developments, climate events, natural disasters, public health crises; (6) volatility in input costs (such as raw materials, transportation and energy); (7) attraction, retention and turnover of key employees and executives; (8) product innovation, time-to-market, product safety and quality; (9) cybersecurity incidents, artificial intelligence related risks, data privacy and compliance with data protection laws; (10) exposure to emerging markets, foreign currency fluctuations and international regulatory and political risks; (11) capital allocation, dividend policy and potential impairments of tangible or intangible assets; (12); our indebtedness, credit rating liquidity, and access to capital; (13) pension and postretirement obligations; (14) compliance with federal, state, local and international rules and regulations, and regulatory, environmental, anti-corruption and sanctions laws and related ethical business practices; (15) protection and enforcement of intellectual property; (16) changes in tax laws and policies, tax audits and outcomes, including potential tax liabilities related to prior transactions; and (17) changes in federal, state, local and international rules and regulations.


The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. Important factors are described under “Risk Factors” in our most recent Annual Report on Form 10-K and in our subsequent filings with the SEC, and those disclosures are incorporated herein by reference.


We intend our forward-looking statements to speak only as of the time of such statements and do not undertake or plan to update or revise them as more information becomes available or to reflect changes in expectations, assumptions or results, whether as a result of new information, future events or otherwise. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this press release or included in our other periodic reports filed with the SEC could materially and adversely impact our operations and our future financial results.


Any public statements or disclosures made by us following this press release that modify or impact any of the forward-looking statements contained in or accompanying this press release will be deemed to modify or supersede such outlook or other forward-looking statements in or accompanying this press release.


Use of Non-GAAP Financial Measures


We provide in this press release non-GAAP financial measures, including: (i) comparable, currency neutral sales; (ii) adjusted operating EBITDA and comparable, currency neutral adjusted operating EBITDA; (iii) adjusted operating EBITDA margin; (iv) adjusted EPS ex amortization; (v) free cash flow; (vi) net debt to credit adjusted EBITDA; [and] (vii) adjusted selling and administrative expenses; and adjusted gross profit.


Our non-GAAP financial measures are defined below.


Comparable results for the fourth quarter and full year exclude the impact of divestitures.


Currency Neutral metrics eliminate the effects that result from translating non-U.S. currencies to U.S. dollars. We calculate currency neutral numbers by translating current year invoiced sale amounts at the exchange rates used for the corresponding prior year period. We use currency neutral results in our analysis of subsidiary or segment performance. We also use currency neutral numbers when analyzing our performance against our competitors.


Adjusted operating EBITDA and adjusted operating EBITDA margin exclude depreciation and amortization expense, interest expense, other expense, net, and certain non-recurring or unusual items that are not part of recurring operations such as, restructuring and other charges, impairment of goodwill, gains (losses) on business disposals, loss on assets classified as held for sale, divestiture and integration related costs, strategic initiative costs, regulatory costs and other items.


Adjusted EPS ex Amortization excludes the impact of non-operational items including, restructuring and other charges, impairment of goodwill, divestitures and integration related costs, losses (gains) on business disposals, loss on assets classified as held for sale, pension settlement losses (gains), strategic initiative costs, regulatory costs, redemption value adjustment to EPS and other items that are not a part of recurring operations.


Free Cash Flow is operating cash flow (i.e. cash flow from operations) less capital expenditures.


Net debt to credit adjusted EBITDA is the leverage ratio used in our credit agreements and defined as net debt (which is debt for borrowed money less cash and cash equivalents) divided by the trailing 12-month credit adjusted EBITDA. Credit adjusted EBITDA is defined as income (loss) before interest expense, income taxes, depreciation and amortization, specified items and non-cash items.


Adjusted selling and administrative expenses exclude divestiture and integration related costs, strategic initiative costs, regulatory costs, entity realignment costs and other costs.


Adjusted gross profit excludes divestiture and integration related costs.


These non-GAAP measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, as well as the impact of exchange rate fluctuations. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company’s results under GAAP and may not be comparable to other companies’ calculation of such metrics.


We have also presented a non-GAAP measure, adjusted operating EBITDA, in the Financial Guidance provided above. Adjusted operating EBITDA is defined in the previous section of this release and we believe this measure is useful in understanding the Financial Guidance for the same reasons mentioned in that section. The comparable GAAP metric would be Net income (loss), which we do not provide guidance on. Reconciliations from such estimated GAAP metric to the presented non-GAAP metric would also require unreasonable effort because such reconciliations would depend upon events which are uncertain in timing or amounts, and activities which are not completely controlled by us. This includes, by way of illustration, possible transactions and related costs and amounts, known and unknown matters involving regulatory and other bodies and future events involving third parties.


Welcome to IFF


At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.




_______________________








1 Schedules at the end of this release contain reconciliations of reported GAAP to Non-GAAP metrics. See Use of Non-GAAP Financial Measures for explanations of our Non-GAAP metrics.








2 Comparable results for the fourth quarter and full year 2025 exclude the impact of divestitures.







 




International Flavors & Fragrances Inc.








Consolidated Statements of Income (Loss)








(Amounts in millions except per share data)








(Unaudited)







 



 






Three Months Ended December 31,






 






Year Ended December 31,








 






 






2025






 






 






 






2024






 






 






% Change






 






 






2025






 






 






 






2024






 






 






% Change








Net sales






$






2,589






 






 






$






2,771






 






 






(7






)%






 






$






10,890






 






 






$






11,484






 






 






(5






)%








Cost of sales






 






1,699






 






 






 






1,791






 






 






(5






)%






 






 






6,952






 






 






 






7,360






 






 






(6






)%








Gross profit






 






890






 






 






 






980






 






 






(9






)%






 






 






3,938






 






 






 






4,124






 






 






(5






)%








Research and development expenses






 






174






 






 






 






170






 






 






2






%






 






 






694






 






 






 






671






 






 






3






%








Selling and administrative expenses






 






469






 






 






 






517






 






 






(9






)%






 






 






1,834






 






 






 






1,995






 






 






(8






)%








Restructuring and other charges






 






16






 






 






 






23






 






 






(30






)%






 






 






70






 






 






 






29






 






 






141






%








Amortization of acquisition-related intangibles






 






134






 






 






 






143






 






 






(6






)%






 






 






568






 






 






 






610






 






 






(7






)%








Impairment of goodwill






 






—






 






 






 






—






 






 






NMF






 






 






1,153






 






 






 






64






 






 






NMF








Losses (Gains) on sale of assets






 






—






 






 






 






—






 






 






NMF






 






 






1






 






 






 






(11






)






 






(109






)%








Operating profit (loss)






 






97






 






 






 






127






 






 






(24






)%






 






 






(382






)






 






 






766






 






 






(150






)%








Interest expense






 






49






 






 






 






69






 






 






(29






)%






 






 






229






 






 






 






305






 






 






(25






)%








Gain on extinguishment of debt






 






—






 






 






 






—






 






 






NMF






 






 






(488






)






 






 






—






 






 






NMF








(Gains) losses on business disposals






 






(2






)






 






 






2






 






 






(200






)%






 






 






109






 






 






 






(346






)






 






(132






)%








Loss on assets classified as held for sale






 






7






 






 






 






33






 






 






NMF






 






 






115






 






 






 






317






 






 






NMF








Other expense, net






 






21






 






 






 






138






 






 






(85






)%






 






 






65






 






 






 






182






 






 






(64






)%








Income (loss) before income taxes






 






22






 






 






 






(115






)






 






(119






)%






 






 






(412






)






 






 






308






 






 






(234






)%








Provision for (benefit from) income taxes






 






4






 






 






 






(55






)






 






(107






)%






 






 






(40






)






 






 






41






 






 






(198






)%








Net income (loss)






 






18






 






 






 






(60






)






 






(130






)%






 






 






(372






)






 






 






267






 






 






(239






)%








Net income attributable to non-controlling interest






 






—






 






 






 






—






 






 






NMF






 






 






2






 






 






 






4






 






 






(50






)%








Net income (loss) attributable to IFF shareholders






$






18






 






 






$






(60






)






 






(130






)%






 






$






(374






)






 






$






263






 






 






(242






)%








 






 






 






 






 






 






 






 






 






 






 






 








Net income (loss) per share - basic






$






0.07






 






 






$






(0.23






)






 






 






 






$






(1.46






)






 






$






1.04






 






 






 








Net income (loss) per share - diluted






$






0.07






 






 






$






(0.23






)






 






 






 






$






(1.46






)






 






$






1.04






 






 






 








 






 






 






 






 






 






 






 






 






 






 






 








Average number of shares outstanding - basic






 






256






 






 






 






256






 






 






 






 






 






256






 






 






 






256






 






 






 








Average number of shares outstanding - diluted






 






257






 






 






 






256






 






 






 






 






 






256






 






 






 






256






 






 






 







NMF Not meaningful




International Flavors & Fragrances Inc.








Condensed Consolidated Balance Sheets








(Amounts in millions)








(Unaudited)







 



 






December 31,








 






2025






 






2024








Cash, cash equivalents and restricted cash






$






590






 






$






469








Receivables, net






 






1,731






 






 






1,624








Inventories






 






2,245






 






 






2,133








Assets held for sale






 






151






 






 






3,056








Prepaid expenses and other current assets






 






877






 






 






686








Total current assets






 






5,594






 






 






7,968








 






 






 






 








Property, plant and equipment, net






 






4,029






 






 






3,739








Goodwill and other intangibles, net






 






14,312






 






 






15,520








Other assets






 






1,602






 






 






1,496








Total assets






$






25,537






 






$






28,723








 






 






 






 








Short-term borrowings






$






1,254






 






$






1,413








Other current liabilities






 






2,679






 






 






2,939








Total current liabilities






 






3,933






 






 






4,352








 






 






 






 








Long-term debt






 






4,740






 






 






7,564








Non-current liabilities






 






2,684






 






 






2,938








 






 






 






 








Shareholders' equity






 






14,180






 






 






13,869








Total liabilities and shareholders' equity






$






25,537






 






$






28,723









International Flavors & Fragrances Inc.








Consolidated Statements of Cash Flows








(Amounts in millions)








(Unaudited)







 



 






Year Ended December 31,








 






 






2025






 






 






 






2024






 








Cash flows from operating activities:






 






 






 








Net (loss) income






$






(372






)






 






$






267






 








Adjustments to reconcile to net cash provided by operations:






 






 






 








Depreciation and amortization






 






962






 






 






 






1,015






 








Deferred income taxes






 






(251






)






 






 






(323






)








Loss on assets classified as held for sale






 






115






 






 






 






317






 








Gains on sale of assets






 






1






 






 






 






(11






)








Losses (Gains) on business disposals






 






109






 






 






 






(346






)








Stock-based compensation






 






88






 






 






 






77






 








Gain on extinguishment of debt






 






(488






)






 






 






—






 








Pension contributions






 






(29






)






 






 






(29






)








Pension-related (benefit) expense






 






(11






)






 






 






125






 








Impairment of goodwill






 






1,153






 






 






 






64






 








Changes in assets and liabilities, net of acquisitions:






 






 






 








Trade receivables






 






(68






)






 






 






(217






)








Inventories






 






(41






)






 






 






(34






)








Accounts payable






 






(57






)






 






 






40






 








Accruals for incentive compensation






 






(106






)






 






 






190






 








Other assets/liabilities, net






 






(155






)






 






 






(65






)








Net cash provided by operating activities






 






850






 






 






 






1,070






 








Cash flows from investing activities:






 






 






 








Additions to property, plant and equipment






 






(594






)






 






 






(463






)








Additions to intangible assets






 






(2






)






 






 






(5






)








Proceeds from disposal of assets






 






21






 






 






 






21






 








Net proceeds received from business disposals






 






2,743






 






 






 






875






 








Cash received (paid) on foreign currency forward contracts






 






105






 






 






 






(102






)








Joint venture capital contributions






 






(4






)






 






 






—






 








Net cash provided by investing activities






 






2,269






 






 






 






326






 








Cash flows from financing activities:






 






 






 








Cash dividends paid to shareholders






 






(409






)






 






 






(514






)








Net borrowings (repayments) of commercial paper (maturities less than three months)






 






314






 






 






 






—






 








Principal payments of debt






 






(2,913






)






 






 






(1,030






)








Deferred and contingent consideration paid






 






—






 






 






 






(36






)








Withholding tax paid on stock-based compensation






 






(24






)






 






 






(16






)








Purchase of treasury stock






 






(38






)






 






 






—






 








Other, net






 






(21






)






 






 






(10






)








Net cash used in financing activities






 






(3,091






)






 






 






(1,606






)








Effect of exchange rate changes on cash, cash equivalents and restricted cash






 






91






 






 






 






(54






)








Net change in cash, cash equivalents and restricted cash






 






119






 






 






 






(264






)








Cash, cash equivalents and restricted cash at beginning of year






 






471






 






 






 






735






 








Cash, cash equivalents and restricted cash at end of year






$






590






 






 






$






471






 







The following table reconciles cash, cash equivalents and restricted cash between the Company's balance sheets as of December 31, 2025 and 2024 to the amounts reported on the Company's statement of cash flows for the periods ended December 31, 2025 and 2024.




AMOUNTS IN MILLIONS






December 31, 2025






 






December 31, 2024






 






December 31, 2023








Current assets






 






 






 






 






 








Cash and cash equivalents






$






590






 






$






469






 






$






703








Cash and cash equivalents included in Assets held for sale






 






—






 






 






2






 






 






26








Restricted cash






 






—






 






 






—






 






 






6








Cash, cash equivalents and restricted cash






$






590






 






$






471






 






$






735









International Flavors & Fragrances Inc.








Reportable Segment Performance








(Amounts in millions)








(Unaudited)







 



 






Three Months Ended December 31, 2025








 






Taste






 






Food Ingredients






 






H&B






 






Scent






 






Total








Net sales






$






588






 






 






$






802






 






 






$






589






 






 






$






610






 






 






$






2,589








Cost of sales






 






(367






)






 






 






(638






)






 






 






(322






)






 






 






(370






)






 






 








Research & development expenses






 






(44






)






 






 






(15






)






 






 






(55






)






 






 






(61






)






 






 








Selling & administrative expenses






 






(101






)






 






 






(100






)






 






 






(89






)






 






 






(91






)






 






 








Depreciation expense add-back (a)






 






18






 






 






 






33






 






 






 






32






 






 






 






18






 






 






 








Adjusted Operating EBITDA






$






94






 






 






$






82






 






 






$






155






 






 






$






106






 






 






$






437









Reconciliation of Adjusted Operating EBITDA:






 








Total Adjusted Operating EBITDA






$






437






 








Depreciation & Amortization






 






(237






)








Interest Expense






 






(49






)








Other Expense, Net






 






(21






)








Restructuring and Other Charges (b)






 






(16






)








Gains (Losses) on Business Disposals (c)






 






2






 








Loss on Assets Classified as Held for Sale (d)






 






(7






)








Divestiture and Integration Related Costs (e)






 






(35






)








Strategic Initiatives Costs (f)






 






(11






)








Regulatory Costs (g)






 






(35






)








Entity Realignment Costs (h)






 






(3






)








Other (k)






 






(3






)








Income (Loss) Before Taxes






$






22






 









Segment Adjusted Operating EBITDA Margin






 








Taste






16.0






%








Food Ingredients






10.2






%








Health & Biosciences






26.3






%








Scent






17.4






%








Consolidated






16.9






%









 






Three Months Ended December 31, 2024








 






Taste






 






Food Ingredients






 






H&B






 






Scent






 






Pharma






 






Total








Net sales






$






576






 






 






$






819






 






 






$






550






 






 






$






578






 






 






$






248






 






 






$






2,771








Cost of sales






 






(360






)






 






 






(630






)






 






 






(298






)






 






 






(330






)






 






 






(173






)






 






 








Research & development expenses






 






(43






)






 






 






(13






)






 






 






(50






)






 






 






(58






)






 






 






(6






)






 






 








Selling & administrative expenses






 






(104






)






 






 






(108






)






 






 






(95






)






 






 






(101






)






 






 






(31






)






 






 








Depreciation expense add-back (a)






 






18






 






 






 






32






 






 






 






29






 






 






 






17






 






 






 






4






 






 






 








Adjusted Operating EBITDA






$






87






 






 






$






100






 






 






$






136






 






 






$






106






 






 






$






42






 






 






$






471









Reconciliation of Adjusted Operating EBITDA:






 








Total Adjusted Operating EBITDA






$






471






 








Depreciation & Amortization






 






(243






)








Interest Expense






 






(69






)








Other Expense, Net






 






(138






)








Restructuring and Other Charges (b)






 






(23






)








Gains (Losses) on Business Disposals (c)






 






(2






)








Loss on Assets Classified as Held for Sale (d)






 






(33






)








Divestiture and Integration Related Costs (e)






 






(56






)








Strategic Initiatives Costs (f)






 






(11






)








Regulatory Costs (g)






 






(9






)








Other (k)






 






(2






)








Income (Loss) Before Taxes






$






(115






)









Segment Adjusted Operating EBITDA Margin






 








Taste






15.1






%








Food Ingredients






12.2






%








Health & Biosciences






24.7






%








Scent






18.3






%








Pharma Solutions






16.9






%








Consolidated






17.0






%









 






Twelve Months Ended December 31, 2025








 






Taste






 






Food Ingredients






 






H&B






 






Scent






 






Pharma






 






Total








Net sales






$






2,481






 






 






$






3,278






 






 






$






2,283






 






 






$






2,479






 






 






$






369






 






 






$






10,890








Cost of sales






 






(1,500






)






 






 






(2,531






)






 






 






(1,246






)






 






 






(1,424






)






 






 






(248






)






 






 








Research & development expenses






 






(172






)






 






 






(54






)






 






 






(219






)






 






 






(241






)






 






 






(8






)






 






 








Selling & administrative expenses






 






(396






)






 






 






(400






)






 






 






(348






)






 






 






(366






)






 






 






(42






)






 






 








Depreciation expense add-back (a)






 






65






 






 






 






130






 






 






 






124






 






 






 






67






 






 






 






5






 






 






 








Adjusted Operating EBITDA






$






478






 






 






$






423






 






 






$






594






 






 






$






515






 






 






$






76






 






 






$






2,086









Reconciliation of Adjusted Operating EBITDA:






 








Total Adjusted Operating EBITDA






$






2,086






 








Depreciation & Amortization






 






(962






)








Interest Expense






 






(229






)








Other Expense, Net






 






(65






)








Restructuring and Other Charges (b)






 






(70






)








Impairment of Goodwill (i)






 






(1,153






)








Gains (Losses) on Business Disposals (c)






 






(109






)








Loss on Assets Classified as Held for Sale (d)






 






(115






)








Gain on Extinguishment of Debt (j)






 






488






 








Divestiture and Integration Related Costs (e)






 






(125






)








Strategic Initiatives Costs (f)






 






(35






)








Regulatory Costs (g)






 






(106






)








Entity Realignment Costs (h)






 






(8






)








Other (k)






 






(9






)








Income (Loss) Before Taxes






$






(412






)









Segment Adjusted Operating EBITDA Margin






 








Taste






19.3






%








Food Ingredients






12.9






%








Health & Biosciences






26.0






%








Scent






20.8






%








Pharma Solutions






20.6






%








Consolidated






19.2






%









 






Twelve Months Ended December 31, 2024








 






Taste






 






Food Ingredients






 






H&B






 






Scent






 






Pharma






 






Total








Net sales






$






2,428






 






 






$






3,365






 






 






$






2,203






 






 






$






2,439






 






 






$






1,049






 






 






$






11,484








Cost of sales






 






(1,470






)






 






 






(2,626






)






 






 






(1,183






)






 






 






(1,361






)






 






 






(719






)






 






 








Research & development expenses






 






(160






)






 






 






(71






)






 






 






(190






)






 






 






(225






)






 






 






(25






)






 






 








Selling & administrative expenses






 






(403






)






 






 






(391






)






 






 






(368






)






 






 






(376






)






 






 






(115






)






 






 








Depreciation expense add-back (a)






 






65






 






 






 






131






 






 






 






115






 






 






 






68






 






 






 






25






 






 






 








Adjusted Operating EBITDA






$






460






 






 






$






408






 






 






$






577






 






 






$






545






 






 






$






215






 






 






$






2,205









Reconciliation of Adjusted Operating EBITDA:






 








Total Adjusted Operating EBITDA






$






2,205






 








Depreciation & Amortization






 






(1,015






)








Interest Expense






 






(305






)








Other Expense, Net






 






(182






)








Restructuring and Other Charges (b)






 






(29






)








Impairment of Goodwill (i)






 






(64






)








Gains (Losses) on Business Disposals (c)






 






346






 








Loss on Assets Classified as Held for Sale (d)






 






(317






)








Divestiture and Integration Related Costs (e)






 






(228






)








Strategic Initiatives Costs (f)






 






(33






)








Regulatory Costs (g)






 






(73






)








Entity Realignment Costs (h)






 






(6






)








Other (k)






 






9






 








Income (Loss) Before Taxes






$






308






 









Segment Adjusted Operating EBITDA Margin






 








Taste






18.9






%








Food Ingredients






12.1






%








Health & Biosciences






26.2






%








Scent






22.3






%








Pharma Solutions






20.5






%








Consolidated






19.2






%









(a)







There is depreciation recorded within cost of sales, research & development expenses, and selling & administrative expenses, which is then added back to calculate segment Adjusted Operating EBITDA. This reflects how the CODM reviews Segment results.








(b)







For 2025, represents costs related to the IFF Productivity Program including severance, fixed asset write-downs and site closure expenses, net of the gain on sale of fixed assets previously written down. For 2024, represents initial costs in connection with the IFF Productivity Program, primarily related to fixed asset write-downs.








(c)







For 2025, primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized as part of the sale of the Nitrocellulose business and Rene Laurent business in France. For 2024, primarily represents gains recognized as part of the sale of the Cosmetic Ingredients business and losses recognized as part of the sale of the Flavors & Essences UK business.








(d)







For 2025, represents the losses recognized on assets classified as held for sale of the Soy, Concentrates and Lecithin disposal group. For 2024, represents the losses recognized on assets classified as held for sale of the Pharma Solutions disposal group and portion of the Savory Solutions business in Turkey.








(e)







For 2025 and 2024, primarily represents costs related to the Company's completed and anticipated divestitures. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts.








(f)







Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services Centers, primarily consulting fees. For 2024, also includes strategic initiatives related to the Company's business unit re-organization efforts.








(g)







Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.








(h)







Represents costs related to a phased restructuring initiative aimed at optimizing its legal entity framework.








(i)







For 2025, represents the impairment of goodwill related to the Food Ingredients reporting unit. For 2024, represents the impairment of goodwill related to the Pharma Solutions disposal group.








(j)







For 2025, represents the gain recognized on the extinguishment of debt in connection with the completion of tender offers.








(k)







For 2025, primarily represents the net impact of costs related to severance, including accelerated stock compensation expense, for certain executives who have separated from the Company. For 2025, also includes the impact of legislation changes in India related to the Wage Code. For 2024, primarily represents gains from sale of assets.







International Flavors & Fragrances Inc.

GAAP to Non-GAAP Reconciliation

(Unaudited)


The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.




Reconciliation of Gross Profit








 






Fourth Quarter








(DOLLARS IN MILLIONS)






2025






 






2024








Reported (GAAP)






$






890






 






$






980








Divestiture and Integration Related Costs (b)






 






1






 






 






—








Adjusted (Non-GAAP)






$






891






 






$






980









Reconciliation of Selling and Administrative Expenses








 






Fourth Quarter








(DOLLARS IN MILLIONS)






 






2025






 






 






 






2024






 








Reported (GAAP)






$






469






 






 






$






517






 








Divestiture and Integration Related Costs (b)






 






(34






)






 






 






(56






)








Strategic Initiatives Costs (f)






 






(11






)






 






 






(11






)








Regulatory Costs (g)






 






(36






)






 






 






(9






)








Entity Realignment Costs (h)






 






(3






)






 






 






(2






)








Other (i)






 






(2






)






 






 






—






 








Adjusted (Non-GAAP)






$






383






 






 






$






439






 







International Flavors & Fragrances Inc.

GAAP to Non-GAAP Reconciliation

(Unaudited)


The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.




Reconciliation of Net Income (Loss) and EPS








 






Fourth Quarter








 






2025






 






2024








(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)






Income (loss) before taxes






 






Provision from Income taxes (j)






 






Net income (loss) attributable to IFF






 






Diluted EPS






 






(Loss) income before taxes






 






Benefit from Income taxes (j)






 






Net (loss) income attributable to IFF






 






Diluted EPS








Reported (GAAP)






$






22






 






 






$






4






 






 






$






18






 






 






$






0.07






 






 






$






(115






)






 






$






(55






)






 






$






(60






)






 






$






(0.23






)








Restructuring and Other Charges (a)






 






16






 






 






 






4






 






 






 






12






 






 






 






0.05






 






 






 






23






 






 






 






6






 






 






 






17






 






 






 






0.07






 








Divestiture and Integration Related Costs (b)






 






35






 






 






 






9






 






 






 






26






 






 






 






0.10






 






 






 






56






 






 






 






12






 






 






 






44






 






 






 






0.16






 








(Gains) Losses on Business Disposals (c)






 






(2






)






 






 






(4






)






 






 






2






 






 






 






—






 






 






 






2






 






 






 






(1






)






 






 






3






 






 






 






0.01






 








Loss on Assets Classified as Held for Sale (d)






 






7






 






 






 






2






 






 






 






5






 






 






 






0.02






 






 






 






33






 






 






 






8






 






 






 






25






 






 






 






0.10






 








Pension Settlement (Gains) Losses (e)






 






(6






)






 






 






(1






)






 






 






(5






)






 






 






(0.02






)






 






 






129






 






 






 






45






 






 






 






84






 






 






 






0.33






 








Strategic Initiatives Costs (f)






 






11






 






 






 






3






 






 






 






8






 






 






 






0.04






 






 






 






11






 






 






 






3






 






 






 






8






 






 






 






0.03






 








Regulatory Costs (g)






 






35






 






 






 






2






 






 






 






33






 






 






 






0.13






 






 






 






9






 






 






 






2






 






 






 






7






 






 






 






0.02






 








Entity Realignment Costs (h)






 






3






 






 






 






1






 






 






 






2






 






 






 






0.01






 






 






 






2






 






 






 






1






 






 






 






1






 






 






 






0.03






 








Other (i)






 






3






 






 






 






—






 






 






 






3






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 








Adjusted (Non-GAAP)






$






124






 






 






$






20






 






 






$






104






 






 






$






0.40






 






 






$






150






 






 






$






21






 






 






$






129






 






 






$






0.52






 









Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization








 






Fourth Quarter








(DOLLARS AND SHARE AMOUNTS IN MILLIONS)






2025






 






2024








Numerator






 






 






 








Adjusted (Non-GAAP) Net Income






$






104






 






$






129








Amortization of Acquisition-related Intangible Assets






 






134






 






 






143








Tax impact on Amortization of Acquisition-related Intangible Assets (j)






 






32






 






 






35








Amortization of Acquisition-related Intangible Assets, net of tax (k)






 






102






 






 






108








Adjusted (Non-GAAP) Net Income ex. Amortization






$






206






 






$






237








 






 






 






 








Denominator






 






 






 








Weighted average shares assuming dilution (diluted)






 






257






 






 






256








Adjusted (Non-GAAP) EPS ex. Amortization






$






0.80






 






$






0.93









(a)







For 2025, represents costs related to the IFF Productivity Program including severance, fixed asset write-downs and site closure expenses, net of the gain on sale of fixed assets previously written down. For 2024, represents initial costs in connection with the IFF Productivity Program, primarily related to fixed asset write-downs.








(b)







For 2025 and 2024, primarily represents costs related to the Company's completed and anticipated divestitures. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts.










 










For the three months ended December 31, 2025 and December 31, 2024, business divestiture costs were approximately $35 million and $56 million, respectively.








(c)







For 2025, primarily represents the gain recognized related to the divestiture of the Rene Laurent business in France. For 2024, primarily represents the impact of adjustments to the gain recognized related to the divestiture of the Cosmetic Ingredients business.








(d)







For 2025, represents the losses recognized on assets classified as held for sale of the Soy, Concentrates and Lecithin disposal group. For 2024, represents the losses recognized on assets classified as held for sale of the Pharma Solutions disposal group.








(e)







For 2024, represents a settlement loss that was recognized as a result of the termination of the International Flavors & Fragrances Inc. Pension Plan. During 2025, a reduction of the previous settlement loss was recognized.








(f)







For 2025 and 2024, represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Service Centers, primarily consulting fees.








(g)







Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.








(h)







For 2025 and 2024, represents costs related to the Company's entity realignment project to optimize the structure of holding companies, primarily consulting fees.








(i)







For 2025, primarily represents the impact of legislation changes in India related to the Wage Code.








(j)







The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at 0%. The tax benefit for amortization is calculated in a similar manner as the tax effects of the non-GAAP adjustments.








(k)







Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax.







International Flavors & Fragrances Inc.

GAAP to Non-GAAP Reconciliation

(Unaudited)


The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.




Reconciliation of Gross Profit








 






Year Ended December 31,








(DOLLARS IN MILLIONS)






2025






 






2024








Reported (GAAP)






$






3,938






 






$






4,124








Divestiture and Integration Related Costs (b)






 






1






 






 






1








Adjusted (Non-GAAP)






$






3,939






 






$






4,125









Reconciliation of Selling and Administrative Expenses








 






Year Ended December 31,








(DOLLARS IN MILLIONS)






 






2025






 






 






 






2024






 








Reported (GAAP)






$






1,834






 






 






$






1,995






 








Divestiture and Integration Related Costs (b)






 






(123






)






 






 






(227






)








Strategic Initiatives Costs (g)






 






(35






)






 






 






(33






)








Regulatory Costs (h)






 






(106






)






 






 






(73






)








Entity Realignment Costs (j)






 






(8






)






 






 






(6






)








Other (l)






 






(8






)






 






 






(2






)








Adjusted (Non-GAAP)






$






1,554






 






 






$






1,654






 







International Flavors & Fragrances Inc.

GAAP to Non-GAAP Reconciliation

(Unaudited)


The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.




Reconciliation of Net (Loss) Income and EPS








 






Year Ended December 31,








 






2025






 






2024








(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)






(Loss) income before taxes






 






Benefit for income taxes (m)






 






Net (loss) income attributable to IFF (n)






 






Diluted EPS






 






Income (loss) before taxes






 






Provision for income taxes (m)






 






Net income (loss) attributable to IFF (n)






 






Diluted EPS








Reported (GAAP)






$






(412






)






 






$






(40






)






 






$






(374






)






 






$






(1.46






)






 






$






308






 






 






$






41






 






 






$






263






 






 






$






1.04






 








Restructuring and Other Charges (a)






 






70






 






 






 






16






 






 






 






54






 






 






 






0.21






 






 






 






29






 






 






 






7






 






 






 






22






 






 






 






0.09






 








Divestiture and Integration Related Costs (b)






 






125






 






 






 






46






 






 






 






79






 






 






 






0.31






 






 






 






225






 






 






 






50






 






 






 






175






 






 






 






0.68






 








Impairment of Goodwill (c)






 






1,153






 






 






 






7






 






 






 






1,146






 






 






 






4.48






 






 






 






64






 






 






 






—






 






 






 






64






 






 






 






0.25






 








Losses (Gains) on Business Disposals (d)






 






109






 






 






 






(153






)






 






 






262






 






 






 






1.02






 






 






 






(346






)






 






 






(24






)






 






 






(322






)






 






 






(1.26






)








Loss on Assets Classified as Held for Sale (e)






 






115






 






 






 






27






 






 






 






88






 






 






 






0.34






 






 






 






317






 






 






 






66






 






 






 






251






 






 






 






0.98






 








Pension Settlement (Gains) Losses (f)






 






(6






)






 






 






(1






)






 






 






(5






)






 






 






(0.02






)






 






 






129






 






 






 






45






 






 






 






84






 






 






 






0.33






 








Strategic Initiatives Costs (g)






 






35






 






 






 






8






 






 






 






27






 






 






 






0.11






 






 






 






33






 






 






 






8






 






 






 






25






 






 






 






0.10






 








Regulatory Costs (h)






 






106






 






 






 






19






 






 






 






87






 






 






 






0.34






 






 






 






73






 






 






 






13






 






 






 






60






 






 






 






0.23






 








Gain on Debt Extinguishment (i)






 






(488






)






 






 






(116






)






 






 






(372






)






 






 






(1.45






)






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 








Entity Realignment Costs (j)






 






8






 






 






 






362






 






 






 






(354






)






 






 






(1.38






)






 






 






6






 






 






 






2






 






 






 






4






 






 






 






0.02






 








U.S. Tax Reform (k)






 






—






 






 






 






1






 






 






 






(1






)






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






—






 








Other (l)






 






9






 






 






 






1






 






 






 






8






 






 






 






0.02






 






 






 






(9






)






 






 






(4






)






 






 






(5






)






 






 






(0.02






)








Adjusted (Non-GAAP)






$






824






 






 






$






177






 






 






$






645






 






 






$






2.52






 






 






$






829






 






 






$






204






 






 






$






621






 






 






$






2.44






 









Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization








 






Year Ended December 31,








(DOLLARS AND SHARE AMOUNTS IN MILLIONS)






2025






 






2024








Numerator






 






 






 








Adjusted (Non-GAAP) Net Income






$






645






 






$






621








Amortization of Acquisition-related Intangible Assets






 






568






 






 






610








Tax impact on Amortization of Acquisition-related Intangible Assets (m)






 






138






 






 






150








Amortization of Acquisition-related Intangible Assets, net of tax (o)






 






430






 






 






460








Adjusted (Non-GAAP) Net Income ex. Amortization






$






1,075






 






$






1,081








 






 






 






 








Denominator






 






 






 








Weighted average shares assuming dilution (diluted)






 






256






 






 






256








Adjusted (Non-GAAP) EPS ex. Amortization






$






4.20






 






$






4.22









(a)







For 2025, represents costs related to the IFF Productivity Program including severance, fixed asset write-downs and site closure expenses, net of the gain on sale of fixed assets previously written down. For 2024, represents initial costs in connection with the IFF Productivity Program, primarily related to fixed asset write-downs.








(b)







For 2025 and 2024, primarily represents costs related to the Company's completed and anticipated divestitures. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts.










 










For the year-ended December 31, 2025, business divestiture costs were approximately $125 million. For the year-ended December 31, 2024, business divestiture and integration related costs were approximately $220 million and $5 million, respectively.








(c)







For 2025, represents the impairment of goodwill related to the Food Ingredients reporting unit. For 2024, represents the impairment of goodwill related to the Pharma Solutions disposal group.








(d)







For 2025, primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized as part of the sale of the Nitrocellulose business and Rene Laurent business in France. For 2024, primarily represents gains recognized as part of the sale of the Cosmetic Ingredients business and losses recognized as part of the sale of the Flavors & Essences UK business.








(e)







For 2025, represents the losses recognized on assets classified as held for sale of the Soy, Concentrates and Lecithin disposal group. For 2024, represents the losses recognized on assets classified as held for sale of the Pharma Solutions disposal group and portion of the Savory Solutions business in Turkey.








(f)







For 2024, represents a settlement loss that was recognized as a result of the termination of the International Flavors & Fragrances Inc. Pension Plan. During 2025, a reduction of the previous settlement loss was recognized.








(g)







Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services Centers, primarily consulting fees. For 2024, also includes strategic initiatives related to the Company's business unit re-organization efforts.








(h)







Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.








(i)







For 2025, represents the gain recognized on the extinguishment of debt in connection with the completion of tender offers.








(j)







For 2025 and 2024, represents costs related to a phased restructuring initiative aimed at optimizing its legal entity framework. In 2025, a one-time tax benefit was achieved as part of this restructuring which is partially offset by the execution costs to implement.








(k)







Tax benefit related to the impacts of the One Big Beautiful Bill Act, effective for 2025.








(l)







For 2025, primarily represents the net impact of costs related to severance, including accelerated stock compensation expense, for certain executives who have separated from the Company. For 2025, also includes the impact of legislation changes in India related to the Wage Code. For 2024, primarily represents gains from sale of assets.








(m)







The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at 0%. The tax benefit for amortization is calculated in a similar manner as the tax effects of the non-GAAP adjustments.








(n)







For 2025, reported net loss is decreased by income attributable to non-controlling interest of $2 million and adjusted net loss is decreased by income attributable to non-controlling interest of $2 million. For 2024, reported net income is decreased by income attributable to non-controlling interest of $4 million and adjusted net income is decreased by income attributable to non-controlling interest of $4 million.








(o)







Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax.







International Flavors & Fragrances Inc.

Debt Covenants

(Amounts in millions)

(Unaudited)


The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.




Reconciliation of Credit Adjusted EBITDA to Net Income








(DOLLARS IN MILLIONS)






Year Ended December 31, 2025








Net income






$






(372






)








Interest expense






 






229






 








Income taxes






 






(40






)








Depreciation and amortization






 






962






 








Specified items(1)






 






1,018






 








Non-cash items(2)






 






303






 








Credit Adjusted EBITDA






$






2,100






 









_______________________








(1)







Specified items consisted of restructuring and other charges, impairment of goodwill, divestiture and integration related costs, strategic initiatives costs, regulatory costs and other costs that are not related to recurring operations.








(2)







Non-cash items consisted of losses (gains) on sale of assets, losses (gains) on business disposals, losses on assets classified as held for sale, reduction of previous pension settlement losses, and stock-based compensation.









Net Debt to Total Debt








(DOLLARS IN MILLIONS)






December 31, 2025








Total debt(1)






$






6,026








Adjustments:






 








Cash and cash equivalents






 






590








Net debt






$






5,436









_______________________








(1)







Total debt used for the calculation of net debt consisted of short-term debt, long-term debt, short-term finance lease obligations and long-term finance lease obligations.







International Flavors & Fragrances Inc.

Comparable Reportable Segment Performance

(Amounts in millions)

(Unaudited)


The following information and schedule provides reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedule is not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.




 






Three Months Ended December 31,






 






Year Ended December 31,








 






 






2025






 






 






 






2024






 






 






 






2025






 






 






 






2024






 








Net Sales






 






 






 






 






 






 






 








Taste(1)






$






588






 






 






$






573






 






 






$






2,481






 






 






$






2,410






 








Food Ingredients






 






802






 






 






 






819






 






 






 






3,278






 






 






 






3,365






 








Health & Biosciences






 






589






 






 






 






550






 






 






 






2,283






 






 






 






2,203






 








Scent(2)






 






610






 






 






 






578






 






 






 






2,479






 






 






 






2,412






 








Pharma Solutions(3)






 






—






 






 






 






—






 






 






 






369






 






 






 






337






 








Consolidated






$






2,589






 






 






$






2,520






 






 






$






10,890






 






 






$






10,727






 








Segment Adjusted Operating EBITDA(5)






 






 






 






 






 






 






 








Taste(1)






$






94






 






 






$






82






 






 






$






478






 






 






$






446






 








Food Ingredients






 






82






 






 






 






97






 






 






 






423






 






 






 






399






 








Health & Biosciences






 






155






 






 






 






132






 






 






 






594






 






 






 






568






 








Scent(2)






 






106






 






 






 






105






 






 






 






515






 






 






 






526






 








Pharma Solutions(3)






 






—






 






 






 






—






 






 






 






76






 






 






 






68






 








Total






 






437






 






 






 






416






 






 






 






2,086






 






 






 






2,007






 








Depreciation & Amortization






 






(237






)






 






 






(243






)






 






 






(962






)






 






 






(1,015






)








Interest Expense






 






(49






)






 






 






(69






)






 






 






(229






)






 






 






(305






)








Other Expense, Net






 






(21






)






 






 






(138






)






 






 






(65






)






 






 






(182






)








Restructuring and Other Charges






 






(16






)






 






 






(23






)






 






 






(70






)






 






 






(29






)








Impairment of Goodwill






 






—






 






 






 






—






 






 






 






(1,153






)






 






 






(64






)








Gains (Losses) on Business Disposals






 






2






 






 






 






(2






)






 






 






(109






)






 






 






346






 








Loss on Assets Classified as Held for Sale






 






(7






)






 






 






(33






)






 






 






(115






)






 






 






(317






)








Gain on Extinguishment of Debt






 






—






 






 






 






—






 






 






 






488






 






 






 






—






 








Divestiture and Integration Related Costs






 






(35






)






 






 






(56






)






 






 






(125






)






 






 






(228






)








Strategic Initiatives Costs






 






(11






)






 






 






(11






)






 






 






(35






)






 






 






(33






)








Regulatory Costs






 






(35






)






 






 






(9






)






 






 






(106






)






 






 






(73






)








Entity Realignment Costs






 






(3






)






 






 






—






 






 






 






(8






)






 






 






(6






)








Other






 






(3






)






 






 






(2






)






 






 






(9






)






 






 






9






 








Impact of Business Divestitures(4)






 






—






 






 






 






55






 






 






 






—






 






 






 






198






 








Income (Loss) Before Taxes






$






22






 






 






$






(115






)






 






$






(412






)






 






$






308






 








 






 






 






 






 






 






 






 








Segment Adjusted Operating EBITDA Margin






 






 






 






 






 






 






 








Taste






 






16.0






%






 






 






14.3






%






 






 






19.3






%






 






 






18.5






%








Food Ingredients






 






10.2






%






 






 






11.8






%






 






 






12.9






%






 






 






11.9






%








Health & Biosciences






 






26.3






%






 






 






24.0






%






 






 






26.0






%






 






 






25.8






%








Scent






 






17.4






%






 






 






18.2






%






 






 






20.8






%






 






 






21.8






%








Pharma Solutions






 






—






%






 






 






—






%






 






 






20.6






%






 






 






20.2






%








Consolidated






 






16.9






%






 






 






16.5






%






 






 






19.2






%






 






 






18.7






%









______________________







(1)


Taste sales and segment adjusted operating EBITDA information for the three months and year-ended December 31, 2024 exclude the results of the Flavors & Essences UK business and Rene Laurent business in France that were divested to present fully comparable scenarios. The divestitures were completed on September 1, 2025 and December 1, 2025, respectively.







(2)


Scent sales and segment adjusted operating EBITDA information for the year-ended December 31, 2024 exclude the results of the Cosmetic Ingredients business to present fully comparable scenarios. The divestiture was completed on April 1, 2024.







(3)


Pharma sales and segment adjusted operating EBITDA information for the three months and year-ended December 31, 2024 exclude the results of the Pharma Solutions disposal group and Nitrocellulose business to present fully comparable scenarios. The divestitures were completed on May 1, 2025 and May 9, 2025, respectively.







(4)


Amounts exclude the results of the Cosmetic Ingredients business, the Pharma Solutions disposal group, the Nitrocellulose business, the Flavors & Essences UK business and Rene Laurent France business that were divested in the second quarter of 2024 (April 2, 2024), second quarter of 2025 (May 1, 2025), second quarter of 2025 (May 9, 2025), third quarter of 2025 (September 1, 2025) and fourth quarter of 2025 (December 1, 2025), respectively, to present fully comparable scenarios.







(5)


Following the completed divestitures of the Pharma Solutions disposal group on May 1, 2025 and the Nitrocellulose business on May 9, 2025, the Company reallocated certain corporate costs previously attributed to the Pharma Solutions segment. These costs have been redistributed across the Taste, Food Ingredients, Health & Biosciences, and Scent segments to align with the updated 2025 operating model.









 






 






Three Months Ended December 31, 2025








 






 






Selling & Administrative Expenses






 






Research & Development Expenses






 






Total Adjusted Operating EBITDA Impact








Taste






 






$






3






 






$






1






 






$






(4






)








Food Ingredients






 






 






3






 






 






—






 






 






(3






)








Health & Biosciences






 






 






3






 






 






—






 






 






(3






)








Scent






 






 






2






 






 






—






 






 






(2






)








Total






 






$






11






 






$






1






 






$






(12






)









 






 






Year Ended December 31, 2025








 






 






Selling & Administrative Expenses






 






Research & Development Expenses






 






Total Adjusted Operating EBITDA Impact








Taste






 






$






7






 






$






1






 






$






(8






)








Food Ingredients






 






 






9






 






 






—






 






 






(9






)








Health & Biosciences






 






 






7






 






 






1






 






 






(8






)








Scent






 






 






5






 






 






1






 






 






(6






)








Total






 






$






28






 






$






3






 






$






(31






)









International Flavors & Fragrances Inc.








GAAP to Non-GAAP Reconciliation








Comparable Foreign Exchange Impact








(Unaudited)













 



Q4 Taste






 






Sales






 






Segment Adjusted Operating EBITDA






 






Segment Adjusted Operating EBITDA Margin








% Change - Reported






 






2%






 






8%






 






1%








Portfolio Impact






 






1%






 






7%






 






1%








% Change - Comparable






 






3%






 






15%






 






2%








Currency Impact






 






(1)%






 






2%






 






0%








% Change - Comparable Currency Neutral






 






2%






 






17%






 






2%








 






 






 






 






 






 






 








Q4 Food Ingredients






 






Sales






 






Segment Adjusted Operating EBITDA






 






Segment Adjusted Operating EBITDA Margin








% Change - Reported






 






(2)%






 






(18)%






 






(2)%








Portfolio Impact






 






0%






 






3%






 






0%








% Change - Comparable






 






(2)%






 






(15)%






 






(2)%








Currency Impact






 






(2)%






 






4%






 






1%








% Change - Comparable Currency Neutral






 






(4)%






 






(11)%






 






(1)%








 






 






 






 






 






 






 








Q4 Health & Biosciences






 






Sales






 






Segment Adjusted Operating EBITDA






 






Segment Adjusted Operating EBITDA Margin








% Change - Reported






 






7%






 






14%






 






2%








Portfolio Impact






 






0%






 






3%






 






1%








% Change - Comparable






 






7%






 






17%






 






2%








Currency Impact






 






(2)%






 






3%






 






1%








% Change - Comparable Currency Neutral






 






5%






 






20%






 






3%








 






 






 






 






 






 






 








Q4 Scent






 






Sales






 






Segment Adjusted Operating EBITDA






 






Segment Adjusted Operating EBITDA Margin








% Change - Reported






 






6%






 






0%






 






(1)%








Portfolio Impact






 






0%






 






1%






 






0%








% Change - Comparable






 






6%






 






1%






 






(1)%








Currency Impact






 






(2)%






 






0%






 






0%








% Change - Comparable Currency Neutral






 






4%






 






1%






 






(1)%








 






 






 






 






 






 






 








Q4 Consolidated






 






Sales






 






Adjusted Operating EBITDA






 






Adjusted Operating EBITDA Margin








% Change - Reported






 






(7)%






 






(7)%






 






0%








Portfolio Impact






 






9%






 






12%






 






1%








% Change - Comparable






 






3%






 






5%






 






0%








Currency Impact






 






(2)%






 






2%






 






1%








% Change - Comparable Currency Neutral






 






1%






 






7%






 






1%









______________________







Note: The sum of these items may not foot due to rounding.




International Flavors & Fragrances Inc.








GAAP to Non-GAAP Reconciliation








Comparable Foreign Exchange Impact








(Unaudited)







 



YTD Taste






 






Sales






 






Segment Adjusted Operating EBITDA






 






Segment Adjusted Operating EBITDA Margin








% Change - Reported






 






2%






 






4%






 






0%








Portfolio Impact






 






1%






 






3%






 






0%








% Change - Comparable






 






3%






 






7%






 






1%








Currency Impact






 






1%






 






3%






 






0%








% Change - Comparable Currency Neutral






 






4%






 






10%






 






1%








 






 






 






 






 






 






 








YTD Food Ingredients






 






Sales






 






Segment Adjusted Operating EBITDA






 






Segment Adjusted Operating EBITDA Margin








% Change - Reported






 






(3)%






 






4%






 






1%








Portfolio Impact






 






0%






 






2%






 






0%








% Change - Comparable






 






(3)%






 






6%






 






1%








Currency Impact






 






0%






 






4%






 






0%








% Change - Comparable Currency Neutral






 






(3)%






 






10%






 






2%








 






 






 






 






 






 






 








YTD Health & Biosciences






 






Sales






 






Segment Adjusted Operating EBITDA






 






Segment Adjusted Operating EBITDA Margin








% Change - Reported






 






4%






 






3%






 






0%








Portfolio Impact






 






0%






 






2%






 






0%








% Change - Comparable






 






4%






 






5%






 






0%








Currency Impact






 






(1)%






 






2%






 






1%








% Change - Comparable Currency Neutral






 






3%






 






7%






 






1%








 






 






 






 






 






 






 








YTD Scent






 






Sales






 






Segment Adjusted Operating EBITDA






 






Segment Adjusted Operating EBITDA Margin








% Change - Reported






 






2%






 






(6)%






 






(2)%








Portfolio Impact






 






1%






 






3%






 






1%








% Change - Comparable






 






3%






 






(2)%






 






(1)%








Currency Impact






 






0%






 






4%






 






1%








% Change - Comparable Currency Neutral






 






3%






 






2%






 






0%








 






 






 






 






 






 






 








YTD Pharma Solutions






 






Sales






 






Segment Adjusted Operating EBITDA






 






Segment Adjusted Operating EBITDA Margin








% Change - Reported






 






(65)%






 






(65)%






 






0%








Portfolio Impact






 






74%






 






76%






 






0%








% Change - Comparable






 






9%






 






12%






 






0%








Currency Impact






 






3%






 






4%






 






0%








% Change - Comparable Currency Neutral






 






12%






 






16%






 






1%








 






 






 






 






 






 






 








YTD Consolidated






 






Sales






 






Adjusted Operating EBITDA






 






Adjusted Operating EBITDA Margin








% Change - Reported






 






(5)%






 






(5)%






 






0%








Portfolio Impact






 






7%






 






9%






 






1%








% Change - Comparable






 






2%






 






4%






 






1%








Currency Impact






 






0%






 






3%






 






1%








% Change - Comparable Currency Neutral






 






2%






 






7%






 






1%









_______________________








Note: The sum of these items may not foot due to rounding.







 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260211509419/en/
Media Relations:

Paulina Heinkel

332.877.5339

Media.request@iff.com


Investor Relations:

Michael Bender

212.708.7263

Investor.Relations@iff.com


Original: IFF Reports Fourth Quarter and Full Year 2025 Results